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Abstract 
 
The MHC class I allele, HLA-B27, is strongly associated with a group of inflammatory 
arthritic conditions collectively known as spondyloarthropathies (SpA). Ankylosing 
spondylitis (AS) shows the strongest association with 90-95 % of patients being HLA-
B27 positive.  The relationship between HLA-B27 and SpA has been known for over 30 
years, however despite ongoing research, the reason for this association has not yet been 
elucidated.  In more recent years, research has focused on intrinsic properties of the 
HLA-B27 allele, in particular its propensity to misfold, forming homodimers.  It has been 
proposed that these homodimers could be associated with the disease process through the 
activation of an ER stress response known as the unfolded protein response (UPR), or 
through aberrant recognition at the cell surface.   
 
We have investigated whether the expression of HLA-B27 is associated with the 
activation of the UPR.  We have studied the expression of BiP, and the cleavage of XBP1 
and ATF6 using stable and transiently expressing cell lines.  We have also investigated 
the formation of non-B27 homodimers using a human cell line stably expressing HLA-
B8, and finally we have studied the expression of homodimers in exosomes, small 
immunomodulatory vesicles released from numerous cell types.  The results presented 
here lead us to conclude that in vitro studies of the UPR are complicated, prone to a 
number of technical issues, and may therefore not be appropriate for gaining information 
that would be of significant use when comparing to the real disease scenario.  Our data 
suggest that non-B27 dimers may be strongly influenced by both the overexpression of 
MHC class I heavy chains and also the redox environment within the cell.   
 
We have isolated a novel fully folded, β2m-associated, MHC class I homodimer in 
exosomes and have detected a novel HLA-A and HLA-B mixed heavy chain dimer.  Our 
results suggest that these dimers form through interactions between the cysteine residues 
in the cytoplasmic tail and that these dimers form in exosomes because they contain 
lower levels of the important antioxidant glutathione when compared to whole cells.  
Together, these results define a new MHC class I structure present on exosomes at 
 iv 
significant levels, which could potentially influence immune recognition by both antigen-
specific T cell receptors and NK family receptors. The data also poses questions about 
whether these novel structures, when they involve HLA-B27, could influence the 
pathogenesis of spondyloarthropathies. 
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Chapter I: Introduction 
 
The Human Immune System – An Overview 
 
The human immune system is a complex arrangement of cells, tissues and organs that 
function together to protect the body from harm.  A fully functioning immune system can 
protect against numerous types of potential pathogens including viruses, bacteria, 
parasites and fungi, and it can even destroy cancer cells as they develop.  The 
complexities of such a system are often explained by dividing a system that normally 
functions as a whole entity into separate sections, or in the case of the immune system, 
into lines of defence. 
 
The first line of defence, the non-specific or innate immune response, occurs immediately 
or within a few hours after the detection of an infection.  The cells involved are designed 
not to detect a single specific antigen but, instead, to detect conserved structures present 
on many microorganisms. 
 
The second line of defence, the specific or adaptive immune response, can take several 
days to develop.  It is a response to a specific antigen that can result in long term 
protection, in addition to enhanced detection and removal if the same antigen is 
encountered again.  Adaptive immunity is further sub-divided into two sections – 
humoral immunity and cell-mediated immunity. 
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Humoral immunity involves the production of antibody and is mediated by B-
lymphocytes, or B cells.  Antibodies circulate as soluble proteins in the blood plasma and 
the lymph.  Humoral immunity is most effective against bacteria, bacterial toxins, and 
viruses prior to these agents entering cells, and for this reason the majority of vaccines 
aim to generate effective antibody responses. 
 
Cell-mediated immunity involves mostly actions performed by T-lymphocytes, or T cells. 
It is initiated by the interaction of T cell receptors (TCRs), present on T-lymphocytes, 
with antigenic peptides presented by MHC molecules on the surface of infected cells.  
This results in the activation of cells from both the innate and adaptive immune systems 
that act together to clear the infection or destroy the infected cells.  Cell mediated 
immunity allows the immune system to recognise virally infected cells, cells with 
intracellular bacteria and cancer cells that display tumour antigens. 
 
Some lymphocytes that encounter antigen develop into memory cells that continue to 
circulate around the body after the initial infection has been cleared.  The development of 
immunological memory is one of the most important properties of the immune system.  
The more immediate proliferation and differentiation of antigen-specific memory cells 
into effector cells allow a secondary response to the same antigen to be more rapid and 
more effective than that to a primary infection.  
 
Ultimately, all aspects of the immune system function together towards the same goal of 
preventing infection within the body and clearing it as quickly as possible when an 
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infection does occur.  When the immune system is compromised opportunistic diseases 
that would normally be easily cleared from the body can take hold.   The dramatic effects 
of a compromised immune system can be seen in such diseases as HIV and AIDS.  The 
downside to the evolution of such a powerful immune system is the risk of it failing to 
maintain the distinction between self and non-self, in which instance autoimmunity may 
develop. 
 
Cells of the Immune System 
 
The cellular component of the immune system develops from multipotent heamatopoietic 
stem cells.  These cells are the pre-cursors for two cell lineages involved in the immune 
response: the myeloid lineage and lymphoid lineage. 
 
The Myeloid Lineage 
 
The myeloid lineage originates from a common myeloid progenitor.   This progenitor 
differentiates to form erythrocytes, megakaryocytes or polymorphonuclear leukocytes of 
which there are two main types; granulocytes and monocytes.  Monocytes can further 
differentiate to form macrophages or dendritic cells.  Mast cells also develop from a 
common myeloid progenitor but these cells complete their maturation in tissues. 
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All granulocytes have multi-lobed nuclei and contain cytoplasmic granules.  There are 
three types of granulocyte; basophils, neutrophils and eosinophils.  Basophils are the 
smallest circulating granulocyte, they store inflammatory mediators in their cytoplasmic 
granules and de-granulation can be induced through physical damage, or chemical toxins 
and cationic proteins released from eosinophils and neutrophils.   
 
Eosinophils are attracted to cells coated with complement, where they release major basic 
protein, cationic proteins, perforins and oxygen metabolites mediating inflammation.  
Neutrophils, the most abundant leukocyte in the blood, migrate to extravascular sites of 
inflammation through a process of rolling, adhesion and diapedesis.  They are primarily 
responsible for the phagocytosis of opsonised particles.  Monocytes and macrophages 
also have important roles in phagocytosis.  Monocytes are found circulating within the 
blood, but chemotactic stimulation results in the migration of monocytes into the tissue 
where they undergo further differentiation to become multifunctional macrophages.  
 
Mast cells are large cells found in connective tissue throughout the body, most 
abundantly in the submucosal tissues and the dermis, and usually do not circulate in the 
blood stream. They also contain specialised granules that contain mediators of 
inflammation, including the vasoactive amine, histamine.  Antigen binding to mast cells 
triggers degranulation and activation, producing a local or systemic reaction.   
 
Dendritic cells (DCs) are a key component of innate and adaptive immunity and are 
extremely efficient in the endocytosis of extracellular antigens.  Once activated, they 
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migrate to local draining lymph nodes where they behave as professional antigen 
presenting cells.  In particular DCs are efficient at activating, or priming, naïve T-
lymphocytes.  DCs are the most potent stimulators of T-lymphocyte responses. 
 
The Lymphoid Lineage 
 
The lymphoid lineage develops from a common lymphoid progenitor and leads to the 
production of T-lymphocytes, B-lymphocytes and Natural Killer cells. 
 
B-lymphocytes are the effector cells of humoral immunity, they develop and mature in 
the bone marrow before being released into the periphery.  Mature B cells express B cell 
receptors (BCRs) on their surface and, once activated, undergo further differentiation to 
form plasma cells.  Plasma cells secrete antibodies that target antigens for destruction. 
 
T-lymphocytes play a central role in the adaptive immune response both directly and 
indirectly.  They develop in the bone marrow but migrate to the thymus to undergo 
maturation.  Mature T-lymphocytes express T cell receptors (TCR) on their surface.  
These receptors recognise antigen in the context of MHC molecules, which can result in 
the destruction of infected cells or the activation of B-lymphocytes. 
 
Natural killer (NK) cells develop in the bone marrow and represent approximately 10-
15% of circulating lymphocytes in the blood.  They are competent killing cells that 
express both activatory and inhibitory receptors.  Whether an NK cell initiates killing of a 
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target cell depends on the balance of inhibitory and activatory signals that are received 
(reviewed in Bryceson and Long, 2008).  NK cells receive inhibitory signals from surface 
MHC (major histocompatibility complex) molecules and therefore play an important role 
in the detection of ‘missing-self’.  NK cells have a multitude of functions in the immune 
system, many of which are still not fully understood. 
 
Innate Immunity 
 
Innate immunity is the immunity you are born with.  It is the body’s first level of defence 
and includes the physical barriers that bar the entry of potential pathogens into the body.  
The response is immediate or within several hours of a detected infection (reviewed in 
Tosi, 2005). 
 
The innate immune response consists of cellular components and soluble factors.  Cells 
involved in innate immunity recognise pathogen-associated molecular patterns (PAMPs) 
through special pattern-recognition receptors (PRR), including Toll-like receptors and 
Nod receptors.  Stimulation of PRR by PAMPs activate downstream signaling pathways 
that induce cytokine production, which attracts other cells involved in innate immunity 
but also stimulates the activation of the adaptive immune response (reviewed in Bourhis 
and Werts, 2007, and Arancibia et al., 2007).  
 
Phagocytic cells (neutrophils, monocytes, macrophages and dendritic cells) express a 
broad spectrum of receptors that participate in pathogen recognition.  Receptor 
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stimulation can trigger phagocytosis or can simply bind the pathogen to the phagocyte to 
enhance internalization.  DCs engulf pathogens and display pathogen-derived peptides in 
the context of MHC molecules on their cell surface.  Antigen presentation by DCs forms 
one of the bridges that connect the innate and adaptive immune systems together.  
Complement proteins in the serum can enhance phagocytosis by binding to invading 
pathogens in a process known as opsonisation.  Complement proteins are recognised by a 
specific set of receptors on the phagocyte stimulating internalisation.  Pathogen 
internalisation by phagocytes is usually accompanied by pro-inflammatory signals and 
the activation of antimicrobial mechanisms (reviewed in Underhill and Ozinsky, 2002).   
 
Upon stimulation, basophils, mast cells and eosinophils release molecules such as 
complement proteins, acute phase proteins and cytokines, which promote inflammation 
and can enhance phagocytosis.  Natural killer cells also have an important function in the 
innate immune response.  However, instead of recognizing pathogen directly, NK cells 
recognize and destroy cells that are expressing reduced levels of MHC molecules on their 
surface, an indication that they are infected, as described in the ‘missing-self hypothesis’ 
(reviewed in Karre, 2002). 
 
The non-discriminating nature of innate immunity is compensated for by the adaptive 
immune system, which adds specificity to the immune response and enhances the 
mechanisms involved in innate immunity.  Most cells involved in an innate immune 
response also have extremely important roles in adaptive immunity, and although they do 
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not themselves respond specifically, without them a specific response would not be 
possible.  
 
Adaptive Immunity 
 
Adaptive immunity continues to develop throughout life and consists of two major 
branches: humoral immunity and cell-mediated immunity. 
 
Humoral Immunity 
 
The main function of the humoral immune response is to destroy extracellular pathogens 
and prevent the spread of intracellular infections.  B-lymphocytes, the effector cells of 
humoral immunity develop in the bone marrow before being released into the circulation. 
 
B-lymphocyte stimulation can occur directly through antigen stimulation of the BCR but 
usually requires co-ordinated signalling from a subset of helper T-lymphocytes (Th), 
resulting in clonal expansion of the B cell.  B-lymphocytes migrate to lymphoid organs 
where they under go BCR receptor education and selection, known as affinity maturation, 
in specialised regions known as germinal centres (GC).  This results in the production of 
high-affinity antibody-secreting plasma cells and also memory cells (reviewed in Allen et 
al., 2007, and Tarlinton et al., 2008). 
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Plasma cells produce large quantities of antibodies that circulate around the body, coating 
infecting organisms in a process known as antibody-mediated opsonisation, targeting 
them for destruction through phagocytosis.  Antibodies bound to the surface of pathogens 
can activate the complement system.  Complement proteins also bind to the surface of 
pathogens, targeting them for degradation through phagocytosis, other complement 
molecules recruit phagocytic cells to the site of infection and some can directly lyse 
pathogens by punching holes in their membranes. 
 
Multiple subsets of memory B-lymphocytes emerge from the GC reaction, including 
long-lived plasma cells that remain terminally differentiated continually producing small 
amounts of high affinity antibody that is released into the circulation.  Other memory B-
lymphocytes that are produced express a greater proliferative capacity, or have a greater 
propensity for plasma cell formation, if the same antigen is detected again.  The 
formation of these memory cells mean that detection and removal of the same antigen 
will be much more rapid and efficient (reviewed in McHeyzer-Williams et al., 2006). 
 
Antibodies  
 
The specificity and diversity of antibodies is achieved through sequential gene 
rearrangements.  Each type of antibody that is produced can be expressed as a soluble 
molecule or in a membrane bound form on the surface of circulating B cells where they 
function as the BCR. 
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Antibodies consist of four polypeptide chains, two heavy (H) chains and two light (L) 
chains.  Each H chain and L chain consists of constant (C) and variable (V) regions.  The 
variable regions determine the antigen-binding specificity and therefore diversity of 
antibodies, this region is called the Fab region and is generated through sequential gene 
rearrangements.  The constant region of the H chain, termed the Fc region, determines the 
functional class of the antibody, of which there are five, each with a different function, 
denoted IgM, IgD, IgE, IgA and IgG. 
 
 
Figure 1. 1:  Schematic representation of an antibody molecule.  The basic structure 
of a mammalian antibody consists of two light chains (each ~ 25 kDa) and two heavy 
chains (each ~ 50 kDa), connected through disulphide bonds.  Constant regions are 
shown in red and variable regions are shown in blue.  The hinge region allows flexibility 
between the two Fab fragments.  
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Cell-Mediated Immunity 
 
T-lymphocytes are the effector cells involved in cell-mediated immunity.  T cells, like B 
cells, are derived from multipotent stem cells in the bone marrow but at an early stage 
migrate to the thymus where they undergo differentiation.  Cell-mediated immunity 
allows the immune system to monitor both the extracellular and the intracellular 
environment.  A sophisticated arrangement of molecular machinery allows the continual 
presentation of intracellular and extracellular antigens at the cell surface.  These antigens 
are presented in the context of MHC molecules and are available for immunosurveillance 
by T-lymphocytes. 
 
The TCR is responsible for the unique specificity of an individual T cell and a large 
number of different TCRs are generated from a series of gene rearrangements.  TCRs are 
heterodimers, composed of either an α- and β-chain or a γ- and δ-chain.  The αβ T cells 
and γδ T cells are different lineages of T cells that have different anatomical locations, 
specificities and functions. 
 
The αβ T cells recognise foreign antigen in the context of classical MHC molecules 
through the TCR.  Whether a T cell functions as a helper T cell or a cytotoxic T cell is 
determined by the expression of the co-stimulatory receptors CD4 and CD8.  CD4+ T 
cells recognise peptide antigen bound to MHC class II molecules and function as helper T 
cells, recruiting, and facilitating the activation of B-lymphocytes.  Expression of the CD8 
co-receptor (CD8+) facilitates the interaction between the TCR and peptide bound to 
 12 
MHC class I molecules.  CD8+ T cells are cytotoxic, signalling the destruction of infected 
cells. 
 
γδ T cells account for 1 -10 % of circulating T cells but can comprise a much higher 
proportion in some regions such as the epithelia of the small intestine.  These cells do not 
recognise conventional ligands but instead recognise diverse non-peptide ligands (Morita 
et al., 1999) including lipids (reviewed in Cui et al., 2005).  Some reports suggest that 
these T cells also recognise the MHC heavy chain related molecules MICA and MICB 
(Groh et al., 1998).  Once stimulated γδ T cells function in a similar way to αβ T cells 
displaying broad cytotoxicity and secreting cytokines and chemokines. 
 
One of the most important features of the adaptive immune response is its ability to 
develop memory.  Memory B- and T- lymphocytes result from infections that activate the 
adaptive immune response.  The mechanisms that lead to the generation of memory T 
cells have not been fully determined.  The classical pathway of memory T cell 
differentiation suggests that naïve T cells, once stimulated develop into effector T cells, 
most of which eventually die, but those that survive go on to develop into memory T 
cells, however there is also evidence that memory T cells can develop directly from naïve 
T cells (reviewed in Moulton and Farber, 2006).  The development of memory T cells 
allows a second infection by the same organism to be detected and removed much faster 
than in the primary response. 
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The MHC 
 
The human major histocompatibility complex genomic region is located on the short arm 
of chromosome 6.  The entire 3.6 Mb genomic sequence of the MHC was first reported in 
1999 by the Human Major Histocompatability Complex Sequencing Consortium (The-
MHC-Sequencing-Consortium, 1999).  In 2004, the gene information for this region was 
reviewed and updated (Shiina et al., 2004).  A total of 239 gene loci have been identified.  
130 of these genes code for expressed genes, 17 for gene candidates, 4 for non-coding 
genes and 88 for pseudogenes. 
 
The MHC is traditionally divided into three sub-regions, denoted class I, class II and 
class III.  The class III region is located between the class I and class II regions and is 
often referred to as the central MHC. 
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Figure 1.2: Gene map of the MHC on chromosome 6.  White, grey, striped and black 
boxes show expressed genes, gene candidates, non-coding genes and pseudogenes, 
respectively.  The position of the coded classical and non-classical MHC class I genes are 
highlighted in red.  Diagram published in Tissue Antigens, Shiina et al 2004 (Shiina et 
al., 2004). 
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Class III Region 
 
The central region of the MHC is one of the most gene dense regions of the human 
genome, coding for more than 60 genes in approximately 900 kb of genomic sequence.  
This region contains a more heterogeneous set of genes than the MHC class I and class II 
regions.  These genes include those involved in the activation of complement cascades, 
inflammation and cell stress, hormonal synthesis, heat shock proteins, extracellular 
matrix organisation as well as members of the immunoglobulin superfamily.  Other genes 
in the class III region encode for proteins whose functions have no direct connection to 
the immune system (reviewed in Yung Yu et al., 2000, and Hauptmann and Bahram, 
2004). 
 
Class II Region 
 
The class II region spans approximately 700 kb of DNA and contains the classical MHC 
class II α- and β-chain genes, HLA-DP, -DQ and -DR and the non-classical HLA-DM 
and -DO genes.  Almost all of the genes encoded in the class II region have an 
immunological function.  Notably the genes for TAP1 and TAP2, involved in MHC class 
I antigen presentation, are also encoded in this region (discussed below) (Shiina et al., 
2004).  
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Classical MHC Class II 
 
The classical MHC class II molecules are constitutively expressed on immune cells such 
as B-lymphocytes, macrophages/monocytes and dendritic cells, where they present 
exogenous antigen to CD4+ T cells.  All of the class II molecules consist of non-
covalently associated α- and β-chains that are both coded for in the class II region of the 
MHC.  The α- and β-chains of all the classical MHC class II molecules have the same 
conformation, two extracellular domains and a membrane spanning tail region.  The 
membrane-distal parts of each chain come together to form a peptide-binding groove that 
is capable of binding a wide array of peptides. 
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Figure 1.3: Schematic diagram of classical MHC class II molecules.  MHC class II 
molecules consist of two non-covalently associated non-identical polypeptide chains, the 
α-chain and the β-chain.  The most membrane distal portions of each chain, α1 and β1, 
come together to form the peptide-binding domain that is capable of binding a wide array 
of peptides.  All domains are stabilised by disulphide bonds with the exception of the α1 
domain. 
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Non-Classical MHC Class II 
 
There are two non-classical MHC class II molecules encoded for within the MHC, HLA-
DM and HLA-DO.  HLA-DM is expressed in all classical MHC class II expressing cells, 
however it is not expressed at the cell surface, but is instead retained intracellularly 
within the MHC class II compartments (MIIC).  The conformation of its α- and β-chains 
result in its peptide-binding groove being almost completely closed off.  As its structure 
implies, HLA-DM does not have a role in antigen presentation but instead facilitates the 
release of CLIP (part of the invariant chain) (discussed below) from the peptide-binding 
groove of classical MHC class II molecules, whilst at the same time, maintaining their 
peptide binding site in an open and peptide-receptive confirmation (reviewed in Denzin et 
al., 2005, and Sadegh-Nasseri et al., 2008). 
 
The peptide loading of classical MHC class II molecules is modified in B cells, DCs and 
thymic epithelial cells because of the expression of HLA-DO.  It is suggested that the 
expression of HLA-DO inhibits the function of HLA-DM although the in vivo relevance 
of this is not yet fully understood.  It is speculated that in resting cells, HLA-DO 
downmodulates steady-state class II antigen processing and, when a B cell or DC requires 
active antigen presentation, HLA-DO levels are reduced.  The net effect being that in 
steady-state conditions presentation of self-peptides is reduced and during infection class 
II antigen presentation is enhanced (reviewed in Denzin et al., 2005). 
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Class I Region 
 
The 1.8 Mb class I region contains the three classical MHC class I genes, HLA-A, -B and 
-C, and the three non-classical MHC class I genes, HLA-E, -F and -G.  This region also 
codes for two expressed MHC class I chain related (MICA and MICB) genes that are 
HLA class I-like molecules and a large group of non-HLA genes. 
 
MIC proteins, although similar to MHC class I, neither bind to β-2-microglobulin (β2m) 
nor exhibit classical class I peptide binding and are not expressed on normal circulating 
lymphocytes.  MIC proteins are transcribed in keritinocytes, endothelial cells, fibroblasts 
and seemingly most epithelial tissue.  MIC proteins are expressed at the cell surface in 
response to cell stress where they can engage the activating NK-receptor, NKG2D 
(reviewed in Stephens, 2001). 
 
Classical MHC Class I 
 
Classical MHC class I molecules, referred to as MHC class Ia molecules, are expressed 
on almost all nucleated cells.  Functional class Ia molecules are heterotrimeric complexes 
consisting of the class I heavy chain (coded for in the MHC) non-covalently associated 
with a β2m molecule (coded for on chromosome 15) and an approximately 8 - 10 amino 
acid peptide.  MHC class Ia molecules present antigen derived from endogenous proteins 
for surveillance by cytotoxic CD8+ T cells (reviewed in Zinkernagel and Doherty, 1997). 
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Figure 1. 4:  Schematic diagram of a classical MHC class I molecule.  MHC class I 
molecules are heterotrimers consisting of an MHC class I heavy chain, non-covalently 
associated with β2m, and an approximately 8-10 amino acid peptide.  The heavy chain 
folds to form 3 domains α1, α2, and α3.  The α1 and α2 domains come together to form 
the peptide-binding domain, which is capable of binding a wide array of peptides.  The 
α3 domain interacts with β2m and also helps to support the peptide-binding region. 
 
3-dimensional structures of MHC class I molecules have been determined by x-ray 
crystallography (Bjorkman et al., 1987, Garrett et al., 1989, Madden et al., 1991).  Class I 
heavy chains consist of three extracellular domains known as α1, α2 and α3, with the α1 
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and α2 domains forming the peptide-binding groove.  The α3 domain interacts with β2m 
and also helps to support the peptide-binding region. 
 
 
Figure 1. 5:  Ribbon diagram of the MHC class I crystal structure.  The α1 and α2 
domains are shown in purple and the α3 domain is shown in blue.  The non-covalently 
associated β2m molecule is shown in grey.  The conserved cysteine residues at positions 
101 and 164 in the peptide-binding groove, and at 203 and 259 in the α3 domain are 
indicated in yellow. Also shown in this representative structure of HLA-B27 is the 
additional unpaired cysteine residue in the peptide groove at position 67. Diagram 
generated from HLA-B27 accession data, for example - PDB:1JGE, using Cn3D 
(www.ncbi.nlm.nih.gov). 
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MHC class I molecules exhibit extensive polymorphism within the HLA-A, -B and –C 
genes, most of which occurs within the α1 and α2 peptide-binding region.  These 
polymorphisms alter the peptide specificity of each allele.  Peptides bound to class I 
molecules possess conserved amino acids that form the anchor residues.  The side chains 
of these amino acids are accommodated in six pockets (A-F) that make up the peptide-
binding groove.   
 
Non-Classical MHC class I 
 
The non-classical MHC class I molecules are referred to as MHC class Ib molecules.  
These molecules share a remarkably similar structure to class Ia molecules however they 
only express very limited polymorphism.  HLA-E, -F and -G have different functions in 
the immune system and are expressed in different cell types. 
 
HLA-E is expressed by the same cells that express classical class Ia molecules.  The 
limited polymorphisms shown by HLA-E result in a peptide-binding groove able to bind 
very specific peptide rather than the promiscuous nature of the class Ia binding groove 
(reviewed in O'Callaghan and Bell, 1998).  HLA-E binds the leader peptides from the 
class Ia molecules resulting in the enhanced expression of HLA-E at the cell surface, here 
HLA-E acts as an inhibitory ligand for NK cells expressing CD94/NKG2 receptors 
(Braud et al., 1998b, Borrego et al., 1998, Braud et al., 1998a, Braud et al., 1997).  The 
function of HLA-E offers another checkpoint to ensure that the MHC class Ia pathway is 
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intact.  If classical class I molecules are not expressed, HLA-E will not be able to bind 
the leader peptide, resulting in lower expression of HLA-E, rendering the cell susceptible 
to NK lysis. 
 
HLA-F is the least understood of the non-classical class I molecules.  HLA-F associates 
with β2m and has a peptide binding groove, similar to the other class I molecules, it has 
not yet been clearly established if this molecule can actually bind peptide (Wainwright et 
al., 2000, Lepin et al., 2000).  HLA-F shows a restricted distribution of tissue expression, 
and the cellular localisation of this allele is disputed, with some reports that it is located 
on the cell surface and conflicting reports suggesting that the molecule remains 
intracellular (Wainwright et al., 2000, Lepin et al., 2000, Lee and Geraghty, 2003).  There 
are reports showing that HLA-F is expressed in placental tissue, suggesting that HLA-F 
may be involved in providing a state of immuno-privilege to the growing foetus, although 
this is still debated (Shobu et al., 2006, Ishitani et al., 2003, Apps et al., 2008, Nagamatsu 
et al., 2006).  The concentration of HLA-F in the golgi is enhanced compared with other 
class I molecules which led in a recent report to the suggestion that HLA-F may have 
evolved in order to monitor the golgi for infection, however this still remains to be 
proven (Boyle et al., 2006). 
 
HLA-G expression is limited to a small subset of cells, principally trophoblasts of 
invading placental tissue (McMaster et al., 1995), where it is believed to have an 
important role in providing a state of immunoprivilege to the growing foetus (reviewed in 
Hunt et al., 2006).  HLA-G transcripts are alternatively spliced, producing both 
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membrane-bound and soluble HLA-G proteins (Moreau et al., 2002).  Soluble HLA-G 
molecules bind to the CD8 co-receptor resulting in the apoptosis of NK cells and T cells 
(Contini et al., 2003), whilst membrane-bound HLA-G has immunosuppressive effects 
through binding to the inhibitory receptors LILRB1/ILT-2, LILRB2/ILT-4 and KIR2DL4 
on NK cells, T cells and APCs (Colonna et al., 1997, Colonna et al., 1998, Rajagopalan 
and Long, 1999).  HLA-G is unusual amongst class I molecules for its ability to form 
β2m-associated homodimers (Boyson et al., 2002, Gonen-Gross et al., 2003).  Disulfide-
linked HLA-G homodimers make up a significant proportion of the total HLA-G 
expressed by trophoblast cells (Apps et al., 2007) and it has been shown that dimeric 
HLA-G molecules have a higher affinity than monomers for LILRB1 and LILRB2 
(Shiroishi et al., 2006, Gonen-Gross et al., 2003, Apps et al., 2007).  
 
Antigen Processing and Presentation 
 
Peptide binding is required to complete the folding of classical, and some non-classical, 
class I and class II molecules.  This process is very specific and ensures only proteins of 
the right length and origins are able to bind to the MHC molecules and therefore be 
presented at the cell surface.  Usually, MHC class I molecules present endogenous 
antigen and MHC class II molecules present exogenous antigen.  However, in dendritic 
cells MHC class I molecules can also present exogenous antigen through a process 
known as cross presentation (reviewed in Rock and Shen, 2005). 
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The two major pathways used for antigen presentation, the MHC class I antigen 
processing pathway and the MHC class II antigen processing pathway, are discussed in 
more detail below. 
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Figure 1. 6:  Schematic diagram of the classical MHC class I and class II antigen processing 
and presentation pathways.  MHC class I molecules assemble in the ER with the help of the 
peptide loading complex.  MHC class I molecules present endogenous peptide antigen at the cell 
surface for surveillance by CD8+ T lymphocytes.  MHC class II molecules present exogenous 
antigen at the cell surface for surveillance by CD4+ T cells. 
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MHC Class II Antigen Processing and Presentation 
 
MHC class II α- and β-chains fold in the ER and associate with the invariant chain (Ii).  
A region of the Ii chain, known as CLIP (class II associated Ii peptide), binds to the MHC 
class II peptide binding domain, stabilising the class II molecule and preventing peptides 
in the ER from binding (Anderson and Miller, 1992, Romagnoli and Germain, 1994, 
Roche and Cresswell, 1990).  The Ii chain also contains an endosomal targeting motif 
that directs the α- and β-chain/Ii complex to the endosomal pathway (Pieters et al., 1993). 
 
The regions of the endosomal/lysosomal pathway where MHC class II molecules 
accumulate are generally referred to as MHC class II compartments (MIIC).  Different 
morphologies of MIIC have been reported and it is suggested that these reflect different 
maturation stages in the MHC class II folding pathway (Kleijmeer et al., 1996, Kleijmeer 
et al., 1997, reviewed in Stern et al., 2006). 
 
MHC class II molecules bind to, and present at the cell surface, peptides derived from 
exogenous antigens.  Exogenous antigen may be ingested through phagocytosis, receptor-
mediated endocytosis or macropinocytosis (reviewed in Vyas et al., 2008, and Watts, 
1997).  Professional APCs use phagocytosis as an important mechanism for the uptake of 
antigen.  Internalised phagosomes eventually fuse with the endosomal/lysosomal 
compartment (Desjardins et al., 1994) delivering peptide antigen to where MHC class II 
molecules are located. 
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In the MIIC the Ii chain is degraded by endosomal/lysosomal proteases known as 
cathepsins, until only the CLIP region remains bound to the peptide-binding groove 
(Riese et al., 1996).  The non-classical MHC class II molecule, HLA-DM, functions as a 
unique chaperone, catalysing the dissociation of CLIP, stabilising peptide-empty class II 
molecules and facilitating peptide exchange, enabling high-affinity peptide/class II 
complexes to form (Denzin and Cresswell, 1995, Denzin et al., 1996). 
 
The final step in antigen processing and presentation is the delivery of the fully-folded 
peptide-bound MHC class II molecule to the cell surface, a process that has not been fully 
defined.  It has been demonstrated that the late MIIC form tubular structures that are 
directed towards the plasma membrane which can deliver the class II molecules to the 
cell surface although the mechanism behind this process is not yet fully understood (Vyas 
et al., 2007, Boes et al., 2003).  Once at the cell surface, peptide loaded MHC class II 
molecules are recognised by CD4+ T cells. 
 
MHC Class I Antigen Processing and Presentation  
 
Endogenous proteins are constantly degraded within the cytosol by the proteasome.  Most 
of the peptides that are generated are destroyed shortly after their production but a small 
fraction is further processed and is subsequently transported into the ER lumen by the 
transporter associated with antigen processing (TAP) (Stoltze et al., 2000, Reits et al., 
2003, Reits et al., 2004). 
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TAP is a heterodimeric transporter, consisting of TAP1 and TAP2, which is part of the 
ATP-binding cassette (ABC) transporter family.  ABC transporters have a four-domain 
structure consisting of two hydrophobic transmembrane domains and two hydrophilic 
nucleotide binding domains (NBD) (reviewed in Higgins, 1992).  The transmembrane 
domain of the two subunits of TAP form the translocation pore within the ER membrane 
(Vos et al., 2000, Koch et al., 2004), and the cytosolic NBD region energisers peptide 
translocation across the membrane by ATP hydrolysis (reviewed in Abele and Tampe, 
2004).  The N-terminal domains have been shown to bind to tapasin, an important 
component of the peptide loading complex (discussed below) (Koch et al., 2004).  TAP 
most efficiently transports peptides of 8 – 10 amino acids in length into the ER lumen, 
but can transport longer proteins up to 40 amino acids in length (Androlewicz and 
Cresswell, 1994, Koopmann et al., 1996).  Within the ER, peptides can be further 
trimmed by the ER-luminal aminopeptidase 1 and 2 (ERAP1/2), to produce peptides that 
bind efficiently to MHC class I molecules (Saric et al., 2002, Saveanu et al., 2005b, 
Serwold et al., 2002).  
 
Peptides transported into the ER are loaded onto peptide receptive MHC class I 
molecules through the help of a macromolecular complex known as the peptide-loading 
complex (PLC).  This complex consists of TAP, tapasin (TPN), calreticulin (CRT), 
ERp57, protein disulfide isomerase (PDI) and MHC class I molecules (Hughes and 
Cresswell, 1998, Morrice and Powis, 1998, Degen and Williams, 1991, Nossner and 
Parham, 1995, Sadasivan et al., 1996, Ortmann et al., 1997, Park et al., 2006). 
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Nascent MHC class I heavy chains are targeted to the ER where they rapidly associate 
with the chaperone calnexin (CNX) (Sugita and Brenner, 1994, Nossner and Parham, 
1995).  However, the role played by CNX is not essential for class I folding as cell 
surface expression still occurs in calnexin-deficient cell lines (Scott and Dawson, 1995).  
Subsequent binding of the MHC class I HC to β2m disfavours binding to CNX and the 
HC/β2m complex binds instead to the related chaperone CRT.   
 
TPN stabilises the class I molecule and bridges the source of the peptides (TAP) to the 
peptide-receptive class I heavy chain (Sadasivan et al., 1996, Ortmann et al., 1997, 
Grandea et al., 1997).  The N-terminal 50 residues of TPN have been shown to mediate 
the interaction between TPN and MHC class I molecules whereas the C terminus seems 
necessary for binding to TAP (Bangia et al., 1999, Lehner et al., 1998).  Tapasin also 
appears to have a role in increasing peptide supply into the ER (Lehner et al., 1998, Li et 
al., 2000).  Work carried out on the TPN deficient cell line 721.220, and TPN knock-out 
mice, have confirmed the importance of TPN for correct MHC class I assembly 
(Greenwood et al., 1994, Peh et al., 1998, Garbi et al., 2000, Grandea et al., 2000). 
 
ERp57 and PDI are thiol oxidoreductases involved in assuring correct disulfide bond 
formation.  Disulphide-bonded intermediates between MHC class I heavy chain and both 
ERp57 and PDI have been reported (Lindquist et al., 2001, Park et al., 2006, Antoniou et 
al., 2002a).  ERp57 can bind both CNX and CRT (Oliver et al., 1999), and we have 
recently demonstrated a direct interaction between ERp57 and MHC class I molecules 
(Santos et al., 2007).  ERp57 predominantly associates with cysteine residues in the 
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peptide binding domain, indicating that ERp57 has direct access to the peptide-binding 
groove during class I assembly (Antoniou et al., 2007).  Recent data suggest that PDI can 
control the oxidation of the peptide binding groove disulfide bond between Cys101 and 
Cys164 of MHC class I molecules, thereby also regulating peptide optimisation (Park et 
al., 2006).   
 
 
Figure 1. 7:  Schematic diagram of the peptide loading complex.  The peptide loading 
complex facilitates the binding of peptides to MHC class I molecules.  The TAP 
transporter (not indicated on the diagram) also forms an important part of the PLC and is 
linked to the other components through an interaction with tapasin.   
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The PLC functions together to ensure that the nascent class I heavy chains are folded 
correctly and supplied with peptide.  Fully folded class I molecules associated with high 
affinity peptide exit the ER and translocate through the golgi apparatus to the cell surface, 
where they can then be recognised by CD8+ T cells. 
 
Tolerance to Self 
 
The ability of the immune system to detect foreign antigens but to ignore self-antigens is 
central to retaining a healthy body.  Tolerance of both B- and T-lymphocytes is 
maintained by several mechanisms. 
 
B Cell Tolerance 
 
During development BCR diversity is generated by random rearrangement of 
immunoglobulin genes, a process that inevitably results in the genesis of receptors that 
recognise self-antigens.  A rescue mechanism, known as receptor editing, allows the 
specificity of a BCR that recognises self-antigen to be changed (Gay et al., 1993, Tiegs et 
al., 1993).  However if this process is unsuccessful, these lymphocytes are deleted before 
they can develop into fully immunocompetent cells in a process known as clonal deletion 
(Nemazee and Burki, 1989). 
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Some self-reactive B cells may escape clonal deletion in the bone marrow and instead be 
released into the circulation.  Self-reactive B cells released into the periphery are silenced 
through a process known as anergy (reviewed in Cambier et al., 2007).  B cell tolerance 
in the periphery is also maintained by helper T cells.  Most B cells require additional 
signals from helper T cells in order to become activated, if helper T cells are tolerant to 
self-antigens the auto-reactive B cell will not differentiate to form an antibody secreting 
plasma cell. 
 
T Cell Tolerance  
 
T cell tolerance is mainly achieved in the thymus during T cell development through 
positive and negative selection.  Some auto-reactive T cells can escape this process and 
enter the periphery further mechanisms are active here to ensure tolerance to self is 
maintained 
 
Central Tolerance through Positive and Negative Selection 
 
During T cell development, CD4 and CD8 receptors are temporarily expressed at the 
same time.  These cells, known as double positive thymocytes, reside in the cortex of the 
thymus.  At this time, thymocytes with TCRs that engage either MHC class I or MHC 
class II molecules with low affinity receive a survival signal, this is known as positive 
selection.  Whether the thymocyte will develop to become only CD4+ or CD8+ is 
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determined by which MHC molecule the TCR was able to engage.  Those cells neglected 
by the MHC molecules will undergo apoptosis (reviewed in Takahama, 2006, Robey and 
Fowlkes, 1994, and Jameson et al., 1995).  Thymocytes that bind peptide/MHC 
complexes with high affinity are deleted, removing potentially self-reactive cells in a 
process known as negative selection (reviewed in Siggs et al., 2006).  The thymocytes 
that survive both positive and negative selection, complete maturation and are released to 
the periphery.  Further regulatory mechanisms function in the periphery to control 
autoreactive T cells. 
 
Peripheral Tolerance 
 
Peripheral tolerance is maintained in several ways.  The primary regulators of peripheral 
tolerance are regulatory T cells (Tregs).  Tregs are a sub-population of CD4+ T cells that 
express high levels of IL-10 and TGFβ.  These cytokines suppress T cell function in 
order to prevent chronic activation and auto-reactivity in the periphery (reviewed in 
Vignali et al., 2008). 
 
T cell inactivation, or anergy, can also occur.  Those T cells that engage an MHC/peptide 
complex in the absence of co-stimulatory receptors are induced into an anergic state.  
Similarly, interaction with a tolerogenic DC (usually an immature DC expressing low 
levels of co-stimulatory molecules) will induce anergy in the T cell.  During an infection 
the levels of co-stimulatory molecules present on APCs are increased, therefore T cell 
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anergy prevents the activation of T cells in the absence of infection (reviewed in Macian 
et al., 2004). 
 
Following an immune response activated T cells must be removed in order to maintain 
self-tolerance and prevent chronic inflammation.  Some activated T-cells undergo 
autonomous cell death whilst others receive signals to die through repeated stimulation of 
their TCR.  This second pathway, known as activation-induced cell death (AICD) may be 
responsible for the deletion of some auto-reactive T cells in the periphery (reviewed in 
Zhang et al., 2004, Brenner et al., 2008, and Green et al., 2003). 
 
Autoimmunity 
 
When an organism becomes unable to distinguish self-antigens from those of an invading 
organism, an immune response will be launched in a process known as autoimmunity. 
Autoimmune responses are usually sustained and persistent resulting in long-term tissue 
destruction.  Autoimmune diseases can be the result of either B cells (antibodies), as in 
Goodpasture’s syndrome, or T cells as in insulin-dependent diabetes mellitus (IDDM). 
 
In Goodpasture’s syndrome, antibodies are produced that recognise collagen in the 
basement membrane of renal glomeruli.  Destruction of this tissue leads to kidney 
dysfunction and failure, and can be rapidly fatal (reviewed in Bergs, 2005).  IDDM is a 
chronic disease, caused by both CD4+ and CD8+ autoreactive T cells.  These cells destroy 
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the insulin-producing β cells found in the pancreatic islets, resulting in an inability of the 
patient to control their blood glucose levels (reviewed in Knip and Siljander, 2008). 
 
It is not known exactly what triggers an autoimmune response although both 
environmental and genetic factors, particularly MHC genotype, influence susceptibility.  
 
HLA and Disease 
 
The classical MHC class I and class II molecules have been associated with more than 
100 diseases, however the molecular mechanisms for most of these disease associations 
remain poorly understood.  Diseases associated with the HLA region can be of a wide 
variety of classes, including immune, neurodegenerative, metabolic and infectious. 
 
The strongest HLA-linked disease association that is known is between the MHC class I 
allele HLA-B27 and a specific group of arthritic diseases known as 
Spondyloarthropathies.  
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HLA-B27 and Spondyloarthropathies 
 
The Arthritis Research Campaign (www.arc.org.uk) estimates that up to 9 million people 
each year in the UK will visit their doctor because of arthritis and related musculoskeletal 
conditions.  The most commonly occurring disorder is osteoarthritis, with around 2 
million people receiving this diagnosis.  Rheumatoid arthritis affects approximately 
350,000 individuals, and ankylosing spondylitis affects between 100,000 to 150,000.  
http://www.arc.org.uk/arthinfo/patpubs/6020/6020.asp. 
 
Ankylosing spondylitis (AS) is a major form of spondyloarthropathy (SpA), the name 
given to a group of arthritic diseases that are associated with HLA-B27 expression and 
predominantly affect the joints of the spine.  Spondyloarthropathies encompasses a 
number of different disorders including: ankylosing spondylitis, reactive arthritis or 
Reiter’s syndrome (ReA), psoriatic arthritis, arthritis-associated inflammatory bowel 
disease, enthesitis related juvenile arthritis and undifferentiated SpA.  
 
The archetypal SpA, ankylosing spondylitis, shows the greatest association with HLA-
B27, with between 90 and 95 % of patients expressing this allele.  The association of 
HLA-B27 with AS has been known for over 35 years (Brewerton et al., 1973, Schlosstein 
et al., 1973) but despite ongoing research the reason for this association still remains a 
mystery.   
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Ankylosing Spondylitis 
 
AS is a chronic systemic inflammatory disease affecting primarily the sacroiliac joint and 
the axial skeleton, but it can also affect the peripheral joints and entheses, as well as 
having extra-articular manifestations (Mansour et al., 2007).  AS shows significant 
inherited susceptibility and affects men more than women, usually with a ratio of 2:1.  
Onset generally occurs in late adolescence or early adulthood, most frequently between 
20 and 30 years of age. 
 
AS patients typically present with low back pain, characterised by stiffness and pain that 
is worse in the morning or after prolonged periods of inactivity, which is improved with 
exercise, but not through rest.  As the disease progresses the involvement of the cervical 
spine increases, usually presenting as neck pain and stiffness (Mansour et al., 2007).  In 
severe cases the cervical bones may fuse causing the head to protrude forward, a 
compensatory flexion of the knee results in the classic stooped posture of the patient with 
advanced AS (Hoh et al., 2008). 
 
Treatments 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line of treatment in AS, 
and are used to control pain and reduce inflammation. Their full effect is rapid and can 
usually be observed 42-78 hours after treatment.  However, they are also associated with 
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significant side effects through prolonged use, including effects on the cardiovascular 
system, gastrointestinal tract and renal function.  A review discussing the potential 
benefits and risks of NSAIDs in AS treatment has recently been published (Song et al., 
2008). 
 
Whether NSAIDs function as ‘disease modifying drugs’, having long-term effects on 
disease progression has not yet been fully determined.  A study in 2005 implicated the 
continuous use of NSAIDs (compared with on demand use) in the reduction of 
radiographic progression of disease (Wanders et al., 2005) although more data is needed 
before a conclusive answer to this question can be given. 
 
Patients can also be prescribed disease-modifying anti-rheumatic drugs (DMARDs) such 
as methotrexate and sulfsalazine.  However the efficacy of these drugs is debatable.  
Sulfsalazine is the most widely studied DMARD for the treatment of AS and large 
randomised control trials have shown that the effects of this drug is limited, reducing 
inflammation in the periphery in some patients but having limited effects on spinal 
inflammation (Clegg et al., 1996, Kirwan et al., 1993).  
 
Some antimalarials, such as hydroxychloroquine, can be used in conjunction with 
DMARDs to treat spondyloarthropathies and it has been suggested that the use of this 
combination of drugs is more effective than DMARD monotherapy (Calguneri et al., 
2004).  Hydroxychloroquine is a lysomotropic agent, and functions primarily by entering 
the lysosomal compartment and raising the pH.  How exactly this treatment affects the 
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disease process in spondyloarthritis has not been determined, although its effects on 
antigen processing, for MHC class II presentation especially, have been exploited by 
immunologists for many years. 
 
More recently, TNFα inhibitors have been shown to offer good improvement to AS 
patients and three TNFα inhibitors are currently available for clinical use, these are 
Infliximab®, Etanercept® and Adalimumab®.  These agents block the effects of the 
immune system by binding to TNFα and preventing its downstream effects, thus 
reducing inflammation.  Since cytokine blockade therapies are relatively recent 
introductions to the AS treatment regime, there must remain some concerns about the 
effects of their long-term use, both in terms of patient compliance and tolerance, and also 
relating to the immune-suppressive action of such anti-TNF agents, which may include 
increased rates of serious infections, and also, potentially, of malignancies (Dixon et al., 
2006, Listing et al., 2005, Bongartz et al., 2006). 
 
Surgery can be performed under some circumstances to restore mobility to some 
damaged joints.  Prolonged and severe disease results in the ossification of the vertebrae 
resulting in a condition known as ‘bamboo spine’.  Fusion of the cervical vertebrae 
pushes the head forward in a ‘chin-on-chest’ position and tends to result in a 
compensatory flexion of the knees.  Surgical correction is available but is technically 
demanding and carries the serious risk of permanent neurological injury (Hoh et al., 
2008). 
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HLA-B27 
 
HLA-B27 is a classical MHC class I molecule expressed by approximately 1 in 10 of the 
general population in the UK.  It is important to note that the majority of people who 
express HLA-B27 will not go on to develop any symptoms of SpA.  However, the 
association of HLA-B27 with this group of diseases is one of the strongest MHC-disease 
associations that is known.  
 
It is also of great importance to note that HLA-B27 functions perfectly well as a typical 
MHC class I molecule.  Antigen presentation by HLA-B27 is extremely efficient, with 
HLA-B27 positive individuals showing increased clearance of hepatitis C compared with 
other alleles (McKiernan et al., 2004) and slower progression from HIV to AIDS 
(reviewed in Carrington and O'Brien, 2003). 
 
Currently 42 subtypes of HLA-B27 have been identified, denoted HLA-B*2701-B*2743 
(with the discrepancy in numbering due to HLA-B*2722 having been removed), and as 
with most MHC class I alleles, the differences between them tend to be in the α1 and α2 
domains.  It is thought that most HLA-B27 alleles evolved from the most frequent 
subtype, B*2705, and it is this founder allele that is most strongly associated with SpA in 
Caucasians.  Intriguingly, alleles B*2706 and B*2709, found in Sardinia and Southeast 
Asia respectively, are not associated, or only very weakly associated, with disease.  
B*2706 differs from B*2705 by five residues (positions 74, 114, 116, 152 and 211) 
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whereas B*2709 differs at only one residue (position 116), potentially implicating these 
residues directly in the disease process. 
 
HLA-B27 contains 4 conserved structural cysteine residues at positions 101, 164, 203 
and 259, which it shares with all MHC class I alleles (Figure 1.8).  These cysteine 
residues form intra-chain disulfide bridges early in the class I molecules folding, and are 
essential to the stability of MHC class I molecules (Antoniou et al., 2004).  The HLA-
B27 allele also possess three unpaired cysteine residues; one at the relatively rare position 
67, located on an α-helix close to the peptide binding site, and two other cysteine residues 
at positions 308 and 325 located within the transmembrane domain and cytoplasmic tail, 
respectively.  Importantly, none of these unpaired residues is unique to HLA-B27 and 
thus is unlikely to be the sole causative factor in AS.  All HLA-B alleles share the 
cysteine at position 308, just at the border of the transmembrane and cytoplasmic 
domains, whilst in contrast no HLA-A alleles have a cysteine at this location and the 
expression of a cysteine residue at position 325 is variable amongst HLA-B alleles.  The 
function of these cysteine residues is unknown, though we propose a new and novel 
function in the later part of this thesis.  The cysteine at position 67 (Cys67) is a feature 
shared by a cohort of other class I alleles including subtypes of HLA-B07, -B14, -B15, -
B35, -B38, B-39, -B40, -B51, -B73 and -B95. 
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Figure 1. 8:  Ribbon diagram of the MHC class I allele HLA-B27.  The α1 and α2 
domains are shown in purple and the α3 domain is shown in blue.  The non-covalently 
associated β2m molecule is shown in grey.  The cysteine residues are indicated in yellow.  
Diagram generated from HLA-B27 accession data, for example - PDB:1JGE, using 
Cn3D (www.ncbi.nlm.nih.gov). 
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Detailed structural analysis of HLA-B27, and peptide elution studies, have enabled a 
HLA-B27 peptide-binding motif to be determined as well as probable peptide 
interactions with the TCR.  Peptides bound to HLA-B27 are anchored at four positions, 
P2, P3, P7 and P9 allowing the side chains of residues at P1, P4, P5, P6 and P8 to interact 
with the TCR (Madden et al., 1991, Madden et al., 1992).  It was also demonstrated that 
HLA-B27 shows an almost absolute restriction for arginine at position 2 of the bound 
peptides (Jardetzky et al., 1991, Madden et al., 1991, Madden et al., 1992).  There are, 
however, some cases in which arginine is not found at position 2, and it is proposed that 
the differences observed for P2 residues might be specific to the origin of the cell-type 
used (Stodulkova et al., 2006).   
 
A small proportion of HLA-B27 molecules react with the monoclonal antibody MARB4 
(Urban et al., 1994).  Although class I molecules tend to bind a nonomeric peptides, it has 
been shown that the HLA-B27 molecules that react with this antibody can be bound to 
unusually long peptides, up to 33 amino acids in length (Urban et al., 1994).  However, 
peptides longer than the standard length of nine amino acids (although not as long as 33 
amino acids) have been reported previously both for HLA-B27 and the non-disease 
associated allele HLA-A2.  Thus the length of bound peptide is also unlikely to be a sole 
driver of AS disease (Parker et al., 1992, Robbins et al., 1989). 
 
HLA-B*2705 exhibits the unusual characteristic of being partially TAP and TPN 
independent (Peh et al., 1998).  This can lead to the binding and presentation of low 
affinity peptides in complexes that are less stable on the cell surface, resulting in an 
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increased expression of HC10-reactive free heavy-chains on tapasin deficient cell lines 
(Peh et al., 1998).  Further investigation has shown that the non-disease associated alleles 
B*2706 and B*2709 are equally TPN independent with B*2706 showing the highest 
level of HC10 reactive material on the cell surface (Goodall et al., 2006).  In normal TPN 
sufficient cells however, B*2705 alleles appear to utilise the TPN-dependent pathway 
(Peh et al., 1998) suggesting tapasin-independent folding may only occur when infection 
results in perturbed tapasin function (Park et al., 2004).   
 
A key step forward in AS research occurred with the development of transgenic rats 
expressing HLA-B27.  The expression of HLA-B27 in several transgenic rat lines leads 
to the development of an arthritic condition that closely resembles many of the features of 
AS, whilst a control transgenic expressing the non-disease associated HLA-B7 allele 
remains healthy, thus providing strong evidence that HLA-B27 has a direct role in 
disease pathogenesis (Hammer et al., 1990, Khare et al., 1995, Taurog et al., 1999).  
 
Theories for HLA-B27 Associated Disease 
 
Several hypotheses have been put forward to explain the association of B27 with this 
group of diseases.  It was suggested by Edwards et al. that a viable hypothesis for the role 
of HLA-B27 in SpA must explain five observations: 1) the predilection of 
spondyloarthropathies for specific tissues and young adult males; 2) the strong, but not 
absolute, link with B27; 3) the association of peripheral arthritis with intracellular 
bacterial infection; 4) the genesis of similar diseases in B27-transgenic rodents; and 5) 
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the ability of B27 to modulate the expression of other diseases (Edwards et al., 2000).  As 
yet, no such unifying hypothesis is available, but each hypothesis discussed below has 
found some support in the literature. 
 
Arthritogenic Peptide Hypothesis and Molecular Mimicry 
 
It would be logical to assume that the pathological role of HLA-B27 is related to its 
antigen presentation function.  The classical ‘Arthritogenic Peptide Hypothesis’ is based 
upon just that, the normal physiological functions of an MHC class I molecule.  This 
theory, proposed in 1990, suggests that normal tolerance to HLA-B27, acquired through 
thymic selection, is somehow broken resulting in auto-immunity and on-set of disease 
(Benjamin and Parham, 1990). 
 
MHC class I molecules constitutively present a large peptide repertoire on the cell 
surface.  Most of these peptides arise endogenously, and are then presented to CD8+ T 
cells for immunosurveillance.  Presentation of an antigenic peptide by HLA-B27 would 
result in a B27-restricted cytotoxic T-lymphocyte response.  The arthritogenic peptide 
hypothesis predicts that the activating antigen shows molecular mimicry to a self HLA-
B27 peptide resulting in tolerance to the self-peptide being lost and an autoimmune 
inflammatory response being launched.  
 
It has been established that HLA-B27 is almost distinct from other MHC class I 
molecules for its nearly absolute restriction for peptides with arginine at position 2 
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(Jardetzky et al., 1991, Madden et al., 1991, Madden et al., 1992).  Further research has 
determined that there are differences in the peptide repertoires of disease and non-disease 
associated alleles, with B*2706 and B*2709 unable to bind a small proportion of the 
peptides that are able to bind the disease associated alleles B*2704 or B*2705 
respectively (Sesma et al., 2002, Ramos et al., 2002b).  These data suggest peptide 
specificity may be important for disease association. 
 
The onset of Reactive Arthritis, a related SpA, has long been known to be associated with 
enterobacterial infections.  Because of this association it has been plausible to assume a 
link between enterobacteria and AS.  Indeed evidence from transgenic mice and rats 
suggests an important role for microorganisms in disease onset, because in the HLA-B27 
transgenic rodents disease activity develops after transfer from a specific pathogen-free 
area to a more conventional animal facility (Khare et al., 1995, Khare et al., 1996, Taurog 
et al., 1994). 
 
The search for an arthritogenic peptide led to the discovery that some self-ligands of 
HLA-B27 show similarity to antigenic peptides from gram-negative bacteria.  Frauendorf 
et al. have reported the presence of CD8+ T cells with specificity for a HLA-B27-binding 
peptide, that is derived from the HLA-B27 heavy chain itself and shows similarities to 
enterobacteria-derived peptides, in the peripheral blood of HLA-B27+ patients with AS 
but not in healthy HLA-B27+ controls (Frauendorf et al., 2003). 
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Epidemiological evidence also indicates a role for bacteria in disease onset and severity, 
with HLA-B27+ individuals being at increased risk of prolonged or severe arthritis 
following gastro-intestinal infection.  Several types of gram-negative bacteria have been 
associated with the onset of SpA including Kleibsiella, Chlamydia and Salmonella. 
 
Possible molecular mimicry between HLA-B27 and Kleibsiella pneumaniae has been 
investigated and two peptide antigens from K. pneumaniae proteins that show similarity 
to sequences from HLA-B27 have been described.  Firstly, the ‘QTDRED’ sequence 
found in the K. pneumaniae nitrogenase enzyme (Schwimmbeck et al., 1987).  However 
it is debated whether the nitrogenase enzyme is actually produced in the human gut 
shedding doubt on the potential role of this protein in AS.  Secondly, the ‘DRDE’ 
sequence from the K. pneumaniae pulD secretion protein (Fielder et al., 1995).  This 
same study also identifies a sequence from pulA secretion protein that shows homology 
with sequences from types I, III and IV collagen.  Antibodies against these K. 
pneumoniae proteins were increased in HLA-B27+ AS patients compared with healthy 
controls and were shown to be autoreactive to HLA-B27 in vitro (Fielder et al., 1995).  
The evidence supporting a role of K. pneumoniae in the disease process has recently been 
summarised (Rashid and Ebringer, 2007). 
 
The role of K. pneumoniae in AS still remains a controversial subject.  In a report in 
2004, Stone et al were unable to detect any differences in cellular or humoral immune 
responses to K. pneumoniae between familial AS and unaffected controls (Stone et al., 
2004), and comparison of the faecal microflora of patients with AS and unaffected 
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controls were unable to detect any significant difference in K. pneumoniae load 
(Stebbings et al., 2002).  These results, and others, mean the role of Klebsiella 
pneumoniae in AS remains undetermined.  
 
Some studies have suggested that the expression of HLA-B27 increases the susceptibility 
to Salmonella infection whilst others have reported conflicting findings (Kapasi and 
Inman, 1992, Huppertz and Heesemann, 1997, Saarinen et al., 2002).  The Granfors lab 
have shown that the elimination of intracellular infection with Salmonella is impaired in 
vitro in HLA-B27 expressing cells, potentially resulting in an increased bacterial load in 
HLA-B27+ individuals (Laitio et al., 1997, Virtala et al., 1997).  It has also been shown 
that HeLa cells expressing HLA-B27 have an altered signalling response when infected 
with Salmonella bacteria compared with HLA-A1 (Ikawa et al., 1998) and, in the U937 
human monocytic cell line, it has been reported that the expression of HLA-B27 
enhances the activation of NF-κB in response to LPS (Penttinen et al., 2002).  However, 
a recent report by Goodall et al. found that the expression of HLA-B27 did not 
profoundly alter the response to LPS in the U937 cell line (Goodall et al., 2006). 
 
HLA-B27, in vitro, can bind a peptide derived from its own cytoplasmic region that 
shows significant homology with a peptide derived from Chlamydia trachomatis (Ramos 
et al., 2002a).  However whether this Chlamydia peptide is produced in vivo is still to be 
determined. 
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The continued search for an arthritogenic peptide led to the discovery of a self-peptide 
derived from the vasoactive peptide type 1 receptor, known as pVIPR.  It has been 
demonstrated that this peptide shares sequence homology to a peptide derived from the 
latent membrane protein of Epstein Barr virus (EBV).  It was postulated that the 
arthritogenic peptide, may not be a presented solely by disease associated alleles but may 
in fact be presented by all alleles but held in different combinations.  A sub-optimally 
loaded antigen on disease-associated alleles may enable T cells to overcome tolerance.  
There is evidence that the disease associated allele B*2705 does in fact bind pVIPR in a 
dual confirmation compared with a single conformation seen in the non-disease 
associated B*2709 subtype (Hulsmeyer et al., 2004).  Cytotoxic T-lymphocytes directed 
against pVIPR have been found in healthy HLA-B27+ controls, but their numbers are 
increased in patients suffering with AS (Fiorillo et al., 2000).  How an immune response 
targeting this protein could confer the tissue-specific nature of SpA has, however, not 
been determined. 
 
CD8+ T cells that react with collagen-derived self-peptides have been isolated from the 
synovial fluid of some AS patients (Atagunduz et al., 2005) but the significance of this 
finding is yet to be established. 
 
New research, and old problems, seriously challenge the ability of the arthritogenic 
peptide hypothesis to explain the link between HLA-B27 and SpA.  Firstly, despite 
nearly 20 years of investigation, researchers have been unable to determine a single 
convincing specific arthritogenic peptide.  Secondly, not all associated alleles share 
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peptide specificity.  It was postulated that an arthritogenic peptide may possess a tyrosine 
residue in its C-terminus, a peptide binding feature shared by B*2705, B*2704 and 
B*2702 but not B*2706 or B*2709 (Fiorillo et al., 1997, Garcia et al., 1997).  However it 
has been demonstrated that the disease associated allele B*2707 does not naturally 
present peptides with a tyrosine at the C-terminus (Tieng et al., 1997).  Also, the allele 
B*1403 has been found to be associated with AS in some populations (Lopez-Larrea et 
al., 2002) however comparison of the B*1403 and B*2705 peptide repertoire showed 
limited overlap (Merino et al., 2005).  
 
Thirdly, and perhaps most importantly, transgenic rodent studies have shown that 
although disease onset is T-lymphocyte-dependent, CD8+ αβ T cells are not absolutely 
required (May et al., 2003), whilst CD4+ T cells are crucial.  If the animal model does 
indeed reflect human AS, this suggests a more crucial role for cells such as helper T cells 
and perhaps DCs.  Further studies on (the somewhat controversial) HLA-B27+ human 
β2m+ transgenic mice have also indicated that TAP is not required for spontaneous 
disease to occur (Khare et al., 2001) and although it has been shown that HLA-B27 can 
be expressed at the cell surface in the absence of TAP (Peh et al., 1998), the peptide 
repertoire presented in the presence of TAP is likely to be different to that in its absence.  
Although these data do not exclude the possibility of arthritogenic peptide being 
presented by HLA-B27 it does make it seem increasingly unlikely.   
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Homodimers and other Unconventional Structures  
 
The discovery that HLA-B27 exists in confirmations other than the traditional 
heterotrimeric structure of heavy chain, β2m and peptide, has led to the development of 
new theories for its association with disease.  These theories are based on other intrinsic 
properties of the B27 allele rather than its natural antigen presenting abilities. 
 
Transgenic animal studies have directly implicated free HLA-B27 heavy chains (HCs), 
not associated with β2m or peptide, in the development of disease.  In the HLA-
B27+/hβ2m+ transgenic mouse model, the incidence of disease is decreased following in 
vivo treatment with the HLA-B heavy chain specific antibody, HC10 (Khare et al., 1996), 
although to the best of our knowledge, this experiment has not yet been repeated in the 
transgenic rat model.  In AS patients, Tsai et al. have shown an increase in free HC 
surface expression in monocytes compared with normal controls (Tsai et al., 2002), 
although Cauli et al. were unable to detect the same differences (Cauli et al., 2002). 
 
Some β2m-free B27-HCs, recognised by the monoclonal antibody MARB4, have been 
shown to be able to remain bound to peptide at the cell surface (Malik et al., 2002) 
suggesting that free-HCs may perhaps play a role in antigen presentation.  Indeed peptide 
presentation by mouse class I molecules in the absence of β2m has previously been 
demonstrated (Zugel et al., 1994, Lehmann-Grube et al., 1994).   
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Empty HLA-B27 heterodimers, not containing a peptide, have also been shown to be 
present on the surface of some cells and these structures are able to bind exogenous 
antigen (Benjamin et al., 1991) raising the possibility that HLA-B27 presents an 
unconventional peptide for MHC surveillance.  
 
A further unusual structure adopted by HLA-B27 occurs when β2m-free HLA-B27 HCs 
form disulfide-bonded homodimers.  These homodimeric structures have been implicated 
in disease through two main mechanisms: 1) recognition by immunomodulatory receptors 
on the cell surface and 2) accumulation in the ER resulting in the activation of a pro-
inflammatory stress response. 
 
 Homodimer Formation 
 
HLA-B27 homodimers were first identified and isolated in 1999 through in vitro folding 
studies of HLA-B27 (Allen et al., 1999).  Misfolded HLA-B27, particularly homodimers, 
have been implicated in the pathogenesis of AS and related spondyloarthropathies, either 
by misfolding in the ER which may result in the activation of a proinflammatory stress 
response (Colbert, 2000), or through their presence at the cell surface.  Cell surface 
homodimers may be involved in peptide presentation or be recognised themselves as 
neoantigens by some immune receptors (Allen et al., 1999).  ER homodimers and cell 
surface homodimers appear to be distinct populations, with homodimers forming in the 
ER unable to egress to the cell surface (Dangoria et al., 2002, Antoniou et al., 2004) 
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 ER Homodimers  
 
In 1999 Mear et al demonstrated that HLA-B27 has slower folding kinetics than other 
class I alleles and has a tendancy to misfold, a characteristic attributed to residues in the 
B pocket of the peptide-binding groove which has been directly linked with the formation 
of homodimers (Mear et al., 1999, Antoniou et al., 2004). This observation formed the 
basis of the hypothesis proposed by Colbert et al in 2000, in which he postulated that the 
accumulation of these misfolded proteins could lead to the activation of an ER stress 
response, the aim of which is to alleviate stress and re-establish normal physiological 
conditions (Colbert, 2000). 
 
The folding of proteins within the endoplasmic reticulum is tightly regulated by 
molecular chaperones.  If misfolded proteins accumulate within the ER a stress response, 
known as the Unfolded Protein Response (UPR), is activated.  The UPR is a signalling 
pathway regulated by the immunoglobulin binding protein (BiP), that aims of to alleviate 
stress and re-establish normal physiological conditions.  Under normal conditions BiP is 
bound to the three transducers of the stress response, PERK, ATF6 and IRE1.  When 
misfolded proteins accumulate, BiP releases these molecules, binding instead to the 
misfolded proteins.  This allows the stress signal to be relayed across the ER membrane, 
resulting in the transcriptional induction of UPR genes, translational attenuation of global 
protein synthesis and enhanced ER-associated degradation (ERAD).  The UPR, if not 
perturbed, will eventually result in apoptosis (for a concise review see Liu and Kaufman, 
2003).  
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The formation of HLA-B27 homodimers was thought to be dependent on the unpaired 
cysteine at position 67 in the peptide binding groove (Allen et al., 1999, Dangoria et al., 
2002).  However mutational studies of the structural cysteine residues in the B27 
molecule indicated that both Cys67 and Cys164 are involved in homodimer formation 
(Antoniou et al., 2004) and further studies have shown some dimer formation to be 
independent of any individual free cysteine residues present in the HLA-B27 molecule 
(Saleki et al., 2006).  
 
The misfolding hypothesis can potentially explain some observations made in transgenic 
rodent studies.  In transgenic rats disease only occurs in those animals that have a high 
gene copy number with HLA-B27 expression above a certain threshold (Taurog et al., 
1993), and in HLA-B27 transgenic mice, spontaneous arthritis occurs in the absence of 
β2m (Khare et al., 1995).  In both of these situations, HLA-B27 HCs could be more likely 
to misfold, resulting in the activation of the UPR.  In 2004 it was demonstrated in a rat 
cell line model that HLA-B27 heavy chains were found in association with BiP, the key 
regulator of the UPR (Antoniou et al., 2004).  Shortly afterwards Tran et al. showed that 
HLA-B27 alleles are more likely to form heavy chain complexes with BiP than the 
disease resistant allele HLA-B7 (Tran et al., 2004).   
 
Further support for this hypothesis came from the detection of a UPR response in bone-
marrow macrophages from HLA-B27-transgenic rats with active disease, but not in those 
of younger, pre-morbid animals (Turner et al., 2005) and the more recent demonstration 
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that the magnitude of the UPR in rat macrophages correlates well with the accumulation 
of misfolded HLA-B27 heavy chains (Turner et al., 2007).  Evidence of an IFN response 
in cells from rats suffering with disease was also obtained, a response that seems to 
exacerbate the UPR, probably through the up-regulation of HLA-B27 heavy chains 
(Turner et al., 2005).  More recently a study on a human cell line model indicates that 
expression of HLA-B27 alone is enough to activate a stress response (Lemin et al., 2007).   
In contrast to the above, a recent study in transgenic rats has challenged the UPR 
hypothesis.  The accumulation of misfolded HLA-B27 heavy chain and UPR activation 
could be reduced significantly by over-expression of human β2m (Tran et al., 2006).  
These rats, despite showing reduced misfolding and UPR activation still develop arthritis, 
which in many respects is even more akin to human AS than the original HLA-B27 rat 
model.  Turner et al. have suggested though, that the reduction in misfolding caused by 
the increased β2m may not be enough to prevent the activation of the UPR and that 
prolonged expression of increased levels of β2m may actually amplify any ongoing 
immune responses (Turner et al., 2007). 
 
 Cell Surface Homodimers 
 
The expression of cell surface dimers was first demonstrated in cell lines with defective 
antigen presentation pathways (Allen et al., 1999).  Cell surface homodimers can be 
recognised by both HC10 and W6/32, and in 2002 it was demonstrated that these 
represent distinct populations (Allen et al., 1999, Dangoria et al., 2002).  Recognition of 
some dimers with W6/32 indicates that this population of dimers retain at least partial 
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confirmation of the peptide-binding groove (Figure 1.9).  Immunoprecipitations of 
homodimers with W6/32 in T2 cells were unable to co-precipitate β2m indicating these 
dimers exist as two free heavy chains (Allen et al., 1999). 
 
 
Figure 1. 9: MHC Class I structures recognised by the antibodies ME1, W6/32, and 
HC10.  Classical MHC class I molecules are non-covalently associated with β2m and are 
recognized by the antibodies ME1 and W6/32.  Free-heavy chain not associated with β2m 
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is recognized by HC10.  The MHC class I allele HLA-B27 is also known to form 
disulphide bonded homodimers that are usually recognized by HC10 but a small 
proportion may also be recognized by the conformation dependent antibody W6/32. 
 
W6/32 reactive and HC10 reactive dimers can be further distinguished by their formation 
kinetics, and their dependency on TPN, TAP, and β2m (Dangoria et al., 2002).  Dangoria 
et al. found that the formation of W6/32 reactive homodimers was dependent on TPN, 
TAP and β2m, a finding that disagreed with the previous study by Allen et al (Allen et al., 
1999, Dangoria et al., 2002).  In pulse-chase analysis HC10 reactive dimers were 
determined as forming early after heavy chain synthesis suggesting they form within the 
ER, whereas W6/32 reactive dimers formed much later suggesting they are formed 
following exit from the ER (Dangoria et al., 2002).  As both populations can be isolated 
from the cell surface, HC10 reactive dimers must also form later following exit from the 
ER (Dangoria et al., 2002).  Consistent with this finding, Bird et al demonstrated that 
HC10 reactive cell surface homodimers could form from fully folded heterotrimers that 
are internalised and recycled back to the cell surface via an endosomal compartment 
(Bird et al., 2003).   
 
HLA-B27 possess the relatively rare cysteine residue at position 67 in the extracellular 
α1 domain and this cysteine has been strongly implicated in the formation of 
homodimers (Allen et al., 1999, Dangoria et al., 2002, Bird et al., 2003).  A possible 
structure for an HLA-B27 homodimer bound through this residue was suggested in 2002 
(Figure 1.10) (McMichael and Bowness, 2002).  This back-to-back model renders the 
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MHC class one molecules undetectable by confirmation dependent class I antibodies 
such as ME1. 
 
 
 
 
Image unavailable owing to copyright restrictions. 
 
 
 
Figure 1. 10:  Proposed structure of an HLA-B27 homodimer.  The disulphide bond 
between the two Cys67 residues is shown (yellow, centre of the image) and putative 
peptides are depicted as yellow tubes.  This image was published in 2000, in 
Rheumatology by Bowness et al. (Bowness, 2002). 
 
However, Antoniou et al, have shown that the conserved structural cysteine at position 
164 is also involved in homodimer formation which would lead to a significant change in 
the proposed back-to-back structure (Antoniou et al., 2004).  Dangoria et al also 
demonstrated that substitution of residues in the B pocket of HLA-B27 influenced dimer 
formation, and also that HLA-B7 was able to form both HC10 and W6/32-reactive 
dimers (Dangoria et al., 2002), suggesting that dimers are able to form in the absence of 
Cys67.  
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Dimer Recognition by Immune Receptors 
 
Since their initial discovery, cell surface HLA-B27 homodimers have subsequently been 
isolated in transgenic rat studies as well as on populations of peripheral blood and 
synovial fluid monocytes from patients with spondyloarthritis (Kollnberger et al., 2002, 
Tran et al., 2004, Kollnberger et al., 2004).  Their proposed role in AS is different from 
that already discussed in the context of UPR induction. 
 
MHC class I molecules not only interact with the TCR but also with other immune 
receptors including the killer immunoglobulin-like receptors (KIR) and leuckocyte 
immunoglobulin-like receptors (LILR, also known as ILTs) (Lanier, 1998, Colonna et al., 
1998, Colonna et al., 1999a).  KIR are expressed on both NK and T cell subsets and can 
have both activatory and inhibitory effects (Lanier, 1998, Colonna et al., 1999a).  LILR 
show a differential expression pattern to KIR, some LILR, such as LILRB1/ILT2, are 
expressed on B cells, T cells, NK cells and monocytes/macrophages (Colonna et al., 
1998) whilst the expression of others, such as LILRB2/ILT4, is more restricted (Lanier, 
1998). 
 
The recognition of homodimers by some immune receptors has been reported, with HLA-
B27 homodimers able to interact with KIR3DL1, KIR3DL2, LILRB2/ILT4, and 
LILRA1/LIR6 but not LILRB1/ILT2 (Allen et al., 2001, Kollnberger et al., 2002).  
LILRB1 and LILRB2 usually recognise classical HLA-A and HLA-B alleles, but show 
an increased preference for HLA-G (Shiroishi et al., 2003).  KIR3DL1 usually recognise 
 61 
fully folded heterotrimeric HLA-B alleles that have the bw4 motif, including HLA-B27 
(Peruzzi et al., 1996) and KIR3DL2 usually shows specificity for HLA-A alleles 
(Dohring et al., 1996).  LILRA1 is expressed on myelomonocytic cells only (Borges and 
Cosman, 2000, Colonna et al., 1999b), and had no previously identified binding ligands 
(Allen et al., 2001). 
 
Supporting the theory that an abnormal interaction between immune receptors and 
homodimers are implicated in disease, Chan et al have detected increased numbers of NK 
cells and CD4+ T cells expressing KIR3DL2 from patients suffering with 
spondyloarthritis (Chan et al., 2005).  These results demonstrate that HLA-B27 
homodimers are recognised by a specific, although overlapping, subset of receptors 
compared with traditional, fully folded HLA-B27 molecules, and that at least one of these 
receptors is enhanced in patients suffering with spondyloarthritis. 
 
Interaction of KIR with normal trimeric class I molecules is dependent on peptide 
binding (Hansasuta et al., 2004, Peruzzi et al., 1996), and it has been demonstrated that 
HLA-B27 free-HCs and homodimers are able to bind peptide (Allen et al., 1999, Urban 
et al., 1994). However Kollnberger et al. have recently shown that homodimer 
recognition by KIR is independent of any bound peptide (Kollnberger et al., 2007).  In 
the transgenic rat model HLA-B27 homodimers have been detected at the cell surface of 
rodent leukocytes and can be recognised by paired immunoglobulin receptors (PIR) in an 
interaction that is ameliorated by the HC10 antibody (Kollnberger et al., 2004).  
However, as previously mentioned, transgenic rodent studies have also shown that rats 
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expressing enhanced amounts of human β2m show reduced levels of free-HCs but still go 
on to develop disease (Tran et al., 2006).   
 
Homodimers Expressed on Dendritic Cells 
 
The role of DCs in AS has recently become an area of significant interest, and three lines 
of evidence support a role for DCs in AS.  Firstly, CD4+ T cells are required for disease 
to develop, and these T cells are heavily reliant on DCs for activation (Breban et al., 
1996).  Secondly, HLA-B27 derived bone marrow cells transfer disease (Breban et al., 
1993), and thirdly, disease does not occur in the absence of commensal gut flora.  The 
most likely cell to fulfil the above requirements; to be bone marrow derived and transfer 
immunological signals from the gut to the peripheral immune system, are DCs.  
 
Furthermore, recent data has shown that DCs from HLA-B27 transgenic rats are 
defective in their stimulation of T cells (Hacquard-Bouder et al., 2004).  The most recent 
study in this area has shown that expression of HLA-B27 causes this defect by interfering 
with the engagement of co-stimulatory molecules (Hacquard-Bouder et al., 2007).  These 
observations could be extremely important seeing as it has been shown that co-
stimulation is important for the expansion of Tregs (Lin and Hunig, 2003), leading to the 
suggestion that in AS and other SpA, defective activation of these cells may result in a 
loss of tolerance toward self antigens (Hacquard-Bouder et al., 2004). 
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We recently published data showing that, in both the KG1 dendritic-like cell line and in 
human monocyte-derived DCs from a HLA-B27+ individual, HLA-B27 homodimers are 
a transiently expressed population that are induced in response to activation (Santos et al., 
2008).  Homodimers usually appeared 24 hours post activation and, in the human 
monocyte-derived DCs, began to decrease 48-72 hours after activation.  This finding is 
interesting considering recent in situ studies in the rat showing DCs from the intestine 
migrate to mesenteric lymph nodes within 24 to 48 hours (Kobayashi et al., 2004).  This 
could result in the presence of enhanced numbers of HLA-B27 homodimers on the 
surface of DCs whilst they are in the lymph node, possibly having an effect on the 
initiation of any immune response.   
 
Following activation, total levels of MHC class I are increased (Santos et al., 2008), 
leading to the possible scenario where increased expression of class I molecules results in 
the formation of dimers.  It has previously been suggested that over-expression of an 
HLA allele alone is not enough to confer disease susceptibility as the HLA-B7 transgenic 
rats express -B7 to a similar level as the HLA-B27 transgenic rats express -B27 but still 
remain healthy (Taurog et al., 1999).  However, as it has been demonstrated, HLA-B27 is 
more susceptible to form dimers than other alleles and therefore other alleles may need to 
be expressed to a higher level before significant dimer formation is seen.  We, and others, 
have detected non-B27 dimers previously (Santos et al., 2008, Dangoria et al., 2002) 
although their formation (with the exception of HLA-G) has not been fully investigated. 
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Recognition of HLA-B27 by CD4+ T cells 
 
As discussed, evidence suggests that CD4+ T cells rather than CD8+ T cells are involved 
in the disease process.  Transgenic rat studies have shown that there is a T cell 
requirement for disease onset but that CD4+ rather than CD8+ T cells are most important 
(Breban et al., 1996) and depletion in rats of CD8+ αβ T cells had no effect on disease 
progression (May et al., 2003).  However, Khare et al, show that in transgenic mice, 
MHC class II molecules are not required for disease onset (Khare et al., 1998) suggesting 
an unconventional role for CD4+ T cells in this model.   
 
In 2001 Boyle et al. demonstrated that CD4+ T cells isolated from AS patients could 
recognise HLA-B27 (Boyle et al., 2001), and in a review in 2004 postulated that 
abnormal forms of HLA-B27 are recognised by these CD4+ T cells maintaining 
inflammation due to this continual recognition (Boyle et al., 2004).  Supporting this 
theory, it has been shown that cytotoxic CD4+CD28- T-lymphocytes are enhanced in the 
peripheral circulation of AS patients compared with healthy controls (Duftner et al., 
2003). 
 
Auto-display of residues 169-181 
 
In 2004 Guptasarma and Singh proposed a novel theory whereby HLA-B27 heavy chain 
devoid of β2m could rearrange to auto-display residues 169-181 (Luthra-Guptasarma and 
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Singh, 2004).  They propose that these hugely misfolded heavy chains could associate 
with other heavy chains to form homodimers and multimers.  This idea links together two 
of the biggest theories surrounding HLA-B27 and its association with 
spondyloartropathies; heavy chain misfolding, and the arthritogenic peptide hypothesis. 
 
A β2m Deposition Disease 
 
A further theory has been proposed suggesting that the pathogenesis of AS occurs as a 
result of β2m dissociation from peptide-complexed, surface-expressed HLA-B27 
molecules (Uchanska-Ziegler and Ziegler, 2003).  This hypothesis suggests that β2m 
dissociates from fully folded HLA-B27 molecules at a higher rate than non-disease-
associated subtypes. This β2m can accumulate and become trapped in synovia.  Here β2m 
can bind to collagen, form amyloid deposits or interact with synovial fibroblasts, 
inducing the synthesis and secretion of proteins involved in tissue destruction.  This 
process would result in local inflammation that in turn leads to an up-regulation of class I 
molecules, increasing the release of β2m, resulting in chronic inflammation. However, 
Vázquez and López de Castro have shown that HLA-B27 subtypes differentially 
associated with AS are similar in their extent of β2m dissociation providing evidence 
against this hypothesis (Vazquez and Lopez de Castro, 2005). 
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Non HLA-B27 Contributions to Disease 
 
HLA-B27 is the strongest pre-disposing factor for AS but only a small fraction of HLA-
B27 positive individuals actually develop disease.  There is evidence supporting other 
genetic-susceptibility factors as the principal determinants for which HLA-B27+ 
individuals will go on to develop AS. 
 
To date there are four non-MHC genes that have been strongly linked to the heritable 
susceptibility of AS.  The first gene to have replicated association with AS was CYP2D6 
(cytochrome P450 gene debrisoquine 4-hydroxylase) (Beyeler et al., 1996, Brown et al., 
2000).  This gene, encoded on the long arm of chromosome 22, produces an enzyme 
involved in oxidative drug metabolism and loss of function has been associated with AS.  
It has been suggested that this gene may be involved in disease onset if the environmental 
trigger for AS is a natural toxin, its metabolism and therefore removal, maybe reduced if 
this enzyme is defective.  
 
The second gene loci to be implicated in AS was the long arm of chromosome 2, a region 
that corresponds to the IL-1 gene cluster (Brown et al., 1998a, Laval et al., 2001).  In 
particular, polymorphisms within the interleukin 1 receptor gene (IL-1RN) have 
repeatedly been shown to be associated with AS (McGarry et al., 2001, van der Paardt et 
al., 2002, Maksymowych et al., 2003, Chou et al., 2006, Agrawal et al., 2008).  The IL-
1RN gene encodes an anti-inflammatory non-signalling molecule that competes for 
receptor binding with IL-1α and IL-1β.  A commercial interleukin 1 receptor antagonist, 
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Anakinra, is currently used in the treatment of rheumatoid arthritis but has been shown in 
some cases to improve the symptoms of AS (Tan et al., 2004, Haibel et al., 2005) 
 
More recently two other genes were identified as conveying an increased risk of AS, 
ARTS1/ERAP1 (aminopeptidase regulator of TNFR1 shedding/endoplasmic reticulum 
aminopeptidase 1) and IL23R (interleukin-23 receptor) (Burton et al., 2007).  
ARTS1/ERAP1 has diverse functions, it is involved in the trimming of peptides in the ER 
for presentation by MHC class I molecules (Saveanu et al., 2005a), and also in the 
cleavage of cell surface receptors of the pro-inflammatory cytokines TNF, IL-1 and IL-6 
(Cui et al., 2002, Cui et al., 2003b, Cui et al., 2003a).  Defects, or alterations, in either of 
these functions have obvious possible consequences relating to the pathogenesis of SpA. 
 
A polymorphism in the IL23R gene has previously been associated with inflammatory 
bowel disease and psoriasis (Duerr et al., 2006, Cargill et al., 2007) and a new study 
indicates that the same polymorphism is involved in AS (Rahman et al., 2008).  IL-23 is a 
key cytokine in the regulation of the newly defined effector T-cell subset, Th17.  These 
cells are potent promoters of tissue inflammation and are important in both protective and 
pathological roles during inflammation (Kurts, 2008, Ouyang et al., 2008).   
 
Th17 cells produce the cytokine IL-17, which has been strongly implicated in the 
pathogenesis of Rheumatoid arthritis (Lubberts, 2008).  A recent study has found 
increased numbers of Th17 cells in AS and psoriatic arthritis patients, suggesting Th17 
cells may also be involved in SpA (Jandus et al., 2008).  To this regard it is interesting to 
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note that Th17 cells are believed to be important in the immune response to extracellular 
pathogens, of particular interest, considering its association with AS, is the fact that IL-17 
is important in the response to Klebsiella pnuemoniae infection (Happel et al., 2003).  
The exact role played by Th17 cells in AS and other SpA has not yet been elucidated but 
continuing research into this area is likely to be important in the coming years.  
 
There is no doubt that the spondyloarthropathies are multifactoral diseases with both 
genetic and environmental influences.  The association of HLA-B27 and AS remains one 
of the strongest links between the MHC and disease.  A complete understanding of why 
HLA-B27 is so strongly associated with spondyloarthropathies, in particular AS, will 
probably only occur by also understanding the detailed molecular properties of this allele 
and how these relate to both its canonical and non-canonical functions, as well as 
continuing to study other non-HLA-B27 susceptibility factors.   
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HLA-B27 and Exosomes 
 
As part of this study we have investigated whether HLA-B27 homodimers, implicated in 
the pathogenesis of AS and other SpA, are present in immunomodulatory vesicles known 
as exosomes. 
 
Exosomes – An Overview 
 
Exosomes were first discovered through reticulocyte maturation studies and were 
believed to be a method of modulating membrane function by removing unnecessary 
material from the cell (Johnstone et al., 1987).  Since their initial discovery, exosomes 
remained in relative obscurity until 1996 when Raposo et al. showed that exosomes 
released from B-lymphocytes carry functional MHC molecules and have the ability to 
stimulate specific T cell responses in vitro (Raposo et al., 1996).  Since this report was 
published the interest in exosomes has increased dramatically, and exosomes have now 
been isolated from many different cell types including; reticulocytes (Johnstone et al., 
1987), B- and T-lymphocytes (Raposo et al., 1996, Blanchard et al., 2002), dendritic cells 
(Zitvogel et al., 1998), mast cells (Raposo et al., 1997), intestinal epithelial cells (van 
Niel et al., 2001), the placenta (Taylor et al., 2006) and tumour cells (Wolfers et al., 
2001).  Exosomes have also been purified from human plasma (Caby et al., 2005), breast 
milk (Admyre et al., 2007b), malignant effusions (Andre et al., 2002), bronchoalveolar 
lavage (Admyre et al., 2003) and urine (Pisitkun et al., 2004).  However, the in vivo 
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function of exosomes still remains poorly defined and work attempting to fully determine 
how and why these vesicles are formed is ongoing.  Nevertheless, they are the subject of 
great interest for their potential role as ‘cell-free’ vaccine agents. 
 
Exosomes are small membrane bound vesicles 40-150 nm in diameter, formed by inward 
budding of endosomes, resulting in the generation of multivesicular bodies (MVB) (Pan 
et al., 1985).  They are involved in intercellular communication through direct signalling 
(Admyre et al., 2006, Hwang et al., 2003), or through the exchange of proteins (Andre et 
al., 2004), and mRNA (Valadi et al., 2007) between cells.  Exosomes have also been 
implicated in several disease processes (Admyre et al., 2007a, Gould et al., 2003, Fevrier 
et al., 2004), and can be immunostimulatory as well as immunosuppressive, and are 
therefore an extremely important cell-free system that can be manipulated to alter the 
course of the immune response (Kim et al., 2005, Prado et al., 2008). 
 
The isolation of exosomes from biological fluids demonstrates that exosomes are 
produced in vivo (Admyre et al., 2007b, Caby et al., 2005, Admyre et al., 2003, Andre et 
al., 2002, Pisitkun et al., 2004), and the isolation of exosomes from human plasma 
suggests that the blood could act as a physiological fluid for exosome transport, allowing 
exosomes to reach distant targets (Caby et al., 2005).  Indeed, exosomes express CD55 
and CD59, proteins that protect them from complement-mediated lysis, and the physical 
properties of exosomal membranes make them resistant to enzymatic degradation in the 
circulation (Clayton et al., 2003, Laulagnier et al., 2004). 
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Morphology and Lipid Composition 
 
As previously mentioned, exosomes are 40–150 nm in diameter.  They have been shown 
to have a ‘cup’ shaped morphology when imaged using electron microscopy.  It has been 
suggested that this morphology is due to the imaging technique, (Fevrier and Raposo, 
2004), however this structure under electron microscopy has become one of the defining 
characteristics of exosomes.   
 
The lipid composition of exosomal membranes has been reported to be different 
depending on the cell of origin (Vidal et al., 1989, Laulagnier et al., 2004, Wubbolts et 
al., 2003).  Exosomes from B-lymphocytes are enriched in cholesterol, sphingomyelin 
and the glycolipid GM3 and are relatively poor in phosphatidylcholine and 
phosphatidylserine (Wubbolts et al., 2003).  The lipids that are enriched in exosomes are 
characteristic of DRM (detergent-resistant membrames) or raft domains (Ikonen, 2001) 
and consistent with these raft-like properties, the raft-proteins flotillin, stomatin, and lyn 
have been identified in exosomes prepared from reticulocytes, erytholeukeamic cells and 
lymphoblastoid cells (Savina et al., 2002, de Gassart et al., 2003).  DRM, or raft domains, 
may also be important in the segregation of proteins that are destined for exosomes at the 
limiting membrane of the MVB (Wubbolts et al., 2003) and the lipid composition of 
exosomes may also help to prevent exosome degradation when released from the 
originating cell (Laulagnier et al., 2004).   
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Formation and Sorting 
 
Exosomes form via inward budding of the limiting membrane of the endosome, forming 
multivesicular bodies (MVB) (Pan et al., 1985), but they are not simply smaller versions 
of the cell, with the lipid and protein composition of exosomes being different from the 
plasma membrane (Wubbolts et al., 2003, Laulagnier et al., 2004).  The protein 
composition of exosomes has been extensively studied and several tables of proteins 
found in exosomes have been published (Mignot et al., 2006, Wubbolts et al., 2003, 
Thery et al., 2002b, Chaput et al., 2006).  The most abundant type of proteins found on 
exosomes are the tetraspanin family proteins, whilst ER or nuclear resident proteins are 
typically not found within exosomes.   
 
As well as some common proteins, exosomes also bear a selected subset of proteins that 
is dependent on the cell they originate from.  How this selective incorporation is achieved 
is not yet fully understood.   
 
Several mechanisms for the targeting of proteins to MVBs have been proposed.  For 
example, there is evidence that molecular clustering of either proteins or lipids within the 
endosome membrane acts as a sorting signal for targeting to exosomes (Vidal et al., 1997, 
Geminard et al., 2001).  As previously mentioned, DRM or raft domains, may also be 
important in the segregation of proteins that are destined for exosomes at the limiting 
membrane of the MVB, particularly domains containing high amounts of sphingolipids 
which can form ceramide (Wubbolts et al., 2003, Trajkovic et al., 2008).   
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Monoubiquitination has also been indicated in the targeting of proteins to exosomes, by 
re-directing proteins from a default pathway that recycles them back to the plasma 
membrane to the MVB sorting pathway (Katzmann et al., 2001, Reggiori and Pelham, 
2001, Urbanowski and Piper, 2001).  Monoubiquitinated proteins interact with the 
endosomal sorting complex required for transport (ESCRT) complexes and are targeted 
to MVB.   
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Figure 1. 11:  Schematic diagram of exosomes formation and release.  Exosomes are 
formed via inward budding of the limiting membrane of the endosome, forming 
multivesicular bodies (MVB).  MVB can either, fuse with lysosomes and undergo 
degradation, or they can fuse with the plasma membrane releasing exosomes into the 
extracellular environment. 
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ESCRT Pathway 
 
The ESCRT pathway is conserved from yeast to humans and shows relatively few 
species-specific changes, therefore yeast nomenclature is used here throughout with the 
human homologue shown in brackets.  Monoubiquitinated cargo first interacts with the 
Vps27-Hse1-complex (HRS-STAM1/STAM2) through ubiquitin interacting motifs 
(UIM) (Bilodeau et al., 2002).  A FYVE domain in the Vps27 component targets the 
Vps27-Hse1-complex to the endosomal membrane, this domain consists of a compact 60 
amino acid Zn2+ finger that selectively binds to phosphatidylinositol-3-phosphate 
(PI(3)P), a lipid enriched in the membrane of the endosome, in preference to all other 
phosphoinositides (Misra and Hurley, 1999, Burd and Emr, 1998, Stahelin et al., 2002).  
Vps27 also contains a binding motif that recruits the first of the ESCRT complexes – 
ESCRT I (Bache et al., 2003, Katzmann et al., 2003). 
 
ESCRT I is a soluble heterotetrameric complex consisting of Vps23 (Tsg101), Vps28 
(VPS28), Vps37 (VPS37 A-D) and Mvb12 (MVB12) (Babst et al., 2000, Katzmann et 
al., 2001, Curtiss et al., 2007).  In yeast the C-terminal domain of the ESCRT I subunit, 
Vps28, recruits the second ESCRT complex by binding to the NZF (Np14 zinc finger) 
domain in the ESCRT II subunit, Vps36 (EAP45) (Teo et al., 2006).  However the human 
homologue, EAP45, does not contain an NZF region leaving how these complexes 
interact not fully defined (Slagsvold et al., 2005).  The ESCRT II complex consists of 
Vps22 (EAP45), Vps36 (EAP45), and Vps25 (EAP25) (Babst et al., 2002b).   
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ESCRT II transiently associates with the endosomal membrane and initiates the 
formation of ESCRT III (Babst et al., 2002b).  ESCRT III consists of soluble monomers 
that, when recruited to the endosomal membrane, form an insoluble membrane-bound 
complex, consisting of two sub-complexes made up of Vps2 (CHMP2A, B) bound to 
Vps24 (CHNP3), and Vps20 (CHMP6) bound to Vps32/Snf7 (CHMP4A, B, C) (Babst et 
al., 2002a).  Vps20 also directly binds to the Vps25 subunit of ESCRT II (Teo et al., 
2004), and in humans the ESCRT-associated protein, ALIX, connects Tsg101 of ESCRT 
I with CHMP4 of ESCRT III, linking the complexes together (Strack et al., 2003, Katoh 
et al., 2003, von Schwedler et al., 2003). 
 
Vps4 (VPS4A, B), an ESCRT associated protein, is required to catalyse dissociation of 
the ESCRT complexes in an ATP dependent manner (Babst et al., 1997, Babst et al., 
1998).  Vta1 (LIP5) is a positive regulator of Vps4 and also interacts with the accessory 
ESCRT III subunits Vps60/Mos10 (CHMP5) and Did2 (CHMP1) (Azmi et al., 2006, 
Shiflett et al., 2004, Nickerson et al., 2006).  
 
Ubiquitination is used to target proteins to the MVB, however before cargo is loaded into 
the MVB it is first deubiquitinated.  Doa4 is a deubiquitinating enzyme (DUB) that is 
targeted to the endosome membrane, the timing of which is helped by an interaction with 
the ESCRT accessory molecule Bro1 (ALIX) (Amerik et al., 2006, Luhtala and Odorizzi, 
2004).   
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Although the ESCRT complexes have important roles in MVB biogenesis it is still 
unknown how the complexes promote the invagination of the endosomal membrane.  It 
has been suggested that the lipid composition of the MVB may play a role in vesicle 
invagination, with mammalian MVBs reported to be rich in 2,2’ lysobisphosphatidic acid 
(Matsuo et al., 2004).  However the presence of this lipid has not been reported in yeast, 
and considering the high conservation of these complexes, it seems unlikely that an 
entirely different method for budding exists in yeast and mammals.  It cannot be excluded 
however, and lipid composition could be the basis of a second mechanism for MVB 
formation used by mammals. 
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Figure 1. 12:  Schematic diagram of the ESCRT machinery.  Monoubiquitinated 
proteins interact with the ESCRT complexes targeting them for inclusion into the MVB 
pathway. 
 
Exosome Target Cell Stimulation 
 
How exosomes mediate their affects in vivo is relatively poorly understood.  In vitro 
studies have suggested that exosomes can stimulate T cells directly (Admyre et al., 2006, 
Hwang et al., 2003) whilst others suggest that they work indirectly by binding to, or 
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fusing with professional antigen presenting cells (Thery et al., 2002a, Denzer et al., 
2000).  In vitro, in the absence of APCs, the expression of ICAM-1 on the surface of DC-
derived exosomes has been shown to be necessary for the binding of exosomes to the 
surface of naïve T cells (Segura et al., 2005).  Segura et al have also shown, both in vitro 
and in vivo, that the interaction between ICAM-1 on the surface of the exosomes and 
LFA-1 (CD11a/CD18) on the recipient DC is essential for exosome capture and 
presentation (Segura et al., 2007).  They propose that LFA-1 on the surface of DCs is a 
specific receptor allowing the efficient antigen transfer in vivo and demonstrate that CD8+ 
DCs, expressing high levels of LFA-1, capture exosomes more efficiently than CD8- 
DCs.   
 
Follicular dendritic cells (FDCs) are important cells in the germinal centre reaction and 
present antigen to B- and T-lymphocytes.  FDCs do not synthesize their own MHC class 
II molecules but instead passively acquire them (Gray et al., 1991).  Immunoelectron 
microscopy images have shown that MHC class II molecules, on the surface of FDCs, are 
expressed in discrete vesicles attached to the cell surface, and that these vesicles resemble 
exosomes (Denzer et al., 2000).  Indeed in vitro binding studies have shown that B cell 
derived exosomes have an increased avidity for FDCs suggesting that these cells could be 
physiological targets for exosomes in vivo (Denzer et al., 2000). 
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Immunomodulation Through Exosomes  
 
Exosomes that can exert immunotolerogenic effects are sometimes referred to as 
‘tolerosomes’.  It has been suggested that exosomes, or tolerosomes, released from the 
intestinal epithelial cells of mice are involved in inducing peripheral tolerance to non-self 
antigens (Karlsson et al., 2001).  However the opposite results were obtained in a second 
study, leaving the exact role played by intestinal epithelial exosomes undetermined (Van 
Niel et al., 2003). 
 
During pregnancy the fetus demonstrates local immune privilege, thought to be 
maintained by the placenta.  A number of reports have shown that Fas ligand (FasL) is 
expressed by trophoblast cells during pregnancy (Bamberger et al., 1997, Uckan et al., 
1997, Pongcharoen et al., 2004), however two further reports have demonstrated that 
FasL is not expressed on the cell surface but is instead packaged into small microvesicles 
that are then secreted into the extracellular space, similar to exosomes (Frangsmyr et al., 
2005, Abrahams et al., 2004).  It has since been demonstrated that placenta-derived 
exosomes are found in the circulation of pregnant women and that these exosomes do in 
fact express FasL, implicating exosomes in maintaining tolerance during pregnancy 
(Taylor et al., 2006). 
 
Furthermore, in rodent studies it has also been demonstrated that the injection of donor-
derived exosomes before, or after, transplantation can significantly prolong cardiac 
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allograft survival in fully MHC-mismatched hosts, once again suggesting exosomes can 
have a tolerogenic function (Peche et al., 2003, Peche et al., 2006). 
 
In marked contrast to the above, however, Zitvogel et al. demonstrated that tumours in 
mice could be eradicated by a single injection of exosomes, implicating exosomes in an 
immunoactivatory role (Zitvogel et al., 1998).  Following the publication of the work by 
Zitvogel et al. clinical trials in humans began.  The first phase I clinical trial was started 
in melanoma patients and shortly afterwards the second phase I clinical trail began in 
non-hodgkins lymphoma patients.  The results were promising with tumour regression or 
long-term stabilisation achieved in some patients (Morse et al., 2005, Escudier et al., 
2005). 
 
If the factors that determine whether an exosome exerts immunosuppressant or 
immunoactivatory affects can be elucidated, or if exosomes could be subject to 
modification, then the possibility of cell free vaccines becomes feasible.  Autoimmune 
diseases and cancers could potentially be treated essentially with the same tool.  To this 
effect, rodent studies have shown that periarticular injection of exosomes derived from 
BMDCs expressing viral IL-10 or recombinant murine IL-10 are able to suppress 
delayed-type hypersensitivity responses in both the injected and the contralateral joint, 
and systemic injection of IL-10 treated DC-derived exosomes in mice was able to prevent 
the onset of collagen induced arthritis (CIA) and to reduce severity in already established 
disease (Kim et al., 2005).  More recently, similar results were obtained using exosomes 
derived from dendritic cells genetically modified to express IL-4 (Kim et al., 2007). 
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Some data suggests that the effects of dendritic cell derived exosomes are dependent 
upon the maturation state of the originating DC, with exosomes derived from mature DCs 
being better stimulators of a T cell response than immature DC derived exosomes, 
possibly due to differing expression of co-stimulatory molecules (Segura et al., 2005, 
Admyre et al., 2006).  However, exosomes isolated from intestinal epithelial cells have 
been shown to induce a humoral immune response despite their distinct lack of co-
stimulatory molecules (Van Niel et al., 2003). 
 
Exosomes in Disease 
 
In order for cancer to develop, tumour cells modulate their environment to promote their 
expansion and survival.  Since the demonstration by Zitvogel et al. that dendritic cell 
derived exosomes bearing tumour antigens can eradicate developed tumours in mice, the 
role of exosomes in cancer has been studied in great detail (Zitvogel et al., 1998).  
However, it now appears that tumour cells can modulate their exosome release to actually 
help promote growth and survival.  To this regard exosomes released from tumours have 
been shown to express FasL and TRAIL (tumour necrosis factor-related apoptosis-
inducing ligand), molecules that stimulate T cell apoptosis, as well as DEL-1 
(developmental endothelial locus-1), which can act as a strong angiogenic factor, and 
HLA-G, a non-classical MHC class I molecule that promotes immune tolerance (Riteau 
et al., 2003, Huber et al., 2005, Hegmans et al., 2004).  Tumour derived exosomes can 
also impair monocyte differentiation into dendritic cells, promoting instead the 
development of a myeloid immunosuppressive cell subset (Valenti et al., 2006), and 
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studies in drug-resistant human ovarian carcinoma cells suggest that the release of 
exosomes from tumour cells may potentially be a mechanism for drug-expulsion and 
chemoresistance (Shedden et al., 2003). 
 
Exosomes have also been implicated in prion diseases, infectious neurodegenerative 
diseases caused by the accumulation of the abnormally folded prion protein scrapie 
(PrPscr).  The mechanism by which PrPscr disseminates from the point of infection is 
unclear.  Exosomes have been isolated that contain regular cellular prion protein (PrPc) 
and infectious PrPscr before and after infection with sheep prions respectively, and 
following intracerebral inoculation of mice with PrPscr exosomes, disease development 
ensued (Fevrier et al., 2004).  A further study has demonstrated that PrPc is released in 
exosomes from activated platelets, suggesting that exosomes released into the blood 
stream could be a novel mechanism for prion disease transmission from the site of 
peripheral exposure (Robertson et al., 2006). 
 
A recent in vitro study showing that B cell derived exosomes can present allergen-
derived peptides and stimulate allergen-specific T cells to proliferate and release 
cytokines has also implicated exosomes in allergy (Admyre et al., 2007a).  These authors 
suggest that exosomes may help to potentiate an allergic response.  In the future, 
modulation of exosomes to alter their affects may potentially lead to a new treatment in 
the management of allergic disease, and a very recent publication demonstrates that, in 
mice, intranasal treatment with tolerogenic exosomes prior to sensitisation/challenge 
resulted in sustained tolerance to the antigenic allergen (Prado et al., 2008).  
 84 
In 2003, The Trojan Exosome hypothesis was postulated, suggesting that retroviruses 
have evolved to exploit the exosome pathway in order to generate retroviral particles 
(Gould et al., 2003), and shortly afterwards the first evidence demonstrating HIV budding 
through the exosome pathway was published (Nguyen et al., 2003).  However, although 
this theory can potentially explain several aspects of retroviral biology, two recent reports 
claiming that exosomes and retroviral particles are distinct entities has shed some doubt 
on the theory (Coren et al., 2008, Cantin et al., 2008), and mean that the Trojan Exosome 
hypothesis remains as yet unproven. 
 
A further novel role for exosomes in immunosurveillance has also recently been 
suggested.  Exosomes released from cells infected with an intracellular pathogen can 
stimulate macrophage activation both in vitro and in vivo, suggesting that exosomes may 
serve an important part in activating an immune response against intracellular pathogens 
(Bhatnagar et al., 2007).  
 
The above examples demonstrate the diverse effects that have so far been attributed to 
exosomes.  Exosomes can be tolerogenic, or activatory, as well as be involved in 
immunosurveillance and disease.  They are currently being investigated as an attractive 
cell-free therapy against tumors, and if exosomes can be used to induce immune 
suppression, they may provide attractive agents in the fight against autoimmunity, 
inflammatory diseases and even allergy.  However, as exosomes have been shown to 
have roles in both eliciting and suppressing the immune response any use of exosomes in 
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vivo would have to be carefully considered and further research to determine what factors 
influence the function of different exosomes is necessary. 
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Chapter II: Materials and Methods 
 
General 
 
Unless otherwise stated all chemicals were obtained from either Sigma or BDH.  
Materials obtained from elsewhere are indicated in the text.  A list of supplier addresses 
can be found at the end of the chapter. 
 
In vitro Cell Culture 
 
Cell Lines and Media 
 
Table 2.1 describes the various cell lines used in this study.  Aspects of the antigen 
presentation pathways that are mutated or absent, and HLA expression (when 
determined) are also detailed. 
 
All cell lines were routinely grown in either DMEM (Dulbecco’s Modified Eagle’s 
Medium), RPMI (RPMI-1640) or IMDM (Iscoves Modified Dulbecco’s Medium), 
supplemented with FBS (Foetal Bovine Serum) and kanamyicin sulfate (all Invitrogen). 
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Cell Line 
 
 
Origin 
 
HLA Expression and Mutations to the Antigen Presentation pathway 
 
 
Culture Media 
HeLa Derived from human 
cervical carcinoma.  
ECACC 93021013. 
  DMEM + 10 % FBS+ 
0.1 mg/ml kanamycin 
C58 Rat thymic 
lymphoma cell line. 
(Silva et al., 1983) 
 
721.220 Human 
lymphoblastoid cell 
line. 
.220 cells lack HLA-A, HLA-B and functional tapasin.  HLA-C 
remains intact on one chromosome resulting in low expression of 
HLA-Cw1 (Greenwood et al., 1994, Copeman et al., 1998) 
HOM-2 Human EBV-
transformed B cell 
line.   
ECACC 98092902. 
HLA-A302, HLA-B2705, HLA-Cw1 
Jesthom Human EBV-
transformed B cell 
line.   
ECACC 88052004. 
HLA-A202, HLA-B2705, and HLA-Cw1. 
 
 
 
 
RPMI + 5 % FBS + 
0.1 mg/ml kanamycin 
KG1 Human dendritic-like 
cell line. 
ATCC CCl-246. 
HLA-A30, HLA-A31, HLA-B35 and HLA-Cw4. 
 
IMDM + 20 % FBS + 
0.1 mg/ml kanamycin 
HEK293 Human embryonic 
kidney cell line. 
ATCC CRL-1573 
 DMEM + 10 % FBS+ 
0.1 mg/ml kanamycin 
Table 2.1: Details of cell lines used in this study.  HLA-expression is indicated, this information was obtained from ECACC or 
ATCC unless otherwise referenced.  Details of components of the antigen presentation pathway that are absent or mutated are also 
listed.
 88 
Cell Propagation 
 
Cells were routinely maintained at 37 °C in a humidified atmosphere of 5 % CO2 in air, 
in medium supplemented with FBS and kanamycin sulfate.  All tissue culture procedures 
were performed in a class 2 containment cabinet. 
 
Suspension cultures were routinely passaged by 1:1 dilution with fresh medium.  
Confluent adherent cultures were washed once with 0.5 % trypsin EDTA (ethylene 
diamine tetraacetic acid) in Hank’s balanced salt solution (Invitrogen) before being 
incubated in 300 µl of the trypsin EDTA solution for 5 minutes to disrupt the cellular 
monolayer, trypsin was then neutralised with 1 ml of the appropriate medium before 
passaging.   
 
All plastic plates and flasks used for cell culture were obtained from VWR. 
 
Cell Counting 
 
Cell viability and proliferation were assessed by trypan blue assay (0.4 %) (Sigma) and 
counted either using a haemocytometer or a Z1 Coulter® Particle Counter (Beckman 
Coulter). 
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Transfection of non-adherent cells using Electroporation  
 
In all instances the plasmid vector containing the gene of interest was pCR3 (Invitrogen).  
Some of the recombinant proteins were C-terminally tagged with SV5 (a 14 amino acid 
tag with sequence GKPIPNPLLGLDST) allowing isolation and detection with the 
antibody pk (Hanke et al., 1992). 
 
Transient and stable transfectants of the 721.220 cell line were created using the Amaxa 
Nucleofactor system (Amaxa).  1 x 106 – 5 x 106 cells were resuspended in 100 µl RPMI 
and mixed with 1 µg of DNA before being transferred to an Amaxa cuvette.  Cells were 
electroporated using Amaxa program A-24 before being transferred to 1 ml of pre-
warmed medium. For transient transfections the cells were harvested 24 hours after 
transfection.  For stable transfectants the cells were put into selective medium containing 
1 mg/ml G418 (Geneticin) (Melford) 24 hours after transfection.  Where required, 
dilution cloning was used to isolate 100 % positive cultures. 
 
Lipid Transfection of adherent cells 
 
Stable and transient transfectants were created using FuGENE 6 (Roche).  In all instances 
the plasmid vector containing the gene of interest was pCR3 or pCDNA3 (Invitrogen).  
Some of the genes were C-terminally tagged, allowing isolation and detection with the 
antibody pk. 
 90 
For all transfections, 1 µg of plasmid DNA was added to 100 µl of DMEM (without 
serum), and gently mixed before 3 µl of FuGENE 6 was added.  The DMEM, DNA and 
FuGENE 6 was again tapped gently to mix and then left at room temperature for 10 
minutes.  Following this, the mixture was added dropwise to a semi- confluent well of 
cells. 
 
For transient transfections the cells were harvested 24 hours after transfection.  For stable 
transfectants the cells were put into selective medium, containing 1 mg/ml G418, 24 
hours after transfection.  If necessary, positive cultures were enriched using magnetic 
beads and/or dilution cloning.   
 
Enrichment of Cultures using Magnetic Beads 
 
Magnetic beads expressing sheep anti-mouse IgG (Dynabeads®, Dynal Biotech) were 
used to separate positively transfected cells.  Cell cultures were incubated with 0.01 % of 
antibody in medium for 10 minutes on ice.  Cells were then washed in filter sterile PBS 
(phosphate buffered saline) (136 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO42H2O, 1.5 
mM KH2PO4) + 0.1 % BSA (bovine serum albumin) (Sigma) and subject to 300 x g 
centrifugation for 8 minutes.  The supernatant was discarded and cells were resuspended 
in PBS  + 0.1 % BSA.  Following the addition of magnetic beads samples were incubated 
on ice for 20 minutes with gentle agitation to ensure the beads did not settle.  Positive 
cells bound to the beads were recovered using a magnet and washed 4 times using PBS + 
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0.1 % BSA.  The bound cells were resuspended in medium and transferred to a fresh 
culture well.  Cells were washed daily with medium until all beads were removed. 
 
Dilution Cloning 
 
100 µl of selective medium (1 mg/ml G418 in DMEM/RPMI) was added to each well of 
a 96 well plate.  Approximately 0.5 – 1 x 105 cells were resuspended in 100 µl of medium 
and added to the top left hand well.  A 1:1 dilution was carried out down the first column 
of wells and then a further 1:1 dilution across each row.  Wells that produced a single 
colony were selected and grown.  Positive colonies were assessed by flow cytometry and 
SDS-PAGE (polyacrylamide gel electrophoresis). 
 
Cell Freezing and Thawing 
 
Cell lines were suspended in chilled freeze medium (90 % FBS + 10 % DMSO (dimethyl 
sulfoxide)) (Sigma) and frozen to -80 °C using an isopropanol-filled cryo-freezing 
container (Nalgene) to control the freezing rate.  After 24 hours cells were transferred 
into liquid nitrogen storage.  When thawing, cells were warmed in a waterbath at 37 °C 
and immediately resuspended in the appropriate medium.  Cells were plated and returned 
to the incubator for approximately 6 hours after which the medium was changed.  
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KG1 Stimulation 
 
KG1 cells were differentiated/matured with 10 ng/ml phorbyl-12-myristate-13-acetate 
(PMA) (Sigma) and 100 ng/ml ionomycin (Sigma) for 24-48 hours. 
 
Treatment with Chloroquine 
 
Cells were incubated in medium supplemented with 100 µM chloroquine (Sigma) for 24 
hours, at 37 °C in a humidified atmosphere of 5 % CO2 in air, before harvesting.  Cell 
lysates or immunoprecipitations were analysed by SDS-PAGE and western blotting. 
 
Treatment with Diamide 
 
Cells were incubated in medium supplemented with varying concentrations of diamide 
(10 µM, 100 µM, 250 µM, 500 µM or 1 mM) and incubated on a heating block at 37 °C 
for 10 minutes before harvesting.  Cell lysates were analysed by SDS-PAGE and western 
blotting. 
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Biochemistry Techniques 
 
Cell Lysis 
 
0.5 x 106 - 5 x 106 cells were usually lysed using 50-500 µl of lysis buffer (10 mM Tris 
pH 7.6, 130 mM NaCl, 1 % NP40 (Nonidet P-40) (Sigma), 10 mM NEM (N-
ethylmaleimide) and 1 mM PMSF (phenylmethylsulfonyl fluoride)) on ice for 30 
minutes.  Nuclear and cellular debris were removed by centrifugation at 14,000 rpm 
(20,000 x g) at 4 °C for 10 minutes. 
 
Whole cell lysates containg the nuclear material were prepared by washing cells twice 
with PBS before resuspending in approximately 100-300 µl of sample buffer.  Samples 
were passed through a fine gauge syringe five times to shear DNA before heating at 90 
°C for 2 minutes.  
 
Protein Quantification 
 
Protein concentrations were determined using the Bradford method.  Briefly, a standard 
curve was set up using known concentrations of BSA (0-8 µg/ml).  Sample 
measurements were taken at a wavelength of 595 nm on a spectrophotometer. 
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SDS-PAGE 
 
Protein samples were resuspended in SDS sample buffer (2 % SDS, 20 % glycerol, 0.05 
% bromophenol blue, 0.5 M Tris pH 6.8) with or without reducing agent, dithiothreitol 
(DTT) (100 mM) and denatured by heating at 90°C for 2 minutes.  Proteins were 
resolved in 8 % SDS acrylamide gels unless specified.  Electrophoresis was carried out 
using Biorad mini-Protean II electrophoresis equipment (Biorad) in Tris/glycine (25 mM 
Tris, 192 mM glycine, 0.1 % SDS) running buffer for 15 minutes at 100 V followed by 
approximately 45 minutes at 150 V or until the dye front reached the bottom of the gel.  
 
 95 
 
8 % Resolving Gel Stacking Gel 
H20 (ml) 4.6 H20 (ml) 2.1 
30 % 37.5:1 acrylamide: 
bisacrylamide (ml) 
(Thistle Scientific) 
2.7 30 % 37.5:1 acrylamide: 
bisacrylamide (ml) 
0.5 
1.5 M Tris pH 8.8 (ml) 2.5 0.5 M Tris pH 6.8 (ml) 0.38 
10 % SDS (µl) 100 10 % SDS (µl) 30 
10 % APS (µl) 100 10 % APS (µl) 30 
TEMED (µl) 6 TEMED (µl) 3 
 
Table 2.2: 8 % SDS-PAGE resolving gel and stacking gel components. 
 
Two-Dimensional Gel Electrophoresis 
 
2D gel electophoresis allows the separation of proteins according to charge in the first 
dimension and molecular weight in the second dimension.  The first dimension, 
isoelectric focusing (IEF), was carried out in single gel tubes using the Bio-Rad mini-
Protean II IEF apparatus (Bio-Rad).  A pH gradient was set up and maintained by an 
alkaline buffer (20 mM NaOH) in the upper chamber and an acidic buffer (10 mM 
H3PO4) in the lower chamber.  Sample lysates were prepared in 2D-non-reducing sample 
buffer (9.5 M urea, 2 % Triton X-100, 1.6 % Bio-Lyte 5/7 ampholyte, 0.4 % 3/10 
ampolyte) and ran at a constant voltage of 500 V for 4 hours or until the dye front 
reached the bottom of the gel tube.  When the first dimension was complete, the gel was 
gently removed from the glass tube, loaded on to an 8 % SDS-PAGE gel and covered in 
200 µl of SDS sample buffer without reducing agent (2 % SDS, 20 % glycerol, 0.05 % 
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bromophenol blue, 0.5 M Tris pH 6.8).  The second dimension was run at a constant 
voltage of 50 V in a Tris/glycine buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS) for 
25 minutes, or until the dye front had passed from the stacking gel into the resolving gel, 
and then at a constant voltage of 150 V for 45 minutes, or until the dye front reached the 
bottom of the gel.  2D gels were then subject to western blotting. 
 
First dimension IEF gel 
Urea 92 M 5 g 
30 % 37.5:1 acrylamide: 
bisacrylamide 
4 % 1.33 ml 
NP40 2 % 2 ml 10 % NP40 
Bio-Lyte 3/10 ampholyte 2 % 0.5 ml 
APS 0.02 % 20 µl 
TEMED 0.1 % 10 µl 
H2O  1.97 ml 
 
Table 2.3: First dimension IEF gel components. 
 
Western Blot 
 
Protein samples resolved by SDS-PAGE were transferred onto nitrocellulose membranes 
(Whatman, Protran (VWR)) for 30 – 60 minutes at 100 V in a Tris/glycine buffer (25 
mM Tris, 192 mM glycine).  Protein transfer was quickly assessed using the non-
permanent protein stain, Ponceau S (0.1% Ponceau S in 5% acetic acid).  Membranes 
were briefly washed in PBS containing 0.1% Tween 20 (PBST) before being blocked in 
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blocking buffer (PBST + 5% (w/v) skimmed milk powder) for 30 minutes.  Primary 
antibody was diluted into PBST and incubated with the membrane for 1 hour at room 
temperature unless specified.  Membranes were given three 10 minute washes with PBST 
and then if necessary membranes were incubated with the appropriate peroxidase-
conjugated secondary antibody diluted in PBST.  Membranes were then given three 
further 10 minute washes with PBST.  Antibody binding was visualised using ECL 
(enhanced chemiluminescence) reagent (Supersignal Femto substrate (Pierce) or 
Immobilion western HRP substrate (Millipore)) and either exposure to film (Sigma) or 
using the Fujifilm Intelligent Dark Box LAS-3000 (FUJIFILM). Band intensity 
measurements were carried out using Aida Image Analyzer software. 
 
Antibodies 
 
Primary antibodies used for this work are listed in Table 2.4. 
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Antibody Specificity Species Source 
HC10 Detects an epitope in the α1 domain of unfolded HLA-B and -
C heavy chains not associated with β2m (Stam et al., 1986).  
Mouse 
ME1 A conformation dependent antibody that detects an epitope in 
the α1 domain of multiple HLA-B alleles including HLA-
B27, -B7, -B42, -B36, -and –Bw22 (Ellis et al., 1982). 
Mouse 
W6/32 A conformation-dependent antibody that detects an epitope in 
the α2 domain of most B2m-associated HLA-A, HLA-B and 
HLA-C molecules (Barnstable et al., 1978). 
Mouse 
BB7.2 A confirmation dependent antibody that detects folded human 
HLA-A2 (Parham and Brodsky, 1981). 
Mouse 
 
 
 
Hybridoma culture  
supernatants. 
pk  Detects the 14 amino acid tag, SV5 (GKPIPNPLLGLDST), 
derived from a small epitope on the P and V proteins of the 
paramyxovirus of simian virus 5 (Hanke et al., 1992). 
Mouse Gift from Professor Rick 
Randell (St Andrews). 
HCA2 Preferentially detects free HLA-A class I heavy chains (Stam 
et al., 1990). 
Mouse Gift from Professor Jacques 
Neefjes (Amsterdam). 
FITC-B27 A conformation-dependent antibody that labels HLA-B27. Mouse One Lamba Inc. 
ERp57 Recognises human ERp57. Rabbit Gift from N. Bulleid 
(Manchester, UK) 
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Antibody Specificity Isotype Source 
148.3 Recognises human TAP (transporter associated with antigen 
processing).  
Mouse Gift from Professor Robert 
Tampe, Germany. 
Anti-human 
tapasin (Giles) 
Recognises human Tapasin. Rabbit Gift from T. Elliot 
(Southampton, UK) 
GILT Recognises precursor and mature chain GILT of mouse, rat 
and human origin. 
Goat Santa Cruz 
CD48 Recognises mouse, rat and human CD48. Mouse Santa Cruz 
BiP Recognises the C-terminus of mouse, rat and human BiP. Rabbit Santa Cruz 
Anti-Flag Recognises the Flag epitope. Mouse Sigma 
β-actin N-terminal peptide of β-actin. Mouse Sigma 
Alix Detects full-length Alix Mouse Santa Cruz 
PDI Recognises human PDI (protein disulphide isomerase.) Rabbit Stressgen 
Syntaxin Recognises human syntaxin 4 aa 1-280 Mouse Gift from Professor Simon 
Guild (St Andrews, UK) 
Vimentin Recognises human vimentin Rabbit Gift from Professor Simon 
Guild (St Andrews, UK) 
 
Table 2.4: Primary antibodies used throughout this study.  The specificity, species of origin and source of antibodies used in this 
study are detailed above. 
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Simply Blue Safe Stain 
 
SDS-PAGE gels were washed three times for 5 minutes in distilled water to remove any 
excess SDS.  Gels were covered with Simply Blue Safe Stain (Invitrogen) and incubated 
with agitation for 30 minutes.  Gels were then destained in repeated changes of distilled 
water.  If necessary, gels were stained once more and destained again. 
 
Immunoprecipitation 
 
Cell lysates that had been subject to centrifugation at 14,000 rpm (20,000 x g) were then 
pre-cleared with 20 µl protein-G-sepharose beads with rotation at 4 °C for 35 minutes.  
Samples were then immunoprecipitated using 20 µl protein-G beads and antibody at 4 °C 
for 1 hour.  Beads were washed three times with lysis buffer before being resuspended in 
non-reducing sample buffer.  Samples were heated at 90°C to elute antibody-antigen 
complexes from the beads.  Samples were analysed by SDS-PAGE and western blotting.  
 
Pulse-Chase Analysis 
 
Cells were starved in methionine-free RPMI for 15 minutes at 37 °C.  After this time 3.7 
MBq [35S] methionine (MP Biomedicals) was added, samples were vortexed to ensure 
proper mixing before being incubated at 37 °C for 15 minutes.  Labelling was stopped by 
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pelleting the cells and resuspending in medium containing cold methionine.  An aliquot 
was removed and kept on ice (time point zero).  The rest of the sample was returned to 37 
°C.  After 30 and 90 minutes equal aliquots of cells were removed.  Cell pellets were 
resuspended in lysis buffer and immunoprecipitations were performed. 
 
Endoglycosidase H Digestion 
 
Following immunoprecipitation, samples, in 20 µl of lysis buffer, were treated with 1 mU 
Endoglycosidase H (Roche) at 37 °C for 30 minutes before being resuspended in 20 µl 
reducing sample buffer.  Samples were resolved by SDS-PAGE. 
 
Fixing and Developing Radioactive Gels 
 
Gels were fixed in 30 % methanol and 10 % glacial acetic acid (GAA) for 10 minutes 
before being dried (Bio-Rad vacuum gel dryer).  Dried gels were exposed to x-ray film 
(Sigma) for 24 hours up to 7 days at -80 °C in a cassette with intensifying screens.  For 
some exposures Kodak BioMax MS film was used (Sigma). 
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Biotinylation with Streptavidin Pull-Down 
 
Approximately 5-10 x 106 cells were washed 3 times in PBS before being resuspended in 
10 mM NEM on ice for 10 minutes.  Cells were pelleted and washed once in PBS before 
being incubated with 0.1 mg/ml EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in PBS on ice 
for 10 minutes.  Cell pellets were resuspended in TBS + 5 % FCS and kept on ice for a 
further 10 minutes in order to quench any free biotin.  Cell pellets were washed twice in 
TBS before cell lysis. 
 
Cell lysates were subject to 14,000 rpm (20,000 x g) centrifugation at 4°C to remove 
cellular and nuclear debris.  The remaining lysate was pre-cleared with 20µl of protein G 
beads for 25 minutes with rotation at 4 °C.  Samples were then spun at 14000 rpm 
(20,000 x g) at 4 °C for 4 minutes, the pre-cleared lysate was removed and tumbled with 
20 µl Streptavidin immobilised on agarose (Fluka) for 25 minutes at 4 °C.  Beads were 
washed 3 times with PBS before being resuspended in 20 µl NRSB and heated at 90 °C 
for 2 minutes.  Samples were resolved by 8 % SDS-PAGE.  
 
Flow Cytometry 
 
On ice, cells were washed three times in PFN (PBS + 2 % FBS + 0.1 % sodium azide) 
before being stained (0.5-1 x 106 cells/condition) with appropriate antibody for 35 
minutes at 4 °C.  Cells were again washed three times to remove any unbound antibody, 
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followed, if necessary, by incubation with FITC-conjugated secondary antibody.  A 
further three washes were performed with PFN on ice before flow cytometric analysis on 
a Beckton Dickinson FACScan.  Data acquisition and analysis were performed using 
CellQuest software. 
 
Techniques Used For Exosome Analysis 
 
Isolation of Exosomes 
 
Exosomes were isolated using established procedures.  Cells were centrifuged at 1500 
rpm (1000 x g) to pellet before washing once in sterile PBS.  Cells were recultured in 5 
ml of fresh serum-free medium and returned to the incubator for 24 hours.  Cells were 
then pelleted at 1500 rpm (1000 x g) and the supernatent was subject to filtration through 
a 0.2 µm filter (Nalgene) and ultracentrifugation at 34,000 rpm (100,000 x g) for 2 hours 
using an SW55Ti rotor in a Beckman L7-65 centrifuge.  The supernatent was then 
discarded and exosome pellets were resuspended in 30-100 µl of PBS or lysis buffer.  
Protein concentration was determined using the Bradford method.  This filtration 
technique produced the same results as test experiments where supernatants were treated 
with sequential centrifugation: 1000 x g, to remove cells, 10,000 x g to remove debris, 
and 100,000 x g to isolate exosomes. 
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Electron Microscopy 
 
Exosomes were prepared as previously described and resuspended in filter sterile PBS.  
Electron Microscopy was performed at the University of Dundee by Dr Alan Prescott. 
Briefly exosomes were loaded onto grids and air dried, then negatively stained. 
 
Mass Spectrometry 
 
Mass spectrometry analysis was performed by Dr Catherine Botting in the Biomedical 
Sciences Department (BMS), University of St Andrews.  Briefly, exosomes run on SDS-
PAGE gels were stained with Simply Blue Safe Stain (Invitrogen), washed with distilled 
water, before the bands of interest were cut out using clean scalpel blades.  These 
samples then underwent in-gel trytpic digestion and mass spec analysis using the in house 
service at BMS. 
 
Binding of Exosomes to Aldehyde/Sulfate Latex Beads 
 
Approximately 30 µg of exosomes were incubated with 10 µl of 4 µm diameter 
aldehyde/sulfate latex beads (Interfacial Dynamics) for 15 minutes at room temperature, 
followed by 1 hour at 4 °C with gentle agitation in 1 ml of PBS.  The reaction was 
stopped by a 30 minute incubation in 100 mM glycine.  Exosome-coated beads were 
washed three times in PFN and resuspended in 500 µl of PFN.  Beads were incubated for 
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35 minutes with each primary antibody, followed when necessary by incubation in FITC-
conjugated secondary antibody.  Further washes were performed with PFN before 
cytometric analysis on a Beckton Dickinson FACScan.  Data acquisition and analysis 
were performed using CellQuest software. 
 
Immobilising Exosomes in Agar 
 
Approximately 2.5 x 105 cells were washed once before being resuspended in 200 µl of 
sterile PBS.  3 µl of bodipy ceramide (Molecular Probes, Invitrogen) stain was added to 
the cells and they were incubated at 37 °C in a humidified atmosphere of 5 % CO2 in air 
for 20 minutes.  Cells were then washed three times in sterile PBS before being 
resuspended in 50 µl.  3 % agar was melted before being mixed with warmed sterile PBS 
to create a 0.6 % agar solution.  10 µl of stained cells were mixed with 10 µl of 0.6 % 
agar solution (final concentration 0.3 %) and mounted on to microscope slides (VWR).  
Slides were maintained in a humidified chamber at 37 °C in a humidified atmosphere of 5 
% CO2 in air for 24 hrs.  Slides were sealed with nail varnish and viewed under 100 x 
magnification using a fluorescence microscope. 
 
Isolation of Bodipy Stained Exosomes 
 
Cells were washed once in serum free medium before being stained with bodipy 
ceramide.  Cells were incubated at 37 °C in a humidified atmosphere of 5 % CO2 in air 
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for 20 minutes.  Cells were then washed three times in serum free medium before being 
resuspended in 5 ml of serum free medium, transferred to a six well plate and incubated 
at 37 °C in a humidified atmosphere of 5 % CO2 for 24 hours.  Exosomes were isolated 
as previously described and incubated with KG1 cells grown on coverslips (VWR). 
 
Incubation of Jesthom Exosomes with KG1 Cells 
 
KG1 dendritic-like cells, either grown in 6 well plates or on sterile coverslips, were 
stimulated with PMA (10 ng/ml) and Ionomycin (100 ng/ml) for 3 hours to start their 
maturation into dendritic cells. The cells were then incubated with exosomes for 24 
hours. Exosomes were isolated from a 70 ml culture of Jesthom cells (usually 
corresponding to approximately 5-10 µg of exosomes), and half of this preparation was 
used for immunofluorescence and half for FACS and lysate preparation.  Samples were 
analysed by FACS, or lysed and then analysed by SDS-PAGE and western blotting or 
stained with appropriate antibody for immunofluorescence microscopy. 
 
Immunofluorescent Microscopy 
 
Cells grown on coverslips were gently washed in PFN on ice before staining with the 
appropriate antibody for 35 minutes.  Cells were washed three times in PFN to remove 
any unbound antibody and, if necessary, were incubated with the appropriate FITC-
conjugated secondary antibody for 35 minutes on ice.  Cells were washed a further three 
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times with PFN before being mounted, using Vectashield with DAPI (Vector 
Laboratories) on microscope slides.  Slides were sealed with nail varnish and viewed 
under 100 x magnification using a fluorescence microscope. 
 
Incubation with Glutathione (GSH) 
 
Cells were incubated in serum-free medium supplemented with varying concentrations of 
GSH (10 mM, 1 mM, 0.1 mM) for 6 hours before exosomes were isolated as previously 
described.  Samples were lysed and then analysed by SDS-PAGE and western blotting.   
 
Cholesterol Depletion 
 
Cells were incubated in medium supplemented with 10 mM methyl-β-cyclodextrin 
(MBC) for 24 hours at 37 °C in a humidified atmosphere of 5 % CO2 in air.  Exosomes 
were then isolated from the culture supernatent as previously described.  Samples were 
lysed and analysed by SDS-PAGE and western blotting. 
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Separating Peripheral Blood Mononuclear Cells and Isolating 
Exosomes 
 
Local ethical approval for this study was obtained from UTREC (University of St 
Andrews Teaching and Research Ethics Committee). 
 
Peripheral blood was collected from healthy donors, after giving informed consent, in 
tubes containing 50 units of preservative-free heparin (Vacutainer, BD Bioscience) and 
PBMCs were isolated by Histopaque (Sigma) density gradient centrifugation.  Blood 
samples were overlaid onto an equal volume of Histopaque and centrifuged for 30 
minutes at 250 x g with no brake.  The buffy-coat layer was isolated using a sterile 
Pasteur pipette and washed three times with a large volume of PBS + 0.1 % BSA.  Cells 
were then resuspended in DMEM containing 10 % heat-inactivated serum and 0.1 mg/ml 
kanamycin sulphate and incubated at 37 °C in a humidified atmosphere of 5 % CO2 in air 
for at least 2 hours.  This allowed time for the monocytes to adhere to the tissue culture 
plates leaving the lymphocytes in suspension.  Non-adherent cells were then removed by 
gentle rinsing.  Isolated lymphocytes were either left untreated or treated with PHA 
(phytohaemagglutinin) (1 µg/ml) for 48 hours.  Exosomes were isolated from the cell 
supernatants and the cells were used to make cell lysates. 
 
The adherent monocyte population was stimulated with IL-4 (50 ng/ml) and GM-CSF (50 
ng/ml) for 5 days, cells were then either left untreated or treated with LPS 
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(lipopolysaccharide) (50 ng/ml) for 48 hours.  Exosomes were isolated from the cell 
supernatants and the cells were used to make cell lysates. 
 
Isolating Exosomes from Plasma 
 
Peripheral blood was collected from healthy donors in tubes as above.  The blood was 
separated using Histopaque (Sigma) density gradient centrifugation.  Blood samples were 
overlaid onto an equal volume of Histopaque and centrifuged for 30 minutes at 250 x g 
with no brake.  The plasma was removed from the top of the preparation using a sterile 
Pasteur pipette.  Plasma samples were centrifuged at 500 x g for 30 minutes at 4 °C.  The 
supernatent was then removed and spun again for 45 minutes at 12,000 x g at 4 °C.  The 
top 90 % of the supernatent was removed and spun at 100,000 x g for 2 hours using an 
SW55Ti rotor in a Beckman L7-65 centrifuge.  The resulting pellet was resuspended in 
approximately 9 ml of 0.22 µm filter-sterile PBS.  Samples were filtered through a 0.22 
µm filter and subject to ultracentrifugation again at 100,000 x g for 2 hours.  The 
supernatant was then discarded, and exosome pellets were resuspended in lysis buffer 
before analysis by SDS-PAGE and western blot. 
 
GSH Assay 
 
GSH concentrations were estimated using a Glutathione Assay Kit as per manufacturer’s 
instructions (Sigma).  Briefly, exosomes were isolated from Jesthom cell supernatent as 
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previously described and resuspended in filter-sterile PBS.  Jesthom cell lysates were 
prepared as previously described.  Protein concentrations of each sample were estimated 
using the Bradford method.  Samples were deproteinated according to the manufacturer’s 
instructions and the GSH concentration of equal protein concentrations of exosomes and 
lysates were measured as per manufacturer’s instructions at a wavelength of 380 nm 
using a FLUOstar Optima plate reader (BMG Labtech).  This assay measures total GSH 
content using an assay in which GSH is involved in the reduction of DTNB to TNB, with 
the resulting oxidised GSSG being recycled by glutathione reductase and NADPH.  The 
yellow colour of the resulting TNB is measured. 
 
Molecular Biology Techniques 
 
Total RNA Isolation 
 
RNA was isolated from cells using the RNeasy® mini kit (Qiagen) as per manufacturer’s 
instructions. 
 
RNA Quantification 
 
RNA was quantified using the Quant-iT™ RNA assay kits and the Qubit™ fluoremeter 
(Invitrogen) as per manufacturer’s instructions. 
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RT-PCR 
 
RT-PCR (reverse transcription-polymerase chain reaction) was carried out using the 
Qiagen OneStep RT-PCR kit as per manufacturer’s instructions.  Briefly, buffer, dH20, 
dNTPs, enzyme mix (Reverse Transcriptase and Taq Polymerase) and 0.5 µg of RNA 
were mixed before the addition of primers.  Reverse transcription was carried out at 50°C 
for 30 minutes before denaturation of the Reverse Transcriptase enzyme at 95°C for 15 
minutes. 
 
PCR was performed for 35 amplification cycles with the following protocol: denaturation 
at 94°C for 30 seconds, primer annealing at 50°C for 30 seconds, primer extension at 
72°C for 2 minutes. 
 
 
Reaction Mix for RT-PCR 
5 x Buffer (µl) 2.5 
dH20 (µl) 8 – RNA volume 
dNTP (µl) 0.5 
Enzyme mix (µl) 0.5 
Primers (µl) 0.5 + 0.5 
RNA (µg) 0.5 
 
Table 2.5: Components of the reaction mix used for RT-PCR. 
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PstI Digest 
 
RT-PCR products were treated with a final concentration of 1 U/µl of PstI (NEB) at 37 
°C for 90 minutes before being resolved by DNA-PAGE. 
 
DNA-PAGE 
 
DNA samples were diluted 1:6 with loading dye (0.5 ml 0.1M EDTA, 0.4 ml (30 % w/v) 
ficol 400, 0.05 % bromophenol blue) before being resolved on 5 % poly-acrylamide gels.  
Gels were run at a constant voltage of 100 V for 45 minutes or until the bromophenol 
blue dye front reached the bottom of the gel. 
 
5 % Polyacrylamide Gels for DNA-PAGE 
H20 (ml) 3.67 
30 % 29:1 acrylamide: bisacrylamide (ml) 0.83 
10 x TBE (ml) 0.5 
APS (µl) 50 
TEMED (µl) 5 
 
Table 2.6: Components of 5 % polyacrylamide gels for DNA-PAGE. 
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Silver Staining of DNA-PAGE 
 
The DNA was fixed into the gels by immersing in 7.5 % glacial acetic acid (GAA) for 5 
minutes, followed by three 20 minute washes with distilled water.  Gels were incubated 
with silver nitrate solution (0.1 % (w/v) silver nitrate, 0.15 % (v/v) formaldehyde) for 30 
minutes, before being rinsed briefly with distilled water to remove any surface silver 
nitrate.  Gels were then immersed in ice-cold developer solution (3 % (w/v) sodium 
carbonate, 0.15 % (v/v) formaldehyde, 0.00004 % (w/v) sodium thiosulphate).  The 
reaction was stopped with ice-cold 7.5 % GAA when the DNA was sufficiently visible.   
 
Design of Mutagenic Primers 
 
Mutagenic primers were designed using the bioinformatics program, Primer X 
(http://bioinformatics.org/primerx). 
 
Generation and Expression of Mutant HLA-B27 
 
Mutagenesis experiments were carried out on full-length HLA-B27 cDNA contained 
within the pCR3 plasmid.  HLA B27 cDNA was incubated with the mutagenic primers, 
dNTPs, Tgo buffer (Roche) and Tgo DNA polymerase (Roche) and temperature cycled 
for 15 cycles at 95 °C for 30 seconds, 58 °C for 1 minute and 68 °C for 12 minutes.  The 
parental strand was digested using 0.5 U/µl (final concentration) of restriction enzyme 
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DpnI (NEB) at 37 °C for 1 hour and 30 minutes.  The mutated dsDNA was transformed 
into JM109 competent cells (Promega).   
 
Transforming Competent JM109 Bacterial Cells 
 
Approximately 100 ng of DNA was added to 10-25 µl of JM109 cells and left for 30 
minutes on ice.  The cells and DNA were then heat shocked at 42 °C for 1 minute and 
then returned to ice for a further 2 minutes.  The transformed bacteria were incubated 
with 150 µl of Luria Broth (LB) with shaking at 37 °C for 60 minutes, allowing 
expression of the resistance gene.  Samples were plated on LB agar plates containing 100 
µg/ml ampicillin.  Plates were incubated overnight at 37 °C.  Single colonies were 
selected and grown overnight at 37 °C in 5 ml LB supplemented with 100 µg/ml 
ampicillin.  The bacterial cultures were then used for plasmid purification using Qiagen 
plasmid mini/midi prep kits as per manufacturer’s instructions, or frozen with glycerol to 
create stocks. 
 
Sca1 Digestion and Agarose Gel Electrophoresis 
 
Purified plasmid DNA was checked by restriction digestion with Sca1 (Roche) which 
linearises the plasmid.  Samples were analysed on 1 % agarose gels, containing 0.05 % 
ethidium bromide, using 1 x TAE buffer (5 mM sodium acetate, 1 mM EDTA, 40 mM 
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Tris, pH 7.5) at a constant voltage of 100 V for 45 minutes.  DNA was visualised on an 
ultraviolet (UV) transilluminator.   
 
DNA Sequencing 
 
Plasmids were checked and confirmed by DNA sequencing by the Sequencing Service at 
the University of Dundee. 
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Supplier Addresses 
 
Amaxa: Amaxa Biosystems, Cologne, Germany. 
 
BD Bioscience: BD Bioscience, Oxfordshire, UK. 
 
BDH: Supplied by VWR. 
 
Beckman Coulter: Beckman Coulter Ltd, Buckinhamshire, UK. 
 
Becton Dickinson: BD Bioscience, Oxfordshire, UK. 
 
Bio-Rad: Bio-Rad Laboratories Ltd, Hertfordshire, UK. 
 
BMG Labtech: BMG Labtech Ltd, Aylesbury, UK. 
 
Dynal Biotech: Supplied by Invitrogen. 
 
FUJIFILM: Fujifilm UK Ltd, Bedford, UK. 
 
Interfacial Dynamics: Supplied by Invitrogen. 
 
Invitrogen: Invitrogen, Paisley, UK. 
 
Melford: Melford Laboratories Ltd, Suffolk, UK. 
 
Millipore: Millipore (UK) Ltd, Hertfordshire, UK. 
 
MP Biomedicals: MP Biomedicals, Cambridge, UK 
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Nalgene: Supplied by VWR. 
 
NEB: New England BioLabs, Hertfordshire, UK 
 
Pierce: Perbio Science UK Ltd, Northumberland, UK. 
 
Promega: Promega Corporation, Southampton, UK 
 
Qiagen: Qiagen Ltd, West Sussex, UK. 
 
Roche: Roche Applied Science, Roche Diagnostics Ltd, West Sussex, UK. 
 
Santa Cruz: Santa Cruz Biotechnology Inc, Heidleberg, Germany 
 
Sigma: Sigma Aldrich, Dorset, UK. 
 
Thistle Scientific: Thistle Scientific Ltd, Glasgow, UK. 
 
Vector Laboratories: Vector Laboratories Ltd, Peterborough, UK. 
 
VWR: VWR International, Leicestershire, UK. 
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Chapter III: HLA-B27 and the UPR 
 
Introduction 
 
The folding of most proteins within the endoplasmic reticulum is tightly regulated by 
molecular chaperones.  If misfolded proteins accumulate within the ER a stress response, 
known as the Unfolded Protein Response (UPR), is activated.  The aim of the UPR is 
primarily to alleviate stress and re-establish normal physiological conditions.  Activation 
of the UPR results in transcriptional induction of UPR genes, translational attenuation of 
protein synthesis, and ER-associated degradation (ERAD).  The UPR, if not resolved, 
will eventually result in apoptosis.   
 
HLA-B27 has slower folding kinetics than other class I alleles and is prone to misfolding, 
resulting in the formation of dimers and multimers (Mear et al., 1999).  It was postulated 
that the accumulation of these misfolded proteins could lead to the activation of a pro-
inflammatory ER stress response (Colbert, 2000).  The inherent ability of HLA-B27 to 
misfold could put cells into a state of continuous stress and therefore continuous 
activation of the UPR. 
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The Unfolded Protein Response 
  
Within the ER, protein folding is regulated by molecular chaperones.  One such key 
chaperone, which is also of key relevance to the UPR, is the immunoglobulin binding 
protein (BiP).  BiP is involved in the regulation of the three main transducers of the UPR; 
PKR-like ER kinase (PERK), inositol-requiring enzyme-1 (IRE1) and activating 
transcription factor 6 (ATF6).  Under normal conditions, BiP acts as a negative regulator 
of IRE1 (Okamura et al., 2000), PERK (Bertolotti et al., 2000) and ATF6 (Shen et al., 
2005) activation, but when misfolded proteins accumulate BiP dissociates from the UPR 
effectors and associates instead with the misfolding proteins.  
 
PERK 
 
PERK is an ER transmembrane protein with protein kinase activity that is involved in the 
attenuation of protein synthesis in response to ER stress (Harding et al., 1999).  PERK is 
retained in an inactive form through stable binding to BiP, and is released in response to 
ER stress (Bertolotti et al., 2000).  Once released PERK subunits can dimerise, activating 
their kinase ability.  Activated PERK is then able to phosphorylate the α subunit of 
eukaryotic translation initiation factor-2α (eIF2α) (Harding et al., 2000b), which results 
in the transient suppression of protein translation, reducing the load of newly synthesised 
proteins on the ER.  Phosphorylated eIF2α also targets cyclin D1 for degradation, 
preventing stressed cells from progressing through the cell cycle (Raven et al., 2008).   
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Transcription of some specific UPR target genes also occurs in response to 
phosphorylated eIF2α, such as the transcription factor ATF4 (Harding et al., 2000a).  
Translational recovery is mediated by GADD34 (growth arrest and DNA damage-
inducible gene 34), which is upregulated by ATF4 and acts by dephosphorylating eIF2α 
(Novoa et al., 2001).  Phosphorylated eIF2α can also activate NF-κB potentially leading 
to the expression of cell protective genes (Jiang et al., 2003). 
 
If the stress response is not perturbed, the cell will undergo apoptosis, a process that is 
potentiated by the pro-apoptotic transcription factor CHOP, which is expressed in 
response to ATF4 (Harding et al., 2000a).  
 
ATF6 
 
There are two isoforms of ATF6 in mammals, ATF6α and ATF6β, both thought to have 
a role in the UPR (Haze et al., 2001).  However evidence suggests ATF6β is a poor 
transcriptional activator that actually inhibits activation by ATF6α (Thuerauf et al., 
2004).   
 
ATF6 is a type I transmembrane protein with its C-terminus located in the ER lumen and 
its N-terminal domain facing the cytosol (Haze et al., 1999, Haze et al., 2001).  It is 
constitutively expressed and is regulated through stable binding to BiP (Shen et al., 
2005).  Dissociation from BiP exposes a golgi-localisation signal causing ATF6 to 
relocate to the golgi apparatus (Shen et al., 2002).   
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Within the golgi ATF6 undergoes regulated intramembrane proteolysis and is 
sequentially cleaved by two serine proteases, site-1 protease (S1P) and site-2 protease 
(S2P).  S1P cleaves ATF6 in the luminal domain and S2P cleaves the N-terminal 
membrane-anchored half (Ye et al., 2000).  The resulting cytosolic fragment translocates 
to the nucleus, where it can bind to the promoter region and initiate translation of ER 
stress response target genes (Adachi et al., 2008, Kokame et al., 2001, Wang et al., 2000, 
Yoshida et al., 1998). 
 
ATF6 targets include the molecular chaperone BiP (Haze et al., 1999), XBP1, CHOP 
(Yoshida et al., 2000), and P58IPK (van Huizen et al., 2003).  XBP1 mRNA is a target for 
activated IRE1 during an UPR, and once translated acts as a transcription factor for UPR 
target genes (Lee et al., 2003).  Overexpression of CHOP leads to growth arrest and 
promotes apoptosis (reviewed in Oyadomari and Mori, 2004), and it has been suggested 
that upregulation of p58IPK may serve to regulate the stress response in a negative 
feedback manner by interacting with PERK and inhibiting its kinase activity (Lee et al., 
2003, van Huizen et al., 2003, Yan et al., 2002). 
 
IRE1 
 
IRE1 is an ER transmembrane glycoprotein that contains both kinase and RNase 
activities in its cytoplasmic domain (Cox et al., 1993, Sidrauski and Walter, 1997).  
Mammals have two copies of IRE1, IRE1α (Tirasophon et al., 1998) and IRE1β (Wang 
et al., 1998).  IRE1, like PERK, is retained in an inactive state by stable binding to the 
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molecular chaperone BiP, and is released from BiP when a stress response is activated 
(Okamura et al., 2000, Bertolotti et al., 2000).  This results in auto-phosphorylation and 
the subsequent activation of IRE1’s RNase activity (Shamu and Walter, 1996).  The 
substrate for IRE1 is the mRNA of the transcription factor XBP1 (Yoshida et al., 2001, 
Calfon et al., 2002).  XBP1 transcription is increased in response to ATF6 signaling 
(Yoshida et al., 2001). 
 
XBP1 mRNA is constitutively produced in a full-length, or unspliced, form (XBP1u). 
Activated IRE1 cuts XBP1 twice, removing a 26 nucleotide intron from the XBP1 
transcript, the two mRNA fragments are ligated together causing a frameshift in the 
spliced XBP1 transcript (XBP1s), and following translation, XBP1s functions as a potent 
activator of UPR target genes (Calfon et al., 2002).  Both XBP1s and XBP1u mRNA are 
translated into proteins, with XBP1u acting as an inhibitor of the UPR (Yoshida et al., 
2006). 
 
Many XBP1s-specific target genes have been identified (Lee et al., 2003), including; 
EDEM, a protein involved in the ER-associated degradation (ERAD) pathway 
(Hosokawa et al., 2001, Oda et al., 2003).  ERAD involves the retrotranslocation of 
misfolded or aggregated proteins from the ER to the cytosol where they undergo 
proteasomal degradation (reviewed in Meusser et al., 2005); RAMP4, a protein 
implicated in glycosylation and stabilization of membrane proteins in response to stress 
(Yamaguchi et al., 1999) and p58IPK which has been implicated in a negative feedback 
role for controlling the UPR (Lee et al., 2003, van Huizen et al., 2003, Yan et al., 2002).  
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In addition to the splicing of XBP1 mRNA, IRE1 has also been shown to be involved in 
the degradation of ER-targeted mRNA transcripts (Hollien and Weissman, 2006) and 
cleavage of the 28S ribosomal subunit (Iwawaki et al., 2001) suggesting that IRE1 also 
has a role in translational attenuation in response to ER stress. 
 
If the stress response is not curtailed, IRE1 is also implicated in apoptosis through the 
recruitment of TRAF2 (TNF receptor-associated factor 2) (Urano et al., 2000).  The 
IRE1/TRAF2 complex recruits ASK1 (apoptosis signal-regulating kinase 1) activating 
the downstream JNK (c-jun N-terminal kinase) pathway that eventually leads to cell 
death (Nishitoh et al., 1998, Nishitoh et al., 2002). 
 
As part of an activated UPR an inflammatory response is initiated to help stimulate 
apoptosis and to repair tissue damage caused by UPR-associated apoptosis.  NF-κB is 
induced in response to both PERK and IRE1 downstream signaling pathways (Jiang et 
al., 2003, Hu et al., 2006).  NF-κB leads to the expression of TNFα, which has an 
important role in inflammation but also, in the context of ER stress, has an important pro-
apoptotic function (Hu et al., 2006).  
 
Homeostasis in the ER is maintained through the coordinated actions of the three 
branches of the UPR.  The main aim is to alleviate stress through enhancing molecular 
chaperones and reducing further stress by preventing unnecessary transcription.  If these 
mechanisms fail however, the cell will undergo apoptosis removing unhealthy cells from 
the system. 
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Figure 3.1: The Unfolded Protein Response.  When misfolded proteins accumulate in the ER, the UPR is activated.  The aim of the 
UPR is to remove the cause of the stress response and re-establish normal physiological conditions.
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HLA-B27 and the UPR 
 
HLA-B27 has slower folding kinetics than other class I alleles and a tendancy to misfold, 
a characteristic attributed to residues in the B pocket (Mear et al., 1999, Antoniou et al., 
2004).  This observation formed the basis of the hypothesis proposed by Colbert in 2000, 
in which he suggested that the misfolding of HLA-B27 was associated with the activation 
of a pro-inflammatory ER stress response (Colbert, 2000). 
 
The slower folding of B*2705 has been directly linked with the formation of homodimers 
in the ER, with dimer structures able to be induced in the HLA-A2 molecule when its 
folding efficiency is reduced at lower temperatures (Antoniou et al., 2004).  ER 
homodimers are distinct from cell surface dimers and do not egress to the cell surface 
(Dangoria et al., 2002, Antoniou et al., 2004). 
 
The misfolding hypothesis can potentially explain some observations made in transgenic 
rodent studies.  In transgenic rats disease only occurs in those animals that have a high 
gene copy number with HLA-B27 expression above a certain threshold (Taurog et al., 
1993), and in HLA-B27 transgenic mice, spontaneous arthritis occurs in the absence of 
β2m (Khare et al., 1995).  In both of these situations, HCs could be increasingly more 
likely to misfold resulting in the activation of a stress response. 
 
In 2004 it was demonstrated in a rat cell line model that HLA-B27 heavy chains are 
found in association with BiP (Antoniou et al., 2004).  Shortly afterwards it was 
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demonstrated, in splenocytes from HLA-B27 transgenic rats, that HLA-B27 HCs are also 
extensively bound to BiP (Tran et al., 2004).   
 
Turner et al have since shown that bone marrow-derived macrophages from HLA-B27 
transgenic rats show evidence of UPR activation that correlates with the accumulation of 
misfolded heavy chains (Turner et al., 2005, Turner et al., 2007).  They also found 
evidence of an IFN response in cells from rats suffering with disease, a response that 
seems to exacerbate the UPR, probably through the up-regulation of HLA-B27 heavy 
chains (Turner et al., 2005).  More recently a study on a human cell line model indicates 
that expression of HLA-B27 alone is enough to activate a stress response (Lemin et al., 
2007).   
 
To date, therefore, UPR induction associated with HLA-B27 has been described in a 
number of different in vitro and in vivo systems.  However, we had no information on the 
relative contribution of the UPR, if any, to the systems that have been worked on in this 
laboratory for a number of years.  It was therefore decided to investigate this aspect of 
HLA-B27 biology. 
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Results 
 
Transient Expression Model for HLA-B27 and the UPR 
 
Cells expressing HLA-B27 do not express enhanced levels of BiP compared to other 
alleles. 
 
To investigate whether the expression of HLA-B27 resulted in an increase in the level of 
BiP, HeLa cells were transiently transfected with HLA-B27 and HLA-A2.  In addition, a 
series of mutants of these alleles that contain a cysteine to serine mutation at the position 
of a structural cysteine residue, and thus fail to fold efficiently in the ER, were also 
utilised.  All alleles contain the 14 amino acid tag SV5 (also termed V5 when 
commercially used from Invitrogen) on their C-terminus.  This tag is recognized by the 
antibody pk, allowing specific detection of the transfected alleles.   
 
HLA-A2 is a non-disease associated allele that folds efficiently within the ER and would 
therefore not be expected to be associated with an UPR.  The structural mutants are 
unable to fold correctly and therefore do not exit from the ER.  Accumulation of these 
molecules may be expected to lead to the activation of an UPR.  HLA-B27 has slower 
folding kinetics than other class I alleles and is prone to misfolding with the ER, it has 
been suggested that these factors may lead to ER stress and activation of the UPR.   
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BiP is a major player in the UPR, and binds to unfolded proteins in an attempt to aid their 
folding, and an activated UPR results in a characteristic increase in the level of 
expression of this chaperone.  If HLA-B27 is constantly misfolding this may put the cells 
in a state of continuous stress.  To determine whether expression of this allele increases 
the level of the stress responsive chaperone BiP, cell lysates were subject to SDS-PAGE 
and western blotting with antibodies against β-actin (loading control), pk (transfection 
control) and BiP (Figure 3.2 A).  The BiP levels were normalized against the β-actin and 
relative BiP levels were plotted (Figure 3.2 B). 
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Figure 3.2: BiP levels are increased in cell lines transiently expressing disease 
associated and non-disease associated alleles.  Cells were transfected using Fugene 6 
with 1 µg of pCR3 plasmid DNA containing the appropriate class I allele cDNA.  
Transient transfectants were harvested 24 hours after transfection.  (A) Cells were lysed 
and then protein quantified using the Bradford method.  Samples were resolved by 8 % 
SDS-PAGE before western blotting.  Membranes were probed with the indicated 
antibodies.  (B) The relative BiP levels for (A) are shown after being normalised for β-
actin.  Results are representative of at least 3 experiments. 
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BiP levels were consistently higher in the transfected cell lines compared with the HeLa 
wild-type (wt) samples, however levels between different experiments were not 
consistent (Figure 3.2 A & B).  Somewhat unexpectedly, HLA-A2 showed higher levels 
of BiP than HLA-B27.  Furthermore, whilst the structural cysteine mutants usually 
expressed increased BiP levels, this was not always true, despite good levels of mutant 
expression, for example with mutant HLA-B27.C101S.SV5 (Figure 3.2 B). 
 
Treatment of HeLa cells with DTT, a chemical that causes global stress, did not always 
increase the level of BiP.  Possibly, the length of time of treatment with DTT (50 
minutes) was not long enough to cause an increase in protein synthesis of BiP in these 
conditions. 
 
XBP1 splicing occurs in cell lines expressing disease associated, non-disease 
associated and structural cysteine mutant alleles. 
 
XBP1 mRNA is constitutively expressed in the cell (XBP1u).  When a stress response is 
activated XBP1 mRNA undergoes splicing by IRE1, removing 26 bp, leaving the spliced 
XBP1 product (XBP1s).  In order to investigate whether XBP1 was spliced or unspliced, 
and therefore whether a UPR was active or not, we extracted RNA from cell lines 
transiently expressing different HLA class I alleles and RT-PCR was performed with 
XBP1 specific primers (Figure 3.3), kindly donated by Dr Antony Antoniou (UCL, 
London). 
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The XBP1 primers amplify a region of XBP1 that contains the 26 bp that are spliced by 
IRE1 (indicated in red, Figure 3.3).  Primer binding sites are indicated in blue on Figure 
3.3.  If XBP1 is unspliced, the amplified region of XBP1 would be 473 bp in length, and 
if splicing has occurred the amplified product would be 447 bp in length.  The amplified 
region of unspliced XBP1 also contains a PstI restriction site (underlined in black, Figure 
3.3).  If XBP1 is cut with PstI the two resulting fragments would be 282 bp and 191 bp in 
length.  This restriction site is lost if splicing has occurred resulting in spliced XBP1 
being resistant to PstI digestion. 
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Figure 3.3: Sequence of XBP1 amplification products.  Forward and reverse primers 
are indicated in blue.  If the UPR is not active the entire region will be amplified resulting 
in a 473 bp product.  When XBP1 is spliced during a stress response, 26 bp (indicated in 
red) are removed from the sequence resulting in a smaller 447 bp product.  The 6 bp 
recognition site of PstI is indicated with a black line.  If the UPR is active, and XBP1 
undergoes splicing, part of this recognition site is lost resulting in the spliced product 
being resistant to PstI digestion.  If XBP1 is unspliced then PstI cuts in the middle of the 
recognition site resulting in two fragments of 282 bp and 191 bp. 
 
Amplified RT-PCR product was resolved by DNA-PAGE and silver staining.  All of the 
transfected alleles showed splicing of XBP1 (Figure 3.4 A & B).  Untransfected HeLa 
cells did not seem to have undergone XBP1 splicing, indicating that prior to transfection 
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the cells were not under going an active UPR.  Overall, however, both disease and non-
disease associated alleles, and structural mutants all activate XBP1 splicing events.  
 
Figure 3.4: XBP1 splicing occurs in cell lines transiently expressing disease 
associated and non-disease associated alleles.  Cells were transfected using Fugene 6 
with 1 µg of pCR3 plasmid DNA containing the appropriate class I allele cDNA.  
Transient transfectants were harvested 24 hours after transfection.  RNA was isolated 
from the cells and quantified.  RT-PCR was carried out using the Qiagen OneStep RT-
PCR kit with 0.5 µg of RNA and XBP1 specific primers.  The RT-PCR product was 
resolved using DNA-PAGE.  Gels were fixed and RT-PCR product was visualized by 
silver staining. Results are representative of at least 3 experiments. 
 
To further confirm this observation, that XBP1 is present in the spliced form in the 
transfectants, RT-PCR products were subject to PstI digestion (Figure 3.5 A).  Digestion 
of RT-PCR product from all of the alleles resulted in the formation of some digest 
products, as expected, because not all of the XBP1 was in the spliced form (Figure 3.4 A 
& B).  However, densitometry analysis of both the unspliced and spliced XBP1 reveals 
that in transfected alleles at least 60 % of the XBP1 was in the spliced form compared 
with the HeLa cells alone where just over 20 % of the XBP1 was spliced (Figure 3.5 B).  
However, both the disease and non-disease associated alleles appear to have an activated 
stress response compared to the HeLa wt cells.  
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Figure 3.5: PstI digest of RT-PCR products from transiently transfected cells.  (A) 
RT-PCR products were treated with a final concentration of 1 U/µl of PstI at 37 °C for 90 
minutes before being resolved by DNA-PAGE.  Gels were fixed and RT-PCR products 
were visualised by silver staining.  A contaminant band running just below the region of 
spliced and unspliced XBP1 is indicated with an asterisk.  (B) Relative levels of 
unspliced and spliced XBP1 are compared before and after PST1 digestion. Results are 
representative of at least 3 experiments. 
 135 
These results suggest that the use of a transiently transfected cell-model to assess the 
effects of HLA-B27 on the activation of the UPR may not be appropriate.  It may be that 
all of the alleles cause, to some extent, the activation of a stress response or the activation 
may be a response to the transfection process itself.  Although HeLa wt cells underwent a 
mock transfection (Fugene 6 and serum free DMEM but no DNA) it may be that the 
DNA is responsible for the activation of the stress response.  Therefore, in order to 
further investigate the activation of an UPR in response to the presence of HLA-B27 we 
repeated the experiments using cells stably transfected with HLA-A2 and HLA-B27. 
 
Stable Expression Model for HLA-B27 and the UPR 
 
BiP levels are enhanced in both HLA-A2 and HLA-B27 expressing cell lines 
compared to wild-type HeLa cells. 
 
Hela cells were stably transfected with either HLA-A2 or HLA-B27.  In order to aid 
detection, both alleles contain the 14 amino acid SV5 tag on their C-terminus.  To 
confirm the expression of the transfected alleles, cells were assessed by flow cytometry 
using monoclonal antibodies ME1 (folded B27) or BB7.2 (folded A2) (Figure 3.6 A) and 
western blotting with the pk antibody (Figure 3.6 B).  The HLA-B27 allele is expressed 
at slightly higher levels than the HLA-A2 allele.
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Figure 3.6: Characterisation of HeLa cells stably expressing HLA-A2 or HLA-B27.   
Cells were transfected using Fugene 6 with 1 µg of pCR3 plasmid DNA containing the 
appropriate class I allele cDNA with a 14 amino acid C-terminal tag (SV5).  Cells were 
put into selective medium 24 hours after transfection.  If necessary, positive cultures were 
enriched using magnetic beads and/or dilution cloning.  (A) The expression of the 
transfected allele on the cell surface was analysed by flow cytometry using the indicated 
antibodies.  (B) Whole cell lysates were resolved using SDS-PAGE and western blotting.  
The membrane was probed with the pk antibody that detects the C-terminal SV5 tag. 
Results are representative of at least 3 experiments. 
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To determine whether stable expression of these alleles increases the level of the stress 
responsive chaperone BiP, cell lysates were subject to SDS-PAGE and western blotting 
with antibodies against β-actin and BiP (Figure 3.7 A).  The BiP levels were normalized 
against the β-actin and relative BiP levels were plotted (Figure 3.7 B). 
 
 
 
Figure 3.7: BiP levels are increased in cell lines stably expressing disease associated 
and non-disease associated alleles.  (A) Cells were lysed and then protein quantified 
using the Bradford method.  Samples were resolved by 8 % SDS PAGE before western 
blotting.  Membranes were probed with the indicated antibodies.  (B) The relative BiP 
levels for (A) are shown after being normalised for β-actin. Results are representative of 
at least 3 experiments. 
 
BiP levels were increased in both the HLA-A2 and HLA-B27 expressing cell lines, with 
the -A2 expressing cells having higher levels of BiP than those cells expressing the 
disease associated allele -B27.  In both cases the level of BiP was enhanced compared to 
the HeLa wt sample.  HeLa cells treated with DTT also contained an increased amount of 
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the protein BiP compared to the HeLa wt cells, however the level of BiP in the HLA-A2 
and HLA-B27 expressing cell lines was further elevated. 
 
XBP1 is predominantly unspliced in stable cell lines expressing HLA-A2 and HLA-
B27. 
 
To determine whether these enhanced levels of BiP were associated with an activated 
stress response, the status of XBP1 (spliced or unspliced) was investigated.  In order to 
do this, RNA was extracted from the cells and RT-PCR was performed with XBP1 
specific primers (Figure 3.3).  The amplified RT-PCR product was analysed by DNA-
PAGE and silver staining (Figure 3.8). 
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Figure 3.8: XBP1 splicing does not occur in cell lines stably expressing disease 
associated and non-disease associated alleles.  RNA was isolated from the cells and 
quantified.  RT-PCR was carried out using the Qiagen OneStep RT-PCR kit with 0.5 µg 
of RNA and XBP1 specific primers.  The RT-PCR product was resolved using DNA-
PAGE.  Gels were fixed and RT-PCR product was visualized by silver staining. Results 
are representative of at least 3 experiments. 
 
The majority of XBP1 occurs in the unspliced form in cell lines expressing either HLA-
A2 or HLA-B27, comparable to the HeLa wt cells (Figure 3.8).  Treatment of the cells 
with DTT shifts the majority in the opposite direction, with a higher proportion of XBP1 
being in the spliced form (Figure 3.8).  To further assess the status of XBP1 in these cell 
lines RT-PCR product was subject to digestion with PstI (Figure 3.9 A).   
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Figure 3.9: PstI digest of RT-PCR products from stably transfected cells.  (A) RT-
PCR products were treated with a final concentration of 1 U/µl of PstI at 37 °C for 90 
minutes before being resolved by DNA-PAGE.  Gels were fixed and RT-PCR products 
were visualised by silver staining. (B) Relative levels of unspliced and spliced XBP1 are 
compared before and after PstI digestion. Results are representative of at least 3 
experiments. 
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Digestion of RT-PCR product from both alleles resulted in the formation of digest 
products.  Densitometry analysis of both the unspliced and spliced XBP1 bands show that 
in both Hela wt cells and HeLa cells expressing the HLA-A2 allele, approximately 20 % 
of the total XBP1 is spliced (Figure 3.9 B).  These results are comparable with the level 
of splicing seen in HeLa wt cells in the transient transfection model (Figure 3.5 A + B).  
A higher proportion of XBP1 in HeLa cells expressing HLA-B27 was in the spliced 
form, approximately 38 % compared to 20 % in the wt and HLA-A2 cells, but was lower 
than the level of spliced XBP1 in the DTT treated cells (Figure 3.9 B). 
 
ATF6 is not cleaved in HeLa cells stably expressing HLA-A2 or HLA-B27. 
 
Attempts were made to immunoblot for endogenous ATF6 as another indicator of UPR. 
However, several commercially available antisera were tested, but produced no easily 
identifiable bands. Therefore wild-type HeLa cells and HeLa cells stably expressing 
either HLA-B27 or HLA-A2 were transiently transfected with ATF6.  The ATF6 cDNA 
(a gift from Dr A. Antoniou, UCL, London) contained a 3 x flag tag sequence to allow 
detection of the transfected ATF6 with anti-flag tag antibody.   
 
When an UPR is activated, ATF6 translocates from the ER to the golgi and undergoes 
sequential cleavage.  The resulting product then translocates to the nucleus and functions 
as a transcription factor.  In order to investigate whether an UPR was activated in these 
cells, lysates containing the cell nuclei were prepared and analysed by SDS-PAGE and 
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western blotting.  As a positive control, cells transfected with ATF6 were also treated 
with DTT before lysis (Figure 3.10).   
 
 
Figure 3.10: Cleavage of ATF6 was not increased in cell lines stably expressing 
HLA-A2 or HLA-B27.  Cells were transfected using Fugene 6 with 1 µg of plasmid 
DNA containing flag-tagged ATF6.  Transient transfectants were harvested 24 hours after 
transfection.  Cells lysates containing the nuclear fraction were prepared and then 
resolved by 8 % SDS-PAGE before western blotting.  Membranes were probed with anti-
flag tag antibody.  Results are representative of at least 3 experiments. 
 
Transfection of ATF6 into the cell lines was successful and treatment with DTT produced 
the ATF6 cleavage product (Figure 3.10).  In non-DTT treated cells the majority of ATF6 
is not cleaved.  On longer exposure faint bands representing the cleavage product can be 
seen in the HLA-B27 expressing cell line but also in the HeLa wt cells suggesting that 
some cleavage may be occurring due to other stress triggers and not because of the 
expression of HLA-B27 allele alone (data not shown). 
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In stable transfectants of the rat cell line, C58, the expression of BiP varies between 
alleles. 
 
Much of the previous published work on HLA-B27 and the UPR came from work carried 
out on transgenic rats.  To investigate whether rat cells in culture showed an increase in 
the molecular chaperone BiP in response to the expression of HLA-B27, we used stable 
C58 cell lines expressing HLA-B27, HLA-A2 or various structural cysteine mutants, all 
containing the C-terminal SV5 tag.  Cell lysates were analysed by SDS-PAGE and 
western blotting with β-actin, pk and BiP (Figure 3.11 A). The BiP levels were 
normalized against the β-actin and relative BiP levels were plotted (Figure 3.11 B). 
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Figure 3.11: BiP levels vary in stably transfected C58 cell lines.  (A) Cells were lysed 
and then protein quantified using the Bradford method.  Samples were resolved by 8 % 
SDS-PAGE before western blotting.  Membranes were probed with the indicated 
antibodies.  (B) The relative BiP levels for (A) are shown after being normalised for β-
actin.  Mutant A2.α3-/-SV5 denotes a double mutant HLA-A2.C203S+C259S, removing 
both α3 domain conserved cysteines. Results are representative of at least 2 experiments. 
 
BiP levels vary between the different alleles (Figure 3.11 B).  The HLA-A2 allele with a 
cysteine to serine mutation at position 164 has the highest relative level of BiP.  
However, the corresponding mutation in the HLA-B27 allele has a BiP level comparable 
to wild-type C58 cells.  These results suggest that BiP levels do differ between cell lines 
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expressing different HLA alleles but that the differing HLA expression may not be the 
reason for this observed difference. 
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Discussion 
 
HLA-B27 has a tendency to misfold, forming high molecular weight dimeric and 
multimeric complexes that have been implicated in the pathogenesis of disease.  One 
current theory suggests that accumulation of misfolded proteins in the ER can result in 
the activation of a proinflammatory stress response. 
 
BiP Expression 
 
One of the key chaperones involved in the regulation of protein folding in the ER is the 
immunological binding protein, BiP.  The association of HLA-B27 and BiP has been 
previously reported in rat cell line model and in transgenic rats (Antoniou et al., 2004, 
Tran et al., 2004).  We have tried to determine whether, in a human cell line model, the 
expression of HLA-B27 is associated with an increased expression of the chaperone BiP. 
 
We transiently transfected HeLa cells with the non-disease associated allele HLA-A2, the 
disease-associated HLA-B27 or an HLA-A2 or -B27 mutant containing a cysteine to 
serine substitution at the position of a structural cysteine.  These structural mutants are 
unable to fold correctly and are therefore unable to exit from the ER.  Cells were 
transfected 24 hours prior to harvesting and samples were analysed by western blotting. 
 
 147 
Bip levels were consistently higher in the all of the transiently transfected HeLa cells 
compared with the wild-type HeLa cells (Figure 3.2 A & B).  BiP expression is regulated 
at a post-transcriptional level, in a stressed cell protein level will increase through 
enhanced translation efficiency (Gulow et al., 2002).  However the amount of BiP 
expressed by HeLa cells transfected with the same allele, or in the HeLa wild type 
sample, was not consistent between experiments (Figure 3.2 A & B). 
 
HeLa wild-type cells were mock transfected using the same transfection agent, 
suggesting the difference seen between wild-type cells and transient transfectants cannot 
be to do with the transfection agent, but it could however, be caused by the DNA, as 
mock transfectants did not contain DNA.  It is possible that the differing effects seen 
between experiments for the transfected alleles may be associated with the transfection 
efficiency however this would not explain why differences were also observerd for the 
wild-type HeLa cells.  
 
As a positive control we treated wild-type cells with DTT, a chemical that will cause 
global protein misfolding.  In some cases however we were unable to detect an increase 
in BiP following DTT treatment.  This is possibly because the short duration of DTT 
treatment was not long enough to allow increased protein synthesis of BiP.  Significantly 
we did see major effects with DTT treatment subsequently on XBP1 splicing.  Thus the 
immediate DTT impact upon mRNA splicing takes a longer timescale to impact upon 
overall protein expression levels. 
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We had hypothesised that BiP expression would be influenced by the folding capacity of 
the HLA alleles we had transfected, with HLA-A2 expressing the lowest level of BiP and 
HLA-B27 and the cysteine mutants expressing an increased amount of BiP.  However, 
we were unable to detect this with both the wild-type and transfected alleles differing in 
their BiP expression between experiments.  
 
We have also examined BiP expression in cells stably transfected with either the disease-
associated allele HLA-B27, or the non-disease associated allele HLA-A2.  In these cell 
lines the expression of HLA-B27 was slightly higher than of HLA-A2 as determined by 
flow cytometry and western blotting (Figure 3.6 A & B).  In both cell lines BiP levels 
were increased above basal levels (Figure 3.7 A & B).  However, the cell line expressing 
the more efficient folding allele, HLA-A2, had a higher level of BiP than the HLA-B27 
expressing cell line. 
 
The previous work studying the relationship between BiP and HLA-B27 has been carried 
out on transgenic rats or on rat cell lines.  We therefore tried to determine whether the 
expression of HLA-B27 in rat cells resulted in an enhanced expression of BiP.  We used 
stably transfected C58 cells expressing HLA-B27, HLA-A2 or a mutant cell line that 
does not fold properly.  Although in most cases BiP levels were increased above that of 
wt levels there did not seem to be a correlation between HLA-B27 and BiP levels, nor did 
the mutant cell lines show higher levels of BiP expression compared with HLA-A2 
(Figure 3.11 A & B).   
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These results indicate that the overall expression of BiP in cell-lines may not be 
appropriate to determine whether an allele is misfolding.  For the purpose of 
investigations with HLA-B27, BiP binding may be a more useful indicator, and it has 
previously been reported that HLA-B27 is more likely to be bound to BiP than the non-
disease associated allele HLA-B7 (Tran et al., 2004).  
 
XBP1 Splicing 
 
XBP1 splicing in HeLa cells transiently expressing HLA-B27 has been reported 
previously (Lemin et al., 2007).  To further investigate this we determined the state of 
XBP1 in HeLa cells transiently expressing HLA-B27, HLA-A2 as well as mutant cell 
lines expressing a structural cysteine mutation.   
 
All of the transiently transfected alleles showed splicing of XBP1, however this does not 
appear to be the case for the untransfected HeLa cells (Figure 3.4).  These results indicate 
that before transfection the cells were not undergoing an active UPR.  We were unable to 
detect a difference in XBP1 splicing between the different alleles, perhaps suggesting that 
the transfection process itself, rather than the transfected alleles, is responsible for the 
activated stress response. 
 
As with the BiP experiments, we also studied the state of XBP1 in stably transfected cell 
lines expressing HLA-A2 or HLA-B27.  In these cell lines, XBP-1 is predominantly 
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unspliced (Figure 3.8).  However densitometry analysis determined that in cells 
expressing HLA-B27 more XBP1 is spliced than in wt or HLA-A2 expressing cells.   
 
ATF6 Cleavage 
 
The previous study carried out on transiently transfected HeLa cells also looked at the 
status of ATF6 (Lemin et al., 2007).  ATF6 is cleaved during an UPR to produce a 
cyosolic fragment that translocates to the nucleus causing downstream effects.  The data 
presented here perhaps suggest that transiently transfected cells do not make a good 
model for studying the activation of a stress response.  We therefore investigated the 
status of ATF6 in stably transfected HeLa cells expressing either HLA-A2 or HLA-B27. 
 
We were unable to detect any obvious ATF6 cleavage products in either cell line.  On 
longer exposure a faint cleavage band was detectable in the HLA-B27 cell line, however 
it was also detectable in the HeLa wt cell line suggesting another factor other than the 
expression of HLA-B27 was responsible for this.  
 
Summary 
 
The results presented here demonstrate that the use of cell line models to demonstrate an 
activated UPR should be interpreted with great care.  We obtained different results using 
transiently expressing and stably expressing cell lines.  The report by Lemin et al was 
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intriguing as it suggested that the expression of HLA-B27 alone was enough to activate a 
stress response in the ER (Lemin et al., 2007).  However we have demonstrated that the 
transient expression of other alleles in HeLa cells also show similar signs of an activated 
UPR.  Such UPR data, when obtained from ‘real’ cells, ie from patient cells, or animal 
models, may have relevance, but in vitro expression models based on these observations, 
must be treated with additional analysis. 
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Chapter IV: Non-HLA-B27 Homodimers 
 
Introduction 
 
As previously discussed, classical MHC class I molecules are expressed at the cell 
surface of every nucleated cell, with the main function of presenting peptide to CD8+ T 
cells for immunosurveilance.  Conventional fully folded class I molecules are 
heterotrimeric complexes consisting of a class I heavy chain, β2m, and an 8-10 amino 
acid peptide.  The vast majority of current data supports a role for this fully folded 
structure to exist and function essentially as a monomer, one single MHC class I 
molecules being recognised by a single receptor, eg TCR or NK receptor.  However, the 
expression of non-conventional MHC class I structures at the cell surface has been 
widely documented (reviewed in Arosa et al., 2007). 
 
Free Heavy Chains 
 
In 1990, Schnabl et al. showed that MHC class I heavy chains not associated with β2m 
(free HCs) were present on the surface of activated T-lymphocytes (Schnabl et al., 1990).  
This was confirmed by Madrigal and colleagues, who also showed the presence of similar 
molecules on EBV-transformed B-lymphocytes (Madrigal et al., 1991).  More recently, it 
has again been demonstrated that free HCs are not readily detectable on the surface of 
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normal human T cells but are enhanced in response to T cell activation and proliferation 
(Santos et al., 2004).  There is evidence to suggest that small stable populations of MHC 
class I heavy chains not associated with β2m and/or peptide exist ubiquitously on the 
surface of all MHC class I-expressing cells (Carreno ref 1994), however abundant 
expression is predominantly seen at the cell surface of activated lymphocytes (Bix and 
Raulet, 1992, Matko et al., 1994, Schnabl et al., 1990, Madrigal et al., 1991, Santos et al., 
2004).   
 
MHC class I folding in the ER, enabling a stable association with β2m and peptide to 
occur, is a tightly regulated process involving several chaperones and accessory 
molecules.  Nascent MHC class I heavy chains not associated with β2m are usually bound 
to calnexin and are prevented from exiting the ER (Rajagopalan and Brenner, 1994).  
This would imply that most free HCs originate from the unfolding of cell surface 
heterotrimers.  In this regard, Pickl et al. showed that free HCs on the surface of activated 
T cells arise following internalisation of fully folded class I molecules (Pickl et al., 1996), 
and Santos et al. demonstrated that free HCs on the surface of normal T-lymphocytes 
were resistant to Endo H digestion, indicating they had achieved successful transit from 
the ER (Santos et al., 2004).  However, in β2m knockout mice, some surface expression 
of class I molecules has been detected, suggesting that, at least in mice, some free heavy 
chains can exit from the ER without associating with β2m (Bix and Raulet, 1992). 
 
The exact role of free heavy chains has not yet been determined although some evidence 
suggests they are important for the stimulation of T-cells.  Bodnar et al. have 
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demonstrated that free HCs are important in the clustering of MHC class I molecules at 
the cell surface, a process that can be decreased in response to the addition of exogenous 
β2m, reducing the number of free HCs, and therefore clustering, lowers the effectiveness 
of cytotoxic T cells (Bodnar et al., 2003).  Beretta et al. showed that blocking of a cell 
surface protein on monocytes, that was later shown to be free MHC class I heavy chains, 
efficiently inhibits the proliferation of responsive lymphocytes (Beretta et al., 1987, 
Grassi et al., 1991).  Taken overall these data suggest that free HCs can be functionally 
important for the stimulation of some T cells. 
 
MHC Class I Homodimers 
 
Dimeric HLA class I complexes were first identified from human cell lines in the early 
1970s (Cresswell and Dawson, 1975).  These dimers were thought to consist of two 
heavy chains disulfide bonded together, non-covalently associated with β2m.  However a 
second report published by the Strominger lab suggested these dimeric complexes were 
not naturally found in the membrane of the cell but were instead a product formed during 
the purification method (Springer et al., 1977). 
 
Several years later dimeric mouse class I heavy chains were isolated from the surface of a 
number of cell lines, the formation of which is believed to be regulated by the availability 
of β2m (Capps et al., 1993).  These dimers were disulfide bonded through a free cysteine 
residue in the cytoplasmic tail (Capps et al., 1993). 
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The formation of homodimers has functional consequences for immune recognition.  The 
non classical MHC class I molecule, HLA-G, is predominantly expressed during 
pregnancy on fetal trophoblast cells that invade the decidua during placentation 
(McMaster et al., 1995).  It is unusual amongst class I molecules because of its ability to 
form β2m-associated homodimers through an unpaired cysteine residue at position 42, 
situated on an exposed loop beneath the α1 peptide-binding helical region (Boyson et al., 
2002, Gonen-Gross et al., 2003).  A cysteine at this position is unique to HLA-G alleles, 
implying this type of complex is only formed by HLA-G.  There is convincing evidence 
that LILRB1 and LILRB2 recognise the dimeric form of HLA-G more strongly than the 
monomeric form (Shiroishi et al., 2006, Gonen-Gross et al., 2003, Apps et al., 2007) and 
a chimeric LILRB1 reporter cell assay showed that dimeric HLA-G was required at 100-
fold lower concentrations than monomeric HLA-G to induce signalling (Shiroishi et al., 
2006). 
 
HLA-B27 Cell Surface Homodimers 
 
HLA-B27 homodimers were first isolated in 1999 during in vitro folding studies (Allen et 
al., 1999).  Misfolded HLA-B27, particularly homodimers, have been implicated in the 
pathogenesis of AS and related spondyloarthropathies, either by misfolding in the ER 
which may result in the activation of a proinflammatory stress response (Colbert, 2000), 
or through their presence at the cell surface.  Cell surface homodimers may be involved 
in peptide presentation or be recognised themselves as neoantigens by some immune 
receptors (Allen et al., 1999).  
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Homodimers can be recognised by both HC10 and W6/32 monoclonal antibodies, and it 
has been demonstrated that these are distinct populations (Allen et al., 1999, Dangoria et 
al., 2002).  HC10 reactive dimers form early after heavy chain synthesis suggesting they 
form within the ER, whereas W6/32 reactive dimers are formed much later suggesting 
they form following exit from the ER (Dangoria et al., 2002).  However, both populations 
can be isolated from the cell surface, indicating HC10 reactive dimers can also form at a 
later time point (Dangoria et al., 2002).  Consistent with this finding, Bird et al. 
demonstrated that HC10 reactive cell surface homodimers could form from fully folded 
heterotrimers that are internalised and recycled back to the cell surface via an endosomal 
compartment (Bird et al., 2003).   
 
Comparative analysis of dimer formation in cell lines expressing HLA-B8, -A2 or -B53 
showed no evidence of dimer formation although some HLA-B7 dimers were detected, 
dimers formed by HLA-B7 were fewer in total than those formed by HLA-B27, and more 
of the HLA-B7 species were W6/32 reactive (Dangoria et al., 2002).  These data indicate 
that dimer formation is not unique to HLA-B27 but may differ quantitatively and 
qualitatively between MHC class I alleles. 
 
HLA-B27 possess the relatively rare cysteine residue at position 67 in its α1 domain, 
pointing into the peptide-binding groove.  This cysteine has been strongly implicated in 
the formation of HC10 reactive homodimers (Allen et al., 1999, Dangoria et al., 2002, 
Bird et al., 2003).  Since their initial discovery, HLA-B27 homodimers have subsequently 
been detected in HLA-B27 transgenic rats, as well as on populations of peripheral blood 
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and synovial fluid monocytes from patients with spondyloarthritis (Kollnberger et al., 
2002, Tran et al., 2004, Kollnberger et al., 2004).  These HLA-B27 homodimers have 
been identified as ligands for several killer immunoglobulin-like receptors (KIR) and 
leukocyte immunoglobulin-like receptors, notably KIR3DL2 (Kollnberger et al., 2002, 
Allen and Trowsdale, 2004).  
 
Supporting the theory that an abnormal interaction between immune receptors and 
homodimers are implicated in disease, Chan et al have detected increased numbers of NK 
cells and CD4+ T cells expressing KIR3DL2 from patients suffering with 
spondyloarthritis (Chan et al., 2005).  These results demonstrate that B27 homodimers 
are recognised by a specific, although overlapping, subset of receptors compared with 
traditional, fully folded B27 molecules, and that at least one of these receptors is 
enhanced in patients suffering with spondyloarthritis. 
 
In addition to the above, we also recently published data showing that, in the KG1 DC-
like cell line and human monocyte-derived DCs from a HLA-B27+ individual, HLA-B27 
homodimers are a transiently expressed population that are induced in response to 
activation (Santos et al., 2008).  Overexpression of an HLA allele alone is most likely not 
enough to confer disease susceptibility, since the HLA-B7 transgenic rats express -B7 to 
a similar level as the disease-prone HLA-B27 transgenic rats, but remain healthy (Taurog 
et al., 1999).  Overall, HLA-B27 appears to be more susceptible to form dimers than 
other alleles.  Defining the conditions under which non-disease associated MHC class I 
molecules can form dimers may therefore provide crucial information to our 
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understanding of the factors that predispose HLA-B27 to form dimers.  Indeed, if HLA-
B27 dimers are a significant driving force in the development of AS, then we may gain 
important insights from studying how other MHC class I dimers may contribute to 
disease, since we must always be aware that the incidence of HLA-B27 in AS patients is 
around 90-95 %, showing that AS can develop in the context of numerous other MHC 
class I alleles present in the human population. 
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Results 
 
HLA-B8 forms homodimers in the .220 cell line when expressed in combination with 
human tapasin. 
 
The 721.220 cell line (referred to forthwith as .220) lacks HLA-A and HLA-B alleles but 
retains partial expression of HLA-Cw1 (Greenwood et al., 1994).  The cell line is also 
tapasin deficient (Copeman et al., 1998) resulting in many MHC class I alleles being 
expressed at the cell surface after transfection at relatively low levels.  In fact this system 
has been used to define the tapasin dependency of several MHC class I alleles, and also 
to determine residues in the peptide-binding groove which are important for this activity 
(Park et al., 2003).  HLA-B27 is a relatively tapasin-independent allele whereas HLA-B8 
is more dependent on the function of this accessory molecule (Peh et al., 1998).  Normal 
cell-surface expression of tapasin dependent alleles can be restored by transfection with 
tapasin cDNA (Peh et al., 1998) (Park et al., 2003). 
 
Stable .220 cell lines expressing either HLA-B27, HLA-B8 or HLA-B8 and human 
tapasin (htpn) were generated by electroporation (B27), or were already available for use 
in the laboratory from previous studies (B8 and B8.htpn).  The cell lines were 
characterised by flow cytometry (Figure 4.1 A) and western blotting (Figure 4.1 B).   
 
Wild-type .220 cells display low levels of background staining with the W6/32 antibody, 
however the transfected alleles are clearly expressed on the cell surface above this 
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background level (Figure 4.1 A).  The .220.B8 cell line expresses the least class I on the 
cell surface, in line with its reported dependence on tapasin (Peh et al., 1998).  Restoring 
tapasin in .220.B8.htpn cells significantly increases this cell surface expression.  The 
.220.B27 cell line expresses at the cell surface at a level intermediate between .220.B8 
and .220.B8.htpn cells.  Immunoblotting with HC10 of quantified detergent cell lysates 
indicate that the .220.B8.htpn cells have much higher levels of heavy chain in comparison 
to .220.B8 cells (Figure 4.1 B).  In part this may be due to the known ability of tapasin to 
stabilise MHC class I molecules, which otherwise would be unstable and undergo 
degradation.  In contrast .220.B27 cells express the least amount of detectable heavy 
chain, but nevertheless express more of this at the cell surface in a folded conformation 
than .220.B8 cells (Figure 4.1 A), confirming the ability of HLA-B27 to assemble in a 
relatively tapasin independent manner. 
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Figure 4.1: Characterisation of stably transfected .220 cell lines.   (A) The expression 
of the indicated transfected MHC class I allele on the cell surface was analysed by flow 
cytometry.  Cells were stained with W6/32 and FITC anti-mouse IgG.  (B) Whole cell 
lysates were quantified using the Bradford method.  20 ug of protein was loaded in each 
case. Samples were resolved by 8 % SDS-PAGE, transferred to membrane, and 
visualized through western blotting with HC10.  Results are representative of at least 3 
experiments.  
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The formation of HLA-B27 homodimers has been well characterised when expressed in 
.220 cells (Bird et al., 2003, Kollnberger et al., 2007).  However, in the .220.B27 cells we 
generated we were unable to detect higher molecular weight complexes when analysed in 
non-reducing conditions.  In marked contrast, .220.B8.htpn cells display a high molecular 
weight species in the size range expected for a MHC class I dimer of around 80 kDa 
under non-reducing conditions, which, under reducing conditions, resolves to form a 
single monomeric band (Figure 4.2). 
 
 
 
Figure 4.2: .220.B8.htpn cell lysates, but not .220.B27 lysates, contain a higher 
molecular weight complex that resolves to a monomer upon reduction.  Detergent 
cell lysates were quantified using the Bradford method.  20 µg of protein was loaded in 
each lane.  Samples were resolved by 8 % SDS-PAGE, in non-reducing and reducing 
conditions, before western blotting.  The membrane was probed with HC10.  Results are 
representative of at least 3 experiments. 
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This high molecular weight complex is also not present in the .220.B8 cell line, 
suggesting that the formation of this complex is either as a result of the expression of 
tapasin, or due to the increased amount of class I heavy chain, which as mentioned above, 
may in itself be a result of the presence of tapasin. 
 
The presence of a high molecular weight species does not prove the formation of a MHC 
class I dimer, since a similar result could be obtained by an MHC class I molecule being 
disulfide bonded to another (non-MHC class I) molecule of similar size.  Therefore, in 
order to further characterise this higher molecular weight complex, cell lysates were 
subject to 2-dimensional electrophoresis.  The principle behind this analysis is that two 
MHC class I heavy chains linked together would have the same isolelectric point as a 
monomer MHC class I heavy chain, thus a true dimer spot would focus directly above the 
monomer.  However, a heavy chain linked to another species would, more likely than not, 
result in a different focusing dimer spot.  Detergent lysate samples of the .220.B8.htpn 
cells were therefore separated in the first dimension by isoelectric focusing (IEF) and in 
the second dimension by non-reducing SDS-PAGE, followed by western blotting with 
HC10. 
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Figure 4.3: The higher molecular weight band represents a pool of B8 homodimers.  
Non-reducing two-dimensional electrophoresis and immunoblottting was carried out to 
determine if the higher molecular weight complex was a B8 homodimer.  Cell lysates 
were resolved, in the first dimension by isoelectric point and in the second dimension by 
molecular weight, and spots revealed with HC10. Results are representative of at least 2 
experiments. 
 
Figure 4.3 shows the presence of two HC10 reactive spots with essentially the same 
isoelectric point, allowing for minor distortions of the gel, one corresponding to the 
monomeric species seen in the cell lysates and the other running at the same molecular 
weight as the higher molecular weight complex also seen in the lysates (figure 4.2).  This 
is strong evidence that the high molecular weight species represents a HLA-B8 heavy 
chain dimer. 
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HLA-B8 homodimers are expressed at the cell surface. 
 
To determine whether the HLA-B8 dimers are present on the cell surface we utilised a 
technique involving global biotinylation of cell surface proteins, followed by detergent 
lysis and specific isolation of the biotin-lablled cell surface species with streptavidin 
coupled beads.  Immunoblotting is then used to detect the presence of the protein of 
interest, in this case MHC class I heavy chains.  As a control, to check that only cell 
surface MHC class I was being isolated we took advantage of a transfectant of the C58 
cell line expressing HLA-B27 with a cysteine to serine mutation at position 101 (one of 
the conserved structural cysteine residues).  Mutation of this cysteine prevents the class I 
allele from folding correctly and it does not egress from the ER to the cell surface, and 
should therefore not be labelled with the sulfo-derivative of biotin used in this technique. 
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Figure 4.4: .220.B8.htpn homodimers are expressed at the cell surface.  Cells were 
alkylated with NEM for 10 minutes on ice before being incubated with EZ-Link sulfo-
NHS-LC-Biotin for a further 10 minutes on ice.  Free biotin was quenched with TBS 5 % 
FBS before cell lysis.  Lysates were then subject to streptavidin-agarose pull-down.  
Samples were resolved by 8 % SDS-PAGE before western blotting with HC10.  Results 
are representative of at least 3 experiments. 
 
Figure 4.4 shows the results of the cell surface biotinylation and streptavidin pull-down.  
The right-hand panel shows that monomeric class I was isolated from the surface of both 
the .220.B8 and .220.B8.htpn cell lines, and also from the C58.B27.SV5 control cell line.  
Significantly, the B8 dimer molecule described in the .220.B8.htpn cell line was also 
isolated from the cell surface.  The control lysate blot (left panel) demonstrates that the 
C58.B27.C101S.SV5 cell line is expressing the transfected HLA-B27 construct, but it is 
not detected on the cell surface (streptavidin pull-down), indicating that our technique is 
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specifically labelling cell-surface proteins.  This experiment clearly demonstrates that 
MHC class I dimers formed by non-HLA-B27 MHC class I molecules can be expressed 
at the cell surface. 
 
To try to determine what factors influence dimer formation in the .220.B8.htpn cell line 
we first looked at the assembly kinetics of HLA-B8 in the transfectants by determining 
how fast HLA-B8 alleles in the .220.B8.htpn cell line acquired Endo H resistance, an 
indicator of assembly and exit from the ER.  HLA-B27 is known to have slower folding 
kinetics than many other class I alleles, a factor which may influence dimer formation 
within the ER (Antoniou et al., 2004, Mear et al., 1999). 
 
Figure 4.5: Class I molecules in the .220.B8.htpn cell line exit the ER within 30 
minutes after synthesis.  Cells were incubated in methionine-free RPMI for 15 minutes 
prior to labelling with [35S] methionine.  Labelling was stopped by resuspending the cells 
in media containing cold methionine.  Aliquots were taken at 0, 30 and 90 minutes post 
labelling.  Cells were lysed and immunoprecipitated with antibody W6/32.  After 
immunoprecipitations samples were treated with Endo H.  Samples were resolved by 
SDS-PAGE and gels were fixed and dried.  Dried gels were exposed to X-ray film.  Endo 
H sensitive bands are indicated with an S and resistant bands are indicated with an R. 
Results are representative of at least 2 experiments. 
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In the .220.B8.htpn cell line, HLA-B8 can be seen to begin to exit the ER after 30 
minutes (Figure 4.5).  After 90 minutes approximately half of the labelled molecules had 
gained Endo H resistance.  In marked contrast HLA-B8 molecules in the .220.B8 cell line 
failed to gain Endo H resistance even after 90 minutes of chase.  These results indicate 
that the presence of tapasin results in rapid folding kinetics for the HLA-B8 allele.  In the 
context of this system it does not, however, lend support to the theory that slow folding 
kinetics predispose to MHC class I dimer formation, as has been proposed for HLA-B27. 
 
It has been reported that the treatment of HLA-B27 expressing cells with chloroquine 
prevents homodimer expression at the cell surface (Bird et al., 2003).  Chloroquine is a 
lysosomotrophic agent that neutralises the pH in endosomal and lysosomal 
compartments.  We first investigated the affect of chloroquine on the total pool of HLA-
B8 dimers in cell lysates before investigating any specific effects on cell surface dimers.  
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Figure 4.6: Chloroquine treatment influences the level of dimers in whole cell 
lysates.  Cells were grown in RPMI with or without 100 µM chloroquine for 24 hours at 
37 °C in a humidified atmosphere of 5 % CO2 in air.  Cells were lysed in the presence of 
NEM and samples were resolved by 8 % SDS-PAGE before HC10 western blot. 
 
Pre-treatment of cells with chloroquine decreased the detectable pool of B8 dimers 
(Figure 4.6).  However, cell surface biotinylation and streptavidin pull-down studies 
show that although decreased, dimers at the cell surface were not abolished when cells 
were pre-treated with chloroquine (Figure 4.7). 
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Figure 4.7: Chloroquine treatment decreases but does not abolish dimers at the cell 
surface.  Cells were grown in RPMI with or without 100 µM chloroquine for 24 hours at 
37 °C in a humidified atmosphere of 5 % CO2 in air.  Cells were alkylated with NEM for 
10 minutes on ice before being incubated with EZ-Link sulfo-NHS-LC-Biotin for a 
further 10 minutes on ice.  Free biotin was quenched with TBS 5 % FBS before cell lysis.  
Lysates were then subject to streptavidin pull-down.  Samples were resolved by 8 % 
SDS-PAGE and HC10 western blot. 
 
By altering the pH of the endosomal compartment, chloroquine is believed to disrupt the 
endosomal recycling process that is necessary for the formation of HLA-B27 
homodimers at the cell surface.  These results indicate that HLA-B8 dimer formation at 
the cell surface in our system may not be occurring in the same way as for the HLA-B27 
homodimers so far described in the literature (Bird et al., 2003). 
 
Further cell treatments were carried out in order to investigate what may influence dimer 
formation in the HLA-B8 allele.  This laboratory has previously used the oxidising agent 
diamide to probe interactions within the components of the MHC class I peptide loading 
complex (Santos et al., 2007).  The addition of diamide rapidly depletes cellular stocks of 
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glutathione (GSH), thus generating highly oxidising conditions.  Treatment of cells with 
the oxidising agent diamide revealed interesting results.  Cells were treated with 
increasing concentrations of diamide for a period of 10 minutes at 37 oC, and detergent 
cell lysates were then resolved by SDS-PAGE before HC10 western blotting. 
 
 
Figure 4.8: Incubation of cells with diamide can enhance the formation of dimers.  
Cells were treated with diamide in RPMI for 10 minutes at 37 °C.  Cells were lysed and 
then protein quantified using the Bradford method.  Samples were resolved by 8 % SDS-
PAGE before western blotting.  The membrane was probed with HC10.  Results are 
representative of at least 3 experiments. 
 
Changing the cellular environment using the oxidising agent diamide enhances the 
formation of HLA-B8 dimers in a concentration dependent manner (Figure 4.8).  In the 
.220.B8 cell line, where dimers are not usually seen, higher concentrations of diamide 
induces such dimers.  Dimers are also enhanced in the .220.B8.htpn cell line by the 
addition of diamide.  These data indicate that the redox environment is important in the 
formation of the HLA-B8 dimers characterised in the .220 cells. 
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Introduction of the HLA-G-specific cysteine at position 42 into HLA-B27 
 
HLA-G is a non-classical MHC class I allele that has the capacity to form dimers 
between two fully folded monomers.  These dimers form through a unique cysteine 
residue at position 42 in the α1 domain.  Site-directed mutagenesis of HLA-B27 cDNA 
was utilised to generate a HLA-B27 mutant (denoted B27.S42C) with this extra cysteine 
at position 42.  Mutagenic primers were designed using the program Primer X to generate 
the alteration indicated in figure 4.9. 
 
 
Figure 4.9: Sequence of region affected by cysteine 42 mutation.  Mutagenic primers 
were designed using the bioinformatics program, Primer X.  Mutagenesis experiments 
were carried out on full-length HLA-B27 cDNA contained within the pCR3 plasmid.  
The mutated dsDNA was transformed into JM109 competent cells.  The bacterial cultures 
were then used for plasmid purification.  Purified plasmid DNA was checked by 
restriction digestion and confirmed by DNA sequencing. 
 
HLA-B27.S42C cDNA and wt HLA-B27 cDNA were transiently transfected into HeLa 
cells.  Cell lysates were resolved by SDS-PAGE and immunoblotted with HC10.  Lysate 
derived form .220.B8.htpn cells, which display good levels of HLA-B8 dimers, were 
included as a control. 
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Figure 4.10: Introduction of an HLA-G-specific cysteine at position 42 in HLA-B27 
enhances the formation of dimers of a similar molecular weight to B8 homodimers.  
Cells were transfected using Fugene 6 with 1 µg of pCR3 plasmid DNA containing the 
mutated HLA-B27 cDNA or the wild type HLA-B27 cDNA.  Transient transfectants 
were harvested 24 hours after transfection.  Cells were lysed and samples resolved by 8 
% SDS-PAGE before western blotting.  The membrane was probed with HC10. 
 
The introduction of the HLA-G-specific cysteine at position 42 to form B27.S42C 
significantly altered the pattern of dimer bands in comparison to wt HLA-B27 (Figure 
4.10).  A predominant new dimer band resolved in B27.S42C, most likely produced by 
the formation of cys42-linked dimers, which also closely matched the size of HLA-B8 
dimers seen in .220.B8.htpn cells.  Taken together, these data suggest that the dimers 
formed by both HLA-B8 and B27.S42C are folded dimers. 
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Figure 4.11: Stable expression of mutant HLA-B27.S42C.  HeLa cells were 
transfected using Fugene 6 with 1 µg of pCR3 plasmid DNA containing the mutated 
HLA-B27 cDNA, mutated HLA-B27 cDNA with a 14 amino acid SV5 tag, or the wild 
type HLA-B27 cDNA.  Cells were put into selective medium 24 hours after transfection.  
If necessary, positive cultures were enriched using magnetic beads and/or dilution 
cloning.  Cells were lysed and samples resolved by 8 % SDS-PAGE before western 
blotting.  The membrane was probed with HC10. Results are representative of at least 2 
experiments. 
 
Stable cell lines were also created and analysed by western blot (Figure 4.11).  The 
B27.S42C dimer band was visible in cell lines created using untagged and SV5 epitope 
tagged B27.S42C cDNA.  The addition of the 14 amino acid SV5 tag created a small 
increase in size of the new dimer band (lane 3).  Higher molecular weight bands were 
also visible in the B27.S42C mutants, which likely represent the already described 
‘unfolded’ homodimer structure.   
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To confirm that the B27.S42C dimer band was in fact a true homodimer formed between 
HLA-B27 heavy chains, we performed two-dimensional electrophoresis, separating in the 
first dimension by isoelectric focusing and in the second dimension by molecular weight, 
followed by immunoblotting with either HC10 or the SV5 tag specific monoclonal 
antibody pk. 
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Figure 4.12: HLA-B27.S42C dimers are confirmed by 2-dimensional 
electrophoresis.  Stably expressing cell lines were lysed and resolved in the first 
dimension by isoelectric point, and in the second dimension by molecular weight, 
followed by western blot with the either HC10 or, the anti-SV5 tag antibody, pk. Results 
are representative of at least 2 experiments. 
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A higher molecular weight spot visible in the HeLa.B27.SV5 cell line migrated with the 
same isoelectric point as the HLA-B27 monomer (Figure 4.12, top panel) confirming this 
spot as a HLA-B27 dimer.  In both cell lines expressing HLA-B27 with the S42C 
mutation this same spot remained (Figure 4.12, middle and lower panels) but in addition, 
a new dominant set of spots apperared.  These new S42C-induced spots, also retained the 
same isolelectric point as mononmeric HLA-B27 heavy chain, and are therefore 
representative of heavy chian dimers.  Furthermore the relative molecular mass of the 
wtB27 and B27.S42C dimers in these gels corresponds to that seen in normal SDS-
PAGE, as shown in Figures 4.10 and 4.11.  The HC10 immunoblot of HeLa.B27.S42C 
lysate also indicates the MHC class I signal derived from the endogenous HeLa MHC 
class molecules that focus to the left of the HLA-B27 spots, but do not form dimer spots. 
The multiple spots generated by HLA-B27 with the same size, for example in the middle 
panel of Figure 4.12, are usually indicative of either phosporylation of some of the 
proteins, or small charge modifications that occur during the loading and running of the 
gels. 
 
It was next investigated whether or not the B27.S42C dimer detected in HeLa 
transfectants was expressed at the cell surface, using the cell surface biotinylation and 
streptavidin pull-down technique already described. 
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Figure 4.13: B27.S42C homodimers are expressed at the cell surface.  Cells were 
alkylated with NEM for 10 minutes on ice before being incubated with EZ-Link sulfo-
NHS-LC-Biotin for a further 10 minutes on ice.  Free biotin was quenched with TBS 5 % 
FBS before cell lysis.  Lysates were then subject to streptavidin-agarose bead pull-down.  
Samples were resolved by 8 % SDS-PAGE and HC10 western blot. Results are 
representative of at least 2 experiments. 
 
Control lysates from the samples used for the streptavidin pull down (Figure 4.13, left 
panel) show the same pattern of dimers as previously seen for these cell lines (Figures 
4.10 & 4.11).  Streptavidin pull-down indicates that the dimers that are formed in the 
B27.S42C mutant are expressed at the cell surface.  The higher molecular weight dimers 
seen in lysates are not detected at the cell surface, suggesting that these are dimer species 
that do not exit the ER.  
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Formation of dimer structures in other non-disease related MHC class I alleles. 
 
The data presented so far in this chapter suggest that HLA-B8 molecules can be detected 
as homodimer structures when expressed in .220.B8.htpn cells, but not in .220.B8 cells.  
Furthermore the .220.B27 cells generated in this chapter also do not appear to form 
significant dimer structures.  An observation that arises from these experiments is 
whether the high level of HLA-B8 heavy chain expression present in the .220.B8.htpn 
cells is a contributing factor in the formation of these dimers, and that the lower levels of 
HLA-B8 and -B27 in the other .220 lines prevents them from forming dimers. 
 
To address this question transient transfection of MHC class I molecules into HEK293 
cells, a well-established system used for over-expression studies, was investigated.  Rat 
C58 cell lines stably expressing the human MHC class I alleles HLA-B*2705, -B*0702, 
B*5101, and B*3501 were created, and the same alleles were transiently transfected into 
HEK293 cells.  In C58 cells, only HLA-B27 formed dimer-like bands, whereas in marked 
contrast, in HEK293 cells all the tested class I alleles produced complex, multiple dimer 
bands.  This suggest that over expression of MHC class I alleles may be a contributory 
factor in the formation of MHC class I homodimers, and may explain why HLA-B8 
dimers are detectd in .220.B8.htpn cells. 
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Figure 4.14: Dimer formation by non-AS associated HLA class I alleles in HEK293 
cells.  All the HLA class I alleles were cloned into the pCR3 or pCDNA3 mammalian 
expression vectors.  C58 cell lines were generated through electroporation and stable 
lines selected by G418 selection.  HEK293 cells were transiently transfected with 1µg 
DNA and Fugene 6.  After 24 hours, cell lysates were prepared and immunoblotted with 
HC10.  UT represents untransfected cells.  HEK293 cells express only very low levels of 
endogenous MHC class I, and the endogenous rat MHC class I in C58 cells is not 
detected by HC10.  This experiment was performed in conjunction with Dr S Powis. 
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Discussion 
 
The discovery that HLA-B27 misfolds forming non-conventional structures (Mear et al., 
1999), has formed the basis of a new avenue of research into AS, focussing on the 
intrinsic properties of HLA-B27 folding rather than its antigen presenting abilities.  In 
particular the formation of HLA-B27 homodimers has been implicated in the 
pathogenesis of disease (Allen et al., 1999, Colbert, 2000). Nevertheless, if HLA-B27 
dimers are involved in driving forward the inflammatory process that leads to AS, there 
must also be an explanation as to why 5-l0 % of AS patients do not carry the HLA-B27 
gene.  If it were to be the case that other MHC class I alleles could also, under specific 
conditions, form dimeric structures, then this may support the dimer-disease hypothesis. 
 
The formation of homodimers in other class I alleles has been reported previously 
(Dangoria et al., 2002, Santos et al., 2008).  However, the circumstances in which they 
form and what influences their formation has not been fully investigated.  Using 
primarily the .220 cell line, that has previously been used to study the formation HLA-
B27 homodimers (Bird et al., 2003), the formation of HLA-B8 homodimers has been 
studied in this chapter.  
 
Stable .220 cell lines expressing HLA-B27, -B8 or -B8 and human tapasin (B8.htpn) 
were characterised by western blotting and flow cytometry (Figure 4.1).  In the .220.B27 
cell line that we used, low total HLA-B27 expression was detected although HLA-B27 
was still expressed at the cell surface consistent with this allele being relatively tapasin 
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independent (Peh et al., 1998).  In a previous report Bird and colleagues showed that 
HLA-B27 transfected into .220 cells forms dimers (Bird et al., 2003).  These results 
significantly differ from the data shown here, and it is likely, based on the other data 
presented here that this is due to the low levels of HLA-B27 expression in our .220.B27 
cell line.  However, it cannot be ruled out that dimers are forming but at a level lower 
than our current system is able to detect.  
 
HLA-B8 was detected on the surface of .220.B8 cells, and it has previously been 
demonstrated that cell surface expression of this allele shows an intermediate level of 
tapasin dependency (compared with HLA-B27 and other alleles) (Peh et al., 1998).  We 
were unable to detect dimers in the .220.B8 cell line (Figure 4.2), similarly Dangoria et 
al. were also unable to detect HLA-B8 dimers in another human lymphoblastoid cell line, 
C1R (Dangoria et al., 2002).  However in our system, co-expression of HLA-B8 with 
human tapasin enhances the expression of HLA-B8 heavy chain and also results in the 
formation of a higher molecular weight complex that we have confirmed to be a HLA-B8 
homodimer (Figures 4.2 & 4.3).  This dimer formation could either be related to the 
presence of tapasin or to the enhanced expression of HLA-B8.  Re-expression of tapasin 
in a .220 cell line expressing HLA-B27 resulted in an overall reduction in dimer 
formation (Dangoria et al., 2002), suggesting that the increase in HLA-B8 dimers is more 
likely to be due to the enhanced expression of the HLA-B8 heavy chain.  
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To determine whether HLA-B8 dimers are present at the cell surface we performed cell 
surface biotinylation experiments (Figure 4.4), which revealed that HLA-B8 homodimers 
are present at the cell surface. 
 
A higher molecular weight band is also visible in .220.B8.htpn and .220.B8 cell lines as 
well as in the two C58 cell lines expressing HLA-B27 alleles (Figure 4.4).  It is 
interesting to speculate that these bands may represent a more unfolded class I dimer 
structure, however it is not clear whether this band is also present in the .220.B8.htpn 2D 
gel which would confirm it as a class I dimer band.  Previously two structures for dimers 
have been observed, a more folded structure that is detected by W6/32 and an unfolded 
structure detected by HC10 (Dangoria et al., 2002, Allen et al., 1999).  In the study by 
Dangoria et al., the pool of HC10 reactive dimers were more heterogenous than the 
W6/32 reactive pool, with some bands being of a higher molecular weight than the 
W6/32 dimers.  
 
The slower folding of HLA-B27 is one of the factors that have been directly implicated in 
the formation of HLA-B27 homodimers (Mear et al., 1999, Antoniou et al., 2004).  To 
determine whether the folding of HLA-B8 in the .220.B8.htpn cell line could be involved 
in the formation of HLA-B8 dimers, we compared the folding efficiency of HLA-B8 in 
the .220.B8 cell line and the .220.B8.htpn cell line (Figure 4.5).  Pulse chase analysis 
showed that HLA-B8 folded more efficiently in the .220.B8.htpn cell line.  In the .220.B8 
cell line, HLA-B8 molecules had not gained Endo H resistance 90 minutes post chase, 
consistent with the fact that in the absence of tapasin most class I alleles are unable to 
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fold properly, preventing them from exiting the ER.  This result suggests that slower 
folding does not influence the formation of HLA-B8 homodimers in the .220 cell line, 
which is therefore in contrast to the published data on this point. 
 
Cell surface expression of HLA-B27 homodimers in the .220.B27 cell line is dependent 
on the internalisation and recycling of cell surface heterotrimers via an endocytic 
compartment, a process that can be blocked using lysomotrophic agents such as 
chloroquine (Bird et al., 2003).  To determine whether chloroquine could influence the 
formation of HLA-B8 homodimers we incubated cells with chloroquine for 24 hours.  In 
our system chloroquine was able to decrease the total amount of dimers but did not 
prevent their presence at the cell surface altogether (Figure 4.6 & 4.7).  
 
Incubation of cells with diamide, to dramatically alter the redox balance within the cells, 
led to an interesting result (Figure 4.8).  Homodimers were enhanced in a concentration 
dependent manner in the .220.B8.htpn cell line, and could be induced at higher diamide 
concentrations in the .220.B8 cell line.  This suggests that the redox status of cells is 
normally balanced towards the prevention of MHC class I dimer formation. 
 
Dimer formation of the non-classical HLA-G allele occurs in vivo, and these homodimers 
are known to be involved in immune recognition (Shiroishi et al., 2006, Gonen-Gross et 
al., 2003, Apps et al., 2007).  This allele is unique amongst class I alleles because of the 
expression of a cysteine residue at position 42 (Cys42), and HLA-G homodimers form 
through Cys42-Cys42 interactions.  These dimers are fully folded and retain their 
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association with β2m (Boyson et al., 2002, Gonen-Gross et al., 2003).  They are therefore, 
by nature, significantly different from the partially unfolded HLA-B27 dimers proposed 
by Bowness and colleagues (Figure 1.9), which may be involved in AS (Bowness, 2002).   
 
 
Figure 4.15: Crystal structure of a β2m-associated HLA-G dimer.  The crystal 
structure of the disulfide-bonded dimer of the HLA-G-peptide (RIIPRHLQL) complex 
was solved in 2006.  The HLA-G heavy chain and β2m are represented in ribbon model 
and encased in a semitransparent surface (dark blue and pink, heavy chain; light blue and 
light pink, β2m; yellow stick model, peptide RIIPRHLQL) (Shiroishi et al., 2006). 
 
More recent data has shown that HLA-G can also form a β2m-free dimer that is similar in 
structure to β2m-containing HLA-G dimers, but these structures are differentially 
recognised by LILRB1 (Gonen-Gross et al., 2005). 
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To create a version of HLA-B27 that might mimic the dimer structure formed by HLA-G, 
HLA-B27 cDNA was mutated at position 42, changing a serine residue to a cysteine 
residue (Figure 4.9).  We compared HLA-B27.S42C dimers in HeLa cells with the HLA-
B8.htpn dimers by western blotting (Figure 4.10).  Both dimer species migrated with 
virtually identical size, indicating that HLA-B8 dimers in the .220.B8.htpn adopt a more 
folded structure, similar to that of HLA-G dimers.  Higher molecular weight species 
could also be detected in the HeLa.B27 and HeLa.B27.S42C samples.  Two-dimensional 
gel analysis indicated both the higher molecular weight band and the S42C-induced band 
were both homodimers (Figure 4.12).  However, cell surface biotinylation of these cell 
lines indicated that only the lower molecular weight dimer was present at the cell surface 
suggesting the other dimers may represent ER resident homodimers (Figure 4.13).  
 
The hypotheis put forward from this chapter is that the dimers formed by HLA-B8 in the 
.220.B8.htpn cell line form because of the increased expression of HLA-B8.  In support 
of this observation, over-expression of several other non-disease associated HLA class I 
alleles in HEK293 cells resulted in dimer-like structures forming.  We have recently 
shown that HLA-B27 dimers form in the KG1 dendritic cell-like cell line and in 
peripheral monocyte derived dendritic cells following cell activation, a process that 
results in the increase of total class I, suggesting enhanced class I expression can also 
influence HLA-B27 dimer formation (Santos et al., 2008).   
 
Increased expression of HLA-B27 has already been shown to be important in transgenic 
rat models, with only those animals expressing a high gene copy number developing 
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disease (Taurog et al., 1993) and HLA-B27+ AS patients have been shown to express an 
increased level of HLA-B27 heavy chains compared with healthy HLA-B27+ controls 
(Cauli et al., 2002).  It is proposed therefore that under some circumstances, increased 
expression of non-HLA-B27 alleles can result in the formation of MHC class I dimers, 
which may act as recognition structures at the cell surface for immune receptors, or 
contribute to ER stress activation within the environment of the ER.  It could therefore 
conceivably contribute to the disease process in a similar way as proposed for HLA-B27 
homodimers. 
 
 188 
Chapter V: HLA-B27 and Exosomes 
 
Introduction 
 
Exosomes are small vesicles released into the extracellular environment that can have 
both immunostimulatory and immunoinhibitory effects.  Although they are secreted by 
many cell types, those released by cells of the immune system are of particular 
importance to immunologists because of their potential use as immunomodulatory agents.  
 
This laboratory initiated a study into whether exosomes also bear the HLA-B27 dimer 
structures that have been implicated in the pathogenesis of AS, and therefore might be 
agents that would drive forward the disease process.  Initial studies were performed on 
the human EBV-transformed B cell cell-line Jesthom, which has been characterised as 
undergoing features of the UPR (Lemin et al., 2007), a feature relevant to the previous 
work undertaken in this thesis.  
 189 
Results 
 
Exosomes enriched in high molecular weight MHC class I complexes can be isolated 
from the supernatent of Jesthom cells. 
 
Exosomes were initially isolated, by filtration and ultracentrifugation, from the human B 
cell line, Jesthom (a gift from Adam Benham, University of Durham), which naturally 
expresses HLA-B27 and for comparison, were also isolated from the KG1 dendritic cell-
like cell-line.  Exosomes were imaged via electron microscopy. 
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Figure 5.1: Electron microscopy image of isolated exosomes.  Exosomes were isolated 
from (A) Jesthom cells or (B) KG1 cells, resuspended in 0.22 µm filter-sterile PBS and 
visualised using electron microscopy.  Electron microscopy was performed by Dr Alan 
Prescott, University of Dundee.  Results are representative of at least 2 experiments. 
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Electron microscopy revealed vesicles with ‘cup’ shape morphology, the characteristic 
shape of exosomes viewed under electron microscopy, with a diameter of approximately 
100 nm, also typical of exosomes, although exosomes from Jesthom cells appeared 
slightly larger overall (Figure 5.1).   
 
Exosomes usually contain a specific subset of proteins, differing in content from whole 
cell lysates, and are often enriched in MHC molecules and other molecules relevant to 
immune signalling.  We isolated exosomes from Jesthom cells and compared equal 
protein quantities of whole cell lysates with exosome lysates.  Samples were resolved by 
SDS-PAGE before western blotting with HC10. 
 
Figure 5.2: Exosomes contain enhanced amounts of HLA-B27 heavy chain dimers.  
Cell lysates and isolated exosomes were protein quantified using the Bradford method.  3 
µg of each sample was loaded and resolved by 8 % SDS-PAGE and western blotting. 
Results are representative of at least 3 experiments. 
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We found that, compared with whole cell lysates, Jesthom exosomes are enriched in 
MHC class I dimers (Figure 5.2).  This is an intriguing observation considering the 
speculative role of HLA-B27 homodimers in spondyloarthropathies and the reported 
abilities of exosomes to stimulate the immune system.   
 
To further characterise the exosomes from the Jesthom cell line, exosomes were analysed 
by mass spectrometry (Figure 5.3).  Bands were excised from a SDS-PAGE gel of 
exosomes, and submitted for in-gel tryptic digestion and mass fingerprinting. 
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Figure 5.3: Mass spectrometry of exosomes isolated from Jesthom cells.  Exosomes 
isolated from Jesthom cells were resuspened in lysis buffer and quantified using the 
Bradford method.  Approximately 3 µg of exosomes were resolved using 10 % SDS-
PAGE.  Gels were washed to remove any excess SDS before staining with Simply Blue 
Safe Stain.  Ten bands were cut out and analysed by mass spectrometry.  Mass 
spectrometry was performed by Dr Catherine Botting, University of St Andrews. 
 
Mass spectrometry revealed that exosomes isolated from Jesthom cell supernatent 
contained proteins characteristically known to be present in exosomes, (Figure 5.3).  In 
addition, we also identified the presence of CD48, a protein not previously reported in 
association with exosomes.  CD48 binds to the 2B4 molecule, which is expressed on NK 
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cells and some T cell subsets and mediates non-MHC-restricted toxicity (Valiante and 
Trinchieri, 1993) (Garni-Wagner et al., 1993).  
 
We also confirmed some of the mass spectrometry results, and further characterised the 
Jesthom exosomes, through western blotting (Figure 5.4). 
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Figure 5.4: Characterising proteins in exosomes and whole cell lysates.  Cell lysates 
and isolated exosomes were protein quantified using the Bradford method.  Samples were 
then resolved by 8 % or 10 % SDS-PAGE and western blotting.  Membranes were probed 
with antibodies to the indicated proteins.  Results are representative of at least 2 
experiments. 
 
Jesthom exosomes, as would be expected, are devoid of proteins normally resident in the 
ER (TAP1, ERp57, PDI).  They were also essentially devoid of CD74 (invariant chain), 
which has been previously reported to be absent in B cell-derived exosomes (reviewed in 
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Thery et al., 2002b), and also α-tubulin.  Western blotting reveals the presence of low 
levels of GILT (γ-interferon-inducible lysosomal thioredoxin) an enzyme involved in 
disulfide bond reduction in endosomal compartments, and also expected exosomal 
proteins such as vimentin and syntaxin (Mignot et al., 2006).  The mass spectrometry 
identification of CD48 was also confirmed by western blotting. 
 
To further investigate the MHC class I molecules on the surface of exosomes, we bound 
the exosomes to latex beads to permit analysis by flow cytometry (Figure 5.5). 
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Figure 5.5: Proteins on the surface of exosomes were analysed by flow cytometry.  
Exosomes isolated from Jesthom cell supernatant were bound to aldehyde-latex beads 
before analysis with flow cytometry.  Beads (solid grey) and beads with exosomes bound 
(black line) were both stained to show any non-specific binding.  Results are 
representative of at least 3 experiments. 
 
 198 
At the surface of exosomes, MHC class I can be detected in both a folded (eg ME1, 
BB7.2 and W6/32 reactive) and unfolded (HC10 reactive) conformation.  Somewhat 
unexpectedly, in contrast to the western blotting, that had revealed that exosomes 
contained a higher proportion of MHC class I dimers in comparison to monomers, the 
observed HC10 signal was relatively low in comparison to that of ME1.  This observation 
led us to further characterise the nature of these proposed MHC class I dimer structures. 
 
The high molecular weight band is an MHC class I homodimer. 
 
To confirm that this high molecular weight complex, believed to be dimers, was made up 
of two class I heavy chains, we analysed exosomes using two-dimensional 
electrophoresis.  Exosome lysate was separated in the first dimension by isoelectric 
focusing and in the second dimension by molecular weight (Figure 5.6). 
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Figure 5.6: Heavy chain dimers were confirmed by 2D electrophoresis.  Exosomes 
were isolated from Jesthom cell supernatants and were subject to lysis.  Samples were 
resolved in the first dimension by isoelectric point and in the second dimension by 
molecular weight before western blotting.  Membranes were probed with HC10.  Results 
are representative of at least 3 experiments. 
 
Figure 5.6 shows the presence of two HC10 reactive spots with the same isoelectric point, 
one corresponding to the monomeric species seen in the exosome lysates (left panel) and 
the other running at the same position as the higher molecular weight complex also seen 
in the lysate.  Having the same isoelectric point as the monomeric class I molecules make 
the chance of this complex being a class I monomer bound to another molecule unlikely, 
and indicate that this higher molecular weight species is a HLA-B27 homodimer. 
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Unexpectedly, another spot was also identified, migrating to the left and very slightly 
higher than the dimer spot.  Jesthom cells also express the class I allele, HLA-A2, and 
from previously published work, we knew that the HLA-A2 allele migrates to the left of 
HLA-B27 on this type of two-dimensional gel system (Antoniou et al., 2002b).  It was 
therefore hypothesised that this spot may be a mixed dimer consisting of one HLA-B27 
heavy chain and one HLA-A2 heavy chain.  The HC10 antibody used in the blot is 
capable of detecting only HLA-B and -C heavy chains.  Therefore, to confirm this 
hypothesis, we obtained monoclonal antibody HCA2, which recognises unfolded HLA-A 
heavy chains, and performed further two-dimensional electrophoresis, this time blotting 
with HC10 (unfolded B alleles), HCA2 (unfolded A alleles) or both HC10 and HCA2 
(Figure 5.7). 
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Figure 5.7: 2D electrophoresis reveals HLA-A2 dimers and novel A2-B27 dimers.  
(A) (B) and (C) Exosomes were isolated from Jesthom cell supernatants and were subject 
to lysis.  Samples were resolved in the first dimension by isoelectric point and in the 
second dimension by molecular weight before western blotting.  Membranes were probed 
with the indicated antibodies.  (D) Images from (A) and (B) were merged overlaying the 
central band.  Results are representative of at least 3 experiments. 
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Figure 5.7 A once again reveals the presence of dimeric HLA-B27 molecules with a 
further spot slightly higher and to the left of this dimer band.  When probed with HCA2 
(Figure 5.7 B) monomeric and dimeric HLA-A2 heavy chains are detected alongside 
another spot that migrates to the right of these dimers and slightly lower.  Membranes 
probed with HC10 and HCA2 (Figure 5.7 C) show monomeric and dimeric HLA-B27 
and HLA-A2 heavy chains, as in figures 5.7 A and B.  A single spot located between 
HLA-A2 dimers and HLA-B27 dimers migrates slightly lower than HLA-A2 dimers and 
slightly higher than HLA-B27 dimers.  Figure 5.7 D is the merged images of figure 5.7 A 
and B, this reveals the same pattern as the HC10 and HCA2 double blot (Figure 5.7 C).  
Taken together, the evidence strongly supports that this central spot represents a novel 
mixed dimer, consisting of an HLA-B27 heavy chain and an HLA-A2 heavy chain.  The 
identification of this mixed dimer immediately raises questions about these structures in 
comparison to those of HLA-B27 dimers reported to be involved in AS, which rely on a 
disulfide bond between Cys67 residues in HLA-B27.  HLA-A2 does not contain Cys67, 
thus the dimers identified here must be significantly different, warranting further 
characterisation. 
 
To further confirm the presence of both HC10 and HCA2 reactive dimers in exosomes, 
we compared Jesthom cell lysate with Jesthom exosomes by SDS-PAGE and western 
blotting (Figure 5.8). 
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Figure 5.8: HC10 and HCA2 reactive dimers resolve to form a single monomeric 
species in the presence of DTT.  Cell lysates and isolated exosomes were protein 
quantified using the Bradford method.  Samples were resolved, with or without DTT, by 
8 % SDS-PAGE and western blotting.  Membranes were probed with HC10 or HCA2 as 
indicated.  Results are representative of at least 3 experiments. 
 
Figure 5.8 confirms that both HC10 and HCA2 reactive dimers are enhanced in Jesthom 
exosomes compared with whole cell lysates.  In the presence of DTT both HC10 and 
HCA2 reactive dimers resolve to a single monomeric band. 
 
We further investigated the formation of HLA-A dimers using the KG1 dendritic cell-like 
cell line.  KG1 cells naturally express HLA-A3 and HLA-B35.  We prepared exosomes 
from KG1 cell supernatants, which were resolved by SDS-PAGE, before western 
blotting. 
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Figure 5.9: KG1 cells also contain HCA2 reactive dimers.  Exosomes were isolated 
from cell supernatants and were subject to lysis, whole cell lysates were prepared and 
samples were protein quantified using the Bradford method.  Samples were resolved by 8 
% SDS-PAGE before western blotting.  Membranes were probed with HC10 or HCA2 as 
indicated.  Results are representative of at least 2 experiments. 
 
Interestingly, KG1 cells contained HCA2 reactive dimers but not HC10 reactive dimers.  
This result suggests that some alleles are more prone to forming dimers than others, 
utilising a yet to be defined mechanism. 
 
The formation of MHC class I dimers, dependent on disulfide bonds, can be prone to the 
formation of artefactual structures, mostly occurring post-lysis.  To prevent this from 
occurring, it is routine to include the cell permeable alkylating agent NEM in pre-lysis 
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wash buffers and in the lysis buffers.  When isolating exosomes from cell supernatents, 
the supernatants were normally pre-treated with NEM before centrifugation to isolate 
exosomes.  To determine whether these dimers could be forming as a post lysis event due 
to inefficient alkylation, we compared exosomes that had only been treated pre-spin with 
NEM to those treated pre- and post- spin with NEM (Figure 5.10). 
 
 
Figure 5.10: Dimers in exosomes are not a post lysis event.  Jesthom exosomes were 
isolated from cell supernatents and treated prior to ultracentrifugation with NEM, an 
aliquot of exosomes was also treated with NEM post-centrifugation.  Samples were then 
resolved by 8 % SDS-PAGE and western blotting.  Membranes were probed with HC10 
or HCA2 as indicated.  Results are representative of at least 2 experiments. 
 
Treating exosomes post-spin with NEM did not affect dimer formation indicating that 
these dimeric structures were not forming as a post lysis event.  Dimers in exosomes were 
also not enhanced if exosomes were only treated post-spin (data not shown).  Together 
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these results indicate that dimers in exosomes are not occurring due to a post-lysis event 
or because of the method used to isolate the exosomes.   
 
Dimeric complexes in exosomes are immunoprecipitated with conformation 
dependent antibodies. 
 
The identification of a mixed B27-A2 dimeric structure suggested that the exosomal 
MHC class I dimers were different to unfolded HLA-B27 dimers.  To gain further 
information about the structure of the dimers found in exosomes, we therefore performed 
immunoprecipitations (IP) using different MHC class I reactive antibodies, both 
conformation-dependent and -independent, and also an antibody against β2m.   
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Figure 5.11: Exosome dimers are immunoprecipitated with conformation dependent 
antibodies.  Exosomes were isolated from Jesthom cell supernatents and resuspended in 
lysis buffer.  Lysates were then subject to immunoprecipitation with the indicated 
antibodies.  Samples were resolved by 8 % SDS-PAGE and western blot.  Membranes 
were probed with HC10 or HCA2 as indicated.  Results are representative of at least 2 
experiments. 
 
HLA-B27 homodimers that have previously been reported are primarily HC10 reactive 
and consist of two unfolded heavy chains not associated with β2m.  It was therefore 
intriguing to discover that the dimers isolated from exosomes were recognised by W6/32, 
ME1 and BB7.2, and also by the β2m specific-BBM.1 (note that ME1 is of relatively low 
affinity and is often poor in immunoprecipitation studies).  These results indicate the 
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HLA-A and -B dimers in exosomes retain their confirmation and are associated with β2m.  
These results have highly significant consequences for how these dimeric structures 
might be formed and recognised. 
 
Dimers in exosomes may be forming through interactions between the cysteines 
present in the cytoplasmic tail. 
 
The cysteine residue at position 67 in the HLA-B27 heavy chain has been strongly 
implicated in the formation of HLA-B27 dimers, although interactions between the 
structural cysteines residues could also play a part (Allen et al., 1999, Dangoria et al., 
2002, Antoniou et al., 2004, Saleki et al., 2006).  Some dimers have been reported to be 
W6/32 reactive indicating that they retain some of their normal confirmation (Allen et al., 
1999, Dangoria et al., 2002), however fully folded HLA-B27 dimers that are still 
associated with β2m, have not previously been described.   
 
We took advantage of a stable KG1 cell line available in the lab, expressing HLA-B27 
with cysteine to serine mutation at position 67, to investigate the importance of Cys67 on 
the formation of dimers in exosomes. 
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Figure 5.12: Exosome dimers are not dependent on Cysteine 67.  Exosomes were 
isolated from the indicated KG1 cell line supernatant and were subject to lysis.  Samples 
were resolved by 8 % SDS-PAGE, before HC10 western blotting.  Results are 
representative of at least 2 experiments. 
 
Exosomal dimers still formed in the absence of Cys67 suggesting that another cysteine 
residue, or residues, are important for their formation.  If dimers were forming through an 
interaction between one of the structural cysteine residues, however, it is unlikely that 
they would be recognised by the confirmation dependent antibodies W6/32 and ME1, 
which has been shown to be the case in figure 5.11.  Thus the exosomal MHC class I 
dimers described here must be forming through available cysteine residues other than the 
conserved structural residues at positions 101, 164, 203 and 259.  For this reason we 
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hypothesised that the MHC class I dimers in exosomes may be forming through 
interactions between the cysteine residues in the cytoplasmic tail, which a significant 
number of MHC class I molecules possess.  For example HLA-B27 contains two 
unpaired cysteines at positions 308 and 325 (although 308 may be on the very edge of the 
transmembrane region, lying just immediately prior to the RRK stop-transfer signal), 
whilst HLA-A2 contains a single cysteine in its cytoplasmic tail at position 339 as shown 
below: 
 
 
Figure 5.13: Cytoplasmic tail cysteines which are present in HLA-B27 and HLA-A2.  
HLA-B27 contains two cysteine residues in its cytoplasmic tail, at positions 308 and 325 
(indicated in red).  HLA-A2 contains only one cysteine residue at position 339 (indicated 
in red).  The last 25 residues that are missing from the C58.A2.tailless cell line are 
indicated in blue. 
 
To begin the investigation of the role of the cytoplasmic tail in MHC class I dimer 
formation we used a transfectant of the rat C58 cell line expressing an HLA-A2 allele 
with a cytoplasmic tail truncation removing the last 25 residues (Figure 5.13).  It was 
hypothesised that removal of this region would prevent dimer formation in exosomes.  
 211 
 
 
Figure 5.14: Exosomes isolated from C58 cells expressing an A2 allele with a tail 
truncation do not contain dimers.  Exosomes were isolated from the supernatents of 
C58 cells expressing either a normal HLA-A2 allele or an HLA-A2 allele with a tail 
truncation.  Exosomes were resuspended in lysis buffer and samples were resolved by 8 
% SDS-PAGE and HCA2 western blot.  Results are representative of at least 2 
experiments. 
 
Figure 5.14 shows that HLA-A2 dimers are present in exosomes isolated from the 
C58.A2.SV5 cell line but that these dimers are undetectable in the C58.A2.tailless cell 
line.  This result suggests that W6/32 reactive dimers in exosomes are forming through 
interactions between the cysteine residues in the cytoplasmic tails.  Further support for 
this hypothesis is present in figures 5.9, 5.12 and 5.23.  In these figures immunoblotting 
with HC10 of KG1 derived exosomes reveals no dimer structures, whereas blotting with 
HCA2 does reveal dimers (Figure 5.9).  Whilst this result was initially confusing, in light 
of the data presented above on the role of cytoplasmic cysteines, a check of the published 
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sequence of the HLA-A3 and HLA-B35 alleles present in KG1 cells reveals that HLA-
A3 contains Cys339, whereas HLA-B35 does not have Cys325, thus explaining the 
observation.  This also suggests that Cys308 is not significantly involved in exosomal 
dimer formation. 
 
Depleting Jesthom cells of cholesterol may alter exosome composistion or release. 
  
The use of methyl-β-cyclodextrin (MBC) to deplete cells of cholesterol has been reported 
to enhance clustering of MHC class I molecules.  If exosomal MHC class I dimer 
formation involves cytoplasmic tail cysteines, we hypothesised that by depleting 
cholesterol from exosomes we may increase the clustering of MHC class I and therefore 
increase dimer formation. 
 
In an attempt to deplete cholesterol from the exosomes, cells, and supernatant, were 
treated with an increasing concentration of MBC for 30 minutes before exosomes were 
isolated from the supernatent. 
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Figure 5.15: Depleting Jesthom cells of Cholesterol alters exosome formation.  
Jesthom cells were treated with the indicated concentrations of MBC for 30 minutes.  
Exosomes were then isolated from the cell supernatant.  Exosomes were resuspended in 
lysis buffer and samples were resolved by 8 % SDS-PAGE and western blotting.  (A) 
Samples were run non-reduced and the membrane was probed with HC10.  (B) Samples 
were run reduced and the membrane was probed with Alix and Tsg101.  Results are 
representative of at least 2 experiments. 
 
Unexpectedly, treatment with the higher concentrations of MBC (4 mM and 6 mM) 
increased the total class I signal but did not seem to alter the monomer to dimer ratio 
(Figure 5.15 A).  To try to determine whether this was a class I specific increase or 
whether other proteins were also increased, we blotted the same samples again using 
antibodies to detect Alix and Tsg101.  Alix and Tsg101 are involved in the formation of 
exosomes and we had only weakly been able to detect them in previous blots (data not 
shown).  Figure 5.15 B shows that both Alix and Tsg101 are increased following 
treatment with MBC.  These data indicate that depletion of cholesterol from Jesthom cells 
may alter either exosome release or exosome composition.      
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To determine whether the treatment of isolated exosomes with MBC could enhance 
dimer formation we treated isolated exosomes with the same concentration of MBC as 
was previously used to treat cells and supernatants. 
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Figure 5.16: Treatment of exosomes with MBC does not affect dimer formation.  
Exosomes were isolated from the supernatant of Jesthom cells and resuspended in 0.2 µm 
filter-sterile PBS.  Exosomes were protein quantified using the Bradford method.  Equal 
quantities were treated with different concentrations of MBC at 37 °C for 30 minutes.  
Samples were resolved by 8 % SDS-PAGE before western blotting.  (A) Samples were 
run non-reduced (left) and reduced (right) and membranes were blotted with HC10.  (B) 
Samples were run reduced and the membrane was blotted with Alix.  Results are 
representative of at least 3 experiments. 
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Treating isolated exosomes with MBC had no effect on the monomer to dimer ratio 
(Figure 5.16 A).  Samples were also blotted using Alix to determine whether there was 
any change to another exosome protein (Figure 5.16 B).  Alix levels were also unaffected 
by MBC treatment. 
 
These data indicate that cholesterol depletion and therefore clustering of MHC class I 
does not affect the formation of dimers in exosomes.  However, treatment of Jesthom 
cells with the higher concentration of MBC appears to enhance exosome release or alter 
exosomes composistion. 
 
Increasing extracellular glutathione concentration prevents dimer formation in 
exosomes isolated from Jesthom cell supernatants.  
 
To try to answer the question of why these dimers were able to form more readily in 
exosomes than in cells we carried out a number of experiments designed to alter the 
exosomal environment.   
 
Reduced glutathione (GSH) is the major free thiol in most living cells and is involved in 
the maintenance of the oxidation state of protein sulfhydryls.  We hypothesised that the 
cysteines in the cytoplasmic tail of the MHC class I alleles may be kept in a reduced state 
through the action of GSH.  If exosomes were unable to maintain the GSH levels then 
this may allow the cysteine residues to become oxidised allowing disulfide bonds to 
form.  The concentration of GSH alters significantly in different cellular compartments. 
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Within the cytoplasm it can be as much as 10 mM, dropping to around 1 mM in the ER, 
hence the ER is a much more oxidising environment.  Outside cells the GSH 
concentration drops dramatically to around 20 µM.  Jesthom cells were therefore allowed 
to secrete exosomes into an extracellular environment where the GSH level had been 
raised to levels as high as those present in the cytoplasm.  Under these conditions MHC 
class I dimers were essentially unable to form (Figure 5.17). 
 
 
Figure 5.17: Increasing GSH concentration reduces dimer formation in exosomes.  
Supernatants from Jesthom cells were treated with varying concentrations of GSH for 6 
hours.  Exosomes were isolated from the supernatant and resuspended in lysis buffer.  
Samples were resolved by 8 % SDS-PAGE and HC10 western blot. Results are 
representative of at least 2 experiments. 
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Diamide induces the formation of W6/32 reactive dimers in cells.  
 
Leading on from the above observation, if the reducing capacity of the cytoplasm, in 
terms of GSH levels, prevents the formation of MHC class I dimers at the cell surface of 
normal cells, then it is logical to assume that changing the cellular environment to a more 
oxidative environment would drive the formation of these complexes.  To investigate this 
hypothesis, we incubated Jesthom cells with increasing concentrations of diamide, which 
acts by rapidly depleting free GSH levels within cells. 
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Figure 5.18: Treatment of Jesthom cells with diamide induces the formation of 
W6/32 reactive dimers.  (A) Jesthom cells were treated with diamide in RPMI for 10 
minutes at 37 °C.  Cells were lysed and lysates were subject to immunoprecipitation with 
the indicated antibodies.  Samples were resolved by 8 % SDS-PAGE before western 
blotting, membranes were probed with HC10.  (B) Cell lysate image aligned with the 
W6/32 IP image.  Results are representative of at least 2 experiments. 
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Treatment of Jesthom cells with diamide causes an increase in dimers in a concentration 
dependent manner (Figure 5.18 A, lysates).  Immunoprecipitation with HC10 and W6/32 
shows that the induced dimers are conformational dimers (W6/32-reactive), rather than 
misfolded dimers (HC10-reactive) (Figure 5.18 A IP).  Aligning the W6/32 IP with the 
cell lysates image indicate that it is the induced dimer band that is immunoprecipitated 
with W6/32 (Figure 5.18 B).  A non-specific band above the dimer band is also visible in 
the W6/32 IP image. 
 
Jesthom exosomes have reduced levels of glutathione compared with Jesthom cells. 
 
The data presented so far strongly suggests a model wherein exosomes do not contain 
levels of GSH that can maintain the cytoplasmic tails of MHC class I molecules in a 
reduced form, thus permitting the formation of MHC class I dimer structures.  It was 
therefore a priority to directly measure levels of GSH in exosomes in comparison with 
the cell lysates.  To measure the GSH content of exosomes we used a colourimetric 
glutathione assay kit (Sigma).  This assay determines the total GSH (GSH + GSSG) 
content of a sample.  GSH causes reduction of the substrate DTNB to TNB and oxidised 
GSSG is recycled by glutathione reductase and NADPH.  The yellow colour of the 
product, TNB, is measured.  We compared the GSH content of Jesthom cell lysates with 
exosomes isolated from Jesthom cell supernatants. 
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Figure 5.19: Exosomes have lower levels of glutathione compared with whole cells.  
GSH concentrations were estimated using a colourmetric glutathione assay kit as per 
manufacturers instructions.  Samples were prepared in duplicate and were read on a 
FLUOstar Optima plate reader at a wavelength of 380 nm.  The average of both readings 
were used to plot the graphs (the exosomes readings were 0.04 and 0.03, and the cell 
lysate readings were 0.157 and 0.153).  Approximately 7 µg of exosomes and cell lysates 
were measured. 
 
The GSH content of exosomes determined by this assay was significantly lower than in 
whole cell lysates (Figure 5.19), supporting the idea that cytoplasmic tail dimers are able 
to form in exosomes because of the lower overall level of GSH. 
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Exosomes containing dimers can be isolated from peripheral blood cells. 
 
Exosomes have been isolated from many primary cells and biological fluids, proving 
their existence in vivo.  However, although MHC class I and class II have been 
extensively studied in these exosomes, to our knowledge the existence of MHC class I 
dimers in exosomes has not yet been described.  
 
In order to investigate the presence or absence of dimers in exosomes isolated from 
peripheral blood, we separated lymphocytes and monocytes from 3 healthy volunteers 
and matured them in culture.  Activated lymphocytes and dendritic cells were compared 
with unactivated lymphocytes and dendritic cells. 
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Figure 5.20: Exosomes isolated from PBMCs show differing levels of dimer and 
monomer expression.  PBMCs were isolated from whole blood and cultured for 2 hours 
to allow monocytes to adhere to the plastic.  (A) Lymphocytes, which remained in 
suspension, were separated from monocytes and either left untreated or treated with PHA 
for 48 hours.  Exosomes were then isolated from the lymphocyte supernatants, samples 
were resolved by 8 % SDS-PAGE and HC10 western blot.  (B) Monocytes were cultured 
with IL-4 and GM-CSF for 5 days.  They were then either left untreated or treated with 
LPS for 48 hours.  Exosomes were isolated from the monocyte supernatants, samples 
were resolved by 8 % SDS-PAGE and HC10 western blot. 
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No class I signal was detected from exosomes isolated from unstimulated lymphocytes 
however exosomes from stimulated lymphocytes show differing patterns depending on 
the sample (Figure 5.20 A).  Sample A contains only monomer in both exosomes (Figure 
5.20 A, right panel) and lysates (Figure 5.20 A, left panel).  Samples B and C contain 
small amounts of dimer in the cell lysates, however only dimers are detectable in 
exosomes isolated from stimulated lymphocytes (Figure 5.20 A). 
 
The pattern for dendritic cells and exosomes isolated from dendritic cells is relatively 
similar.  Dendritic cells from sample A contain no class I dimer band and exosomes 
isolated from these cells contain only a very small amount of monomer (Figure 5.20 B). 
Samples B and C contain more monomer than dimer in the dendritic cells (Figure 5.20 B, 
left panel) but more dimer than monomer in the exosomes (Figure 5.20 B, right panel).  
The same pattern is seen in stimulated and unstimulated cells however MHC class I is 
enhanced in both forms following stimulation (Figure 5.20 B).  It is clear in this image 
that there is less class I overall in Sample A compared with Samples B and C so this 
cannot be ruled out as a possible reason for why we are unable to detect much signal 
from the exosomes.   
 
These data suggest that some class I alleles are more prone to forming dimers in 
exosomes than others.  As HLA-B27 is well-known to misfold forming dimers we 
hypothesised that this allele may also be more susceptible to forming dimers in 
exosomes, and that lymphocytes from Samples B and C may be HLA-B27 positive.  To 
investigate this hypothesis we analysed some of the primary lymphocytes by flow 
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cytometry using the antibody FITC-B27.  Although this antibody is not 100 % specific 
for HLA-B27, staining would give us an indication of the possibility of these individuals 
being HLA-B27 positive.   
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Figure 5.21: FACS analyses of primary lymphocytes.  PBMCs were isolated from 
whole blood and cultured for 2 hours to allow monocytes to adhere to the plastic. 
Lymphocytes, which remain in suspension, were removed and blocked with 5 % human 
serum.  Cells were stained with FITC-B27 and assessed by flow cytometry. 
 
 227 
Analysis of the primary lymphocytes by flow cytometry indicates that Sample C is highly 
likely to be HLA-B27 positive (Figure 5.21, bottom panel).  The result from Sample B is 
very intriguing.  Sample B was found to express dimers in both exosomes isolated from 
lymphocytes and exosomes isolated from dendritic cells and the lymphocytes show some 
staining with FITC-B27 (Figure 5.21, middle panel).  Sample A had no dimers in either 
exosomes isolated from lymphocytes or exosomes isolated from dendritic cells and 
lymphocytes from this sample showed no staining with FITC-B27 (Figure 5.21, top 
panel). 
 
Although this data is very preliminary, it does suggest that dimers in exosomes may be 
influenced by the class I allele that is expressed and that possibly HLA-B27 positive 
individuals may be more susceptible to dimer formation in exosomes. 
 
Exosomes containing dimers can be isolated directly from blood plasma. 
 
Exosomes isolated from primary cells were maintained in cell culture for either 48 hours 
(lymphocytes) or 7 days (dendritic cells).  To try to eliminate the possibility that dimers 
in exosomes may be forming due to the cells being maintained in cell culture we wanted 
to try and isolate exosomes from blood plasma directly without having any time in cell 
culture.  A published protocol for isolating exosomes from blood plasma was already 
available, which involves additional steps over the normal protocol (Caby et al., 2005). 
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Blood samples were taken from three healthy volunteers, Samples B and C as above 
(Figures 5.20 and 5.21) and Sample D, a known non-B27 control.  Plasma was seperated 
from whole blood and exosomes were then isolated. 
 
 
Figure 5.22: Exosomes containing MHC class I dimers are present in plasma.  
Plasma was separated from whole blood and was subject to centrifugation at 500 x g, 
12000 x g, 0.22 µm filtration and ultracentrifugation to isolate exosomes.  Samples were 
resolved by 8 % SDS-PAGE and HC10 western blot. A non-specific band was also 
identified at around 50 kDa.  
 
Exosomes were isolated from all of the samples, however the monomer:dimer ratio 
differed among the samples (Figure 5.22).  Sample D, the non-B27 control contained 
predominantly monomer and some dimer whereas samples B and C contained 
predominantly dimer and only a faint monomer band can be seen in both samples (Figure 
5.22). 
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Crucially, this result indicates that exosomes containing MHC class I dimeric complexes 
are formed in vivo and that the monomer to dimer ratio can be different between different 
people.  The physiological relevance of dimers on exosomes has not been proven, 
however considering the roles exosomes have been implicated in it certainly seems worth 
studying MHC class I in exosomes in both traditional and non-traditional roles. 
 
Exosomes can transfer MHC class I dimers to KG1-dendritic-like cells.  
 
One of the methods suggested for how exosomes can activate the immune system is 
through the transfer of their class I molecules to dendritic cells.  To test whether it was 
possible to transfer the exosomal MHC class I dimer structures to other cells, we 
incubated exosomes isolated from Jesthom cell supernatent with KG1 dendritic-like cells. 
We analysed KG1 cells by western blotting, flow cytometry and immunofluorescence.  
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Figure 5.23: Exosomes can transfer class I molecules to KG1 cells.  Exosomes were 
isolated from Jesthom cell supernatents and resuspended in 0.22 µm filter-sterile PBS. 
Exosomes were then incubated with stimulated KG1 cells overnight.  (A) Cells were 
lysed and samples resolved by 8 % SDS-PAGE before HC10 western blot.  (B) Cells 
were harvested, stained with FITC-B27 and subject to FACS analysis. 
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KG1 cells contain their own normal class I molecules but are not HLA-B27 positive and 
do not normally express dimers.  Following incubation with Jesthom exosomes, we were 
able to detect induction of a dimer band in the KG1 cell lysates, the dimer band runs at 
the same molecular weight as the dimer band in control Jesthom exosomes (Figure 5.23 
A).  We were also able to detect faint cell surface staining with FITC-B27 (Figure 5.23 
B), an antibody that does not normally stain KG1 cells. 
 
For immunofluorescent staining, KG1 cells grown on coverslips were incubated with 
exosomes isolated from Jesthom cell supernatent before staining with FITC-B27 (Figure 
5.24). 
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Figure 5.24: Exosomes can transfer class I molecules to KG1 cells.  Exosomes were 
isolated from Jesthom cell supernatents and resuspended in 0.22 µm filter-sterile PBS.  
Exosomes were then incubated with stimulated KG1 cells, grown on coverslips, 
overnight.  Cells were stained with FITC-B27 and visualised by immunofluorescence 
microscopy. 
 
The cell in the centre of figure 5.24 shows some punctate staining around its periphery 
whilst the two cells visible in the right and left hand corners showed no staining at all.  It 
is not possible to distinguish in this image whether the exosomes have bound to the cell 
surface or have fused with it.  However the FITC-B27 staining of some of the cells 
indicate that HLA-B27 can be transferred from exosomes to KG1 cells. 
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We were further able to analyse exosomes transfer using a lipid dye.  Bodipy ceramide 
usually stains the golgi apparatus but in excess will also stain other membranes.  In an 
attempt to visualise exosome release from Jesthom cells, we stained Jesthom cells with 
excess bodipy before immobilising them in agar on coverslips, and re-incubating them at 
37 °C with 5 % CO2 in air for 24 hours.   
 
 
Figure 5.25: Exosome-like vesicles immobilised in agar.  Jesthom cells stained with 
excess bodipy were immobilised in agar on microscope slides covered with a coverslip 
and incubated at 37 °C with 5 % CO2 in air, for 24 hours.  Cells were visualised by 
immuno-fluorescence microscopy. 
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A few of the cells imaged were surrounded by small speckles of Bodipy staining.  These 
speckles usually matched up to areas that were also visible in the brightfield image 
(Figure 5.24).  
 
To further try to show transfer between exosomes and KG1 cells we isolated exosomes 
from Jesthom cells that had been stained with excess bodipy.  We incubated stimulated 
KG1 cells with these exosomes for 24 hours. 
 
 
Figure 5.26: Exosomes can transfer staining to unstained KG1 cells.  Exosomes 
isolated from the supernatant of Jesthom cells stained with excess bodipy were incubated 
with stimulated KG1 cells, grown on coverslips, at 37 °C, 5 % CO2 in air, for 24 hours.  
Cells were visualised by immuno-fluorescence microscopy. 
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Some KG1 cells showed staining with Bodipy although the majority showed no staining 
at all (Figure 5.26).  The regions of bodipy appeared in the brightfield image to consist of 
small clusters.  However, the brightfield image suggests that the cell we imaged is not 
very healthy looking and this must be taken into consideration when interpreting this 
result. 
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Discussion 
 
We have isolated exosomes from the human B cell line, Jesthom, the human dendritic-
like cell line KG1, peripheral blood lymphocytes, monocyte-derived dendritic cells, and 
blood plasma.  We confirmed that what we had isolated were classifiable as exosomes by 
a combination of electron microscopy (Figure 5.1), flow cytometry (Figure 5.5) and 
western blotting (Figure 5.4).  Exosomes showed characteristic ‘cup’ shaped morphology 
under electron microscopy and were within the size range of previously published 
exosomes (Li et al., 2006) (Chaput et al., 2006) (Wubbolts et al., 2003) (Abusamra et al., 
2005).  Mass spectrometry revealed the presence of MHC class I and class II proteins as 
well as other known exosome-associated proteins (Figure 5.3) (Mignot et al., 2006).  We 
also identified CD48 and GILT, proteins that had not previously been associated with 
exosomes.  Intriguingly, western blotting revealed that exosomes from Jesthom cells 
contain enhanced amount of HLA-B27 heavy chain homodimers compared with whole 
cell lysates.   
 
Exosomes are being extensively studied because of their ability to modulate the immune 
system, and in the context of HLA-B27 and spondyloarthropathies, HLA-B27 
homodimers are being studied to try to determine their role in disease pathogenesis.  As 
work on exosomes continue, their involvement in different aspects of the immune system 
is becoming clearer.  Expression of specific receptors targeting exosomes to different 
cells of the immune system suggest that exosomes could be yet another way in which the 
immune system can communicate.  The ability of exosomes to interact with immune cells 
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may put dimeric class I molecules in a prime position to influence and modulate the 
outcome of these events. 
 
Following the detection of class I dimers in exosomes we investigated whether GILT (γ-
interferon inducible lysosomal thiol reductase) could also be detected in the exosomes 
preparations.  GILT is an enzyme that catalyses the reduction of disulphide bonds in the 
endosomal/lysosomal compartment (Arunachalam et al., 2000), and thus could have 
contributed to the formation of unfolded MHC class I dimers of the type suggested in the 
work of Bowness and colleagues (Bird et al., 2003).  Although we were able to detect 
GILT, the levels were very low, and further investigation of the dimers present in 
exosomes revealed that they were actually essentially all fully folded, suggesting that 
GILT probably does not influence their formation. 
 
The interaction of exosomes with NK cells has previously been reported (Clayton et al., 
2008, Elsner et al., 2007, Gastpar et al., 2005).  In relation to this, the discovery of CD48 
on the exosomes we have studied is extremely interesting.  The expression of CD48 is 
limited to cells of lymphoid or myeloid origin (Yokoyama et al., 1991), and it is the 
ligand for the 2B4 receptor (Brown et al., 1998b, Latchman et al., 1998).  2B4 is 
expressed on NK cells and some T cell subsets and mediates non-MHC mediated 
cytotoxixity (Valiante and Trinchieri, 1993, Garni-Wagner et al., 1993).  2B4-CD48 
interactions are essential for interleukin-2 (IL-2) driven expansion and activation of NK 
cells (Lee et al., 2006).  The cytotoxic activity of NK cells is determined by both the 
activatory and inhibitory signals that they receive and the usual dominant signal that is 
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received is inhibitory through the interaction of NK cells and normal MHC class I 
molecules (reviewed in Bryceson and Long, 2008).  However if MHC class I dimers are 
recognised differently by NK cells, the expression of CD48 may promote NK cell 
activation.   
 
The detection of novel mixed dimers forming between different class I alleles on 
exosomes is extremely intriguing.  These dimers would also be available for 
immunosurveilance and may influence immune responses.  Whether HLA-B27 is 
necessary as part of the mixed dimer complex has not been elucidated but does deserve 
further study. 
 
How these dimer molecules are seen by the immune system is an extremely important 
question.  It has not been fully determined whether exosomes can be seen directly by 
other cells of the immune system or indirectly through attachment to, or fusion with, an 
APC.  For this reason it was important for us to determine whether our exosomes could 
interact with, and transfer dimers to, other cells.  We took advantage of a dendritic cell-
like cell line that was available in our lab and were able to demonstrate the transfer of 
dimers from exosomes to these cells (Figure 5.23).  We were also able to show the 
potential transfer of lipids from exosomes to KG1 cells using bodipy ceramide stained 
exosomes, however the brightfield image of the cell shown revealed that the cell imaged 
was probably not perfectly healthy and this must be taken into consideration (Figure 
5.25). 
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If dimers can influence whether the immune response is inflammatory or suppressive, the 
transfer of dimers to other cells may be extremely important.  Transfer of dimers may 
influence how the immune system sees a cell that was previously undetected, or ignored. 
 
We have shown that dimers formed in exosomes are fully folded and maintain their 
association with β2m and that the formation of these dimers is not dependent on Cys67.  
We therefore hypothesised that these dimers were forming through an interaction 
between cysteine residues in the cytoplasmic tail.  Indeed results using a cell line 
expressing HLA-A2 with a cytoplasmic tail truncation are consistent with this theory.  
Cytoplasmic tail dimers are not unprecedented, mouse class I alleles joined through a 
cytoplasmic tail cysteine have been previously reported (Capps and Zuniga, 1993) as 
have human class I dimers (Cresswell and Dawson, 1975), however, it was later shown 
that, for human class I molecules, these dimers were formed as a product of the isolation 
process (Springer et al., 1977).   
 
To our knowledge the only previously reported human MHC class I β2m-containing 
homodimer to have been reported is the non-classical HLA-G molecule.  Interestingly, 
this molecule contains a truncated cytoplasmic tail and could not therefore form a 
cytoplasmic tail dimer.  However HLA-G is unique amongst class I molecules because of 
its expression of Cys42.  The presence of this cysteine residue allows the formation of 
fully folded β2m-associated homodimers (Figure 4.15).  It is interesting to suggest that 
the presence of this cysteine residue may be compensating for the lack of a cytoplasmic 
tail, allowing these important dimer structures to still be able to form. 
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We next addressed how and why these dimers apparently readily form in exosomes, but 
not in cells.  One of our initial hypotheses for why dimers formed so readily in exosomes 
involved the close proximity of such a high concentration of MHC class I molecules.  
Cholesterol depletion in cells has been shown to result in the clustering of MHC class I 
molecules at the cell surface (Fooksman et al., 2006).  Exosomes are enriched in 
cholesterol, therefore by depleting exosomes of cholesterol, resulting in the clustering of 
class I molecules, we hoped to promote dimer formation.  Cells, and their exosome-
containing supernatants, were treated with the cholesterol depleting agent methyl-β-
cyclodextrin (MBC), with complex results (Figures 5.15).  When cells and exosome-
containing supernatents were incubated with MBC, MHC class I levels were enhanced in 
exosomes but the monomer to dimer ratio was unaffected.  Further blots showed that the 
enhancement was not solely in class I molecules but also in Alix and Tsg101, important 
components of the ESCRT pathway involved in MVB formation.  Clustering of 
molecules has been one of the proposed mechanisms for how some proteins enter the 
MVB pathway, it is therefore possible that by depleting cells of cholesterol we enhanced 
clustering of proteins at the MVB surface promoting their targeting and inclusion in 
exosomes. 
 
To remove the effect that treating cells with MBC had on exosome formation, we refined 
the procedure and isolated exosomes first before treating them with MBC (Figure 5.16).  
Surprisingly this had no effect on the MHC monomer to dimer ratio implying that the 
previous result was indeed caused by depleting the cells of cholesterol. 
 
 241 
Intracellular GSH is a crucial antioxidant, maintaining an environment that prevents 
aberrant disulfide bonds from forming.  We hypothesised that if GSH levels were lower 
in exosomes than in cells then this may allow unconventional disulfide bonds to form.  
This theory presumes that these dimers are bonded through a cysteine exposed to the 
internal environment of the exosome, of which a cysteine in the cytoplasmic tail would fit 
with our previous observations.  Exosomes form from inward budding of endosomes and 
very little, if anything, is known about how GSH concentrations are controlled in these 
vesicles.  We hypothesised that increasing the GSH concentration towards cytoplasmic 
concentrations would prevent these dimers from forming.  Indeed, treating exosomes 
with increasing concentrations of GSH could inhibit dimer formation (Figure 5.17).   
 
As treatment with GSH reduced dimer formation, then logically treatment with an 
oxidising agent should have the opposite affect.  Treatment of Jesthom cells with diamide 
induced the formation of W6/32 reactive dimers in a concentration dependent manner 
(Figure 5.18).  This result brought to our attention a previous result where the treatment 
of .220.B8.htpn or .220.B8 cells with diamide had enhanced or induced the formation of 
dimers in these cell lines respectively (Figure 4.8).  This result would suggest that the 
dimers formed by HLA-B8 in the .220 cell lines are of a similar type to dimers formed in 
exosomes.  From this perspective it would be very interesting to carry out 
immunoprecipitation experiments on the .220.B8.htpn cell line to confirm this 
hypothesis.  We have shown that treatment of Jesthom cells with diamide induced the 
formation of W6/32 reactive dimers in cells.  However, if we were able to IP W6/32 
dimers from the .220.B8.htpn cell line, this would suggest that under some circumstances 
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these conformational dimers can also be formed in cells without chemical induction, not 
just exosomes. 
 
To test the hypothesis that GSH levels were lower in exosomes we took advantage of a 
colourimetric GSH assay kit.  We used protein concentration, determined via the 
Bradford method, as a method to try and measure equal input quantities of lysates from 
exosomes and cells.  The results from this assay clearly show that although exosomes do 
contain a small quantity of GSH, the concentration in whole cell lysates is much higher 
(Figure 5.19).  These data strongly suggest that MHC class I dimers in exosomes are able 
to form because of a relative lack of GSH. 
 
The isolation and detection of exosomes containing MHC class I dimers from human 
plasma is exciting.  Foremost, this demonstrates that exosomal MHC class I dimers are 
not a result of cell culture manipulation, but are in fact produced in vivo.  This opens up 
the possibility of direct manipulation of exosomes for in vivo applications, since they will 
not therefore be recognised as totally foreign entities.  
 
Furthermore, the work we carried out on exosomes derived from primary lymphocytes 
and monocyte-derived dendritic cells shows that the formation of dimers in exosomes is 
likely to be influenced by which HLA alleles are expressed in any one individual.  A 
survey of the available HLA class I sequences at the IMGT/HLA database 
(www.ebi.ac.uk) reveals that all known HLA-A alleles possess Cys339, and could thus 
potentially be involved in forming exosomal dimer structures.  In contrast, HLA-B alleles 
 243 
show dimorphism, wherein they all contain Cys308, but are split amongst their possession 
of Cys325, with alleles such as HLA-B07, -08, -27, -41, -42 and -44 having it, whereas 
those without include -B14, -B15, -B35, -B37, -B40 and -B51.  Thus each persons HLA 
haplotype may determine the presence of MHC class I exosomal dimers.  In addition, it 
would be feasible that dimers would form between different alleles, wherein a 
heterozygous individual with the haplotype HLA-B07 and -B44 could form exosomal 
B07-B07 dimers, B44-B44 dimers, and B07-B44 dimers.  Furthermore, as we have 
shown here with exosomes from the Jesthom cell line, it is possible also to form dimers 
between HLA-A and -B molecules, though at a relatively low levels, perhaps due to steric 
constraints caused by the positions of the cysteines in the cytoplasmic tails.  Thus the 
potential for novel structures to be recognised by the various class I recognising receptors 
of the immune system would appear to be large.  Figure 5.27 shows a schematic 
representation of the possible MHC class I structures that can be found on cells and 
exosomes. 
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Figure 5.27: Schematic diagram representing MHC class I structures found on cells 
and exosomes.  MHC class I molecules can adopt a number of different confirmations.  
Exosomes express more fully folded class I dimer than monomer and can also contain 
novel mixed-allele dimers.  Cells in some circumstances can also express fully folded 
dimers, as well as unfolded dimers, and free heavy chains in addition to the normal fully 
folded monomer. 
 
Although our work on primary cell derived exosomes is fairly preliminary, an early 
picture is developing that individuals with HLA-B27 tend to have more MHC class I 
dimers on their exosomes.  It would be very interesting to study exosomes released by 
primary cells in more detail, in particular a comparison of exosomes from patients with 
active AS disease compared with non-disease controls.  Whether exosomes have any role 
in the disease process still remains to be determined, but the demonstration of excess 
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HLA-B27 dimers on exosomes should be of particular interest considering their potential 
involvement in the disease process. 
 
Certainly the formation of dimers is likely to alter how these class I molecules are seen 
by the immune system.  The interaction of dimeric class I molecules with T cells have 
previously been reported.  In vivo studies have shown that dimeric mouse class I 
molecules activate T cells and induce a state of unresponsiveness in a peptide specific 
manner, whereas monomers of the same MHC molecule are unable to generate a 
response (Abastado et al., 1995), and further reports demonstrating the 
immunosuppressive capabilities of dimers have also been published (O'Herrin et al., 
2001, Fried et al., 2005).  These studies used soluble dimeric MHC class I complexes, 
therefore the results observed following their interaction with T cells was due solely to 
the MHC class I molecule.  Exosomes have been shown to express co-stimulatory 
molecules, thus the response to a membrane bound MHC class I dimer in the presence of 
these co-stimulatory molecules may well be different to that of soluble MHC class I 
dimers and deserves to be investigated.    
 
The dimers we have reported here may also effect how these class I molecules are seen 
by NK cells.  It has recently been demonstrated that the intracellular cysteine residues in 
the cytoplasmic tail of MHC class I proteins are crucial for extracellular recognition by 
LILR1 of whole cells (Gruda et al., 2007).  Therefore, the formation of disulfide bonds 
between cytoplasmic cysteine residues may alter how the extracellular domain is 
recognised by some NK receptors. 
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The demonstration of novel MHC class I dimers at the surface of exosomes is very 
intriguing.  HLA-B27 dimers have been implicated in the pathogenesis of AS and other 
spondyloarthropathies, and it has been shown that exosomes can be important modulators 
of the immune response.  We have shown that exosomes containing novel folded B27-
B27 dimers and also B27-A2 dimers are released from cell lines maintained in culture, 
and that exosomes rich in dimeric class I complexes can be isolated from PBMCs and 
human plasma, demonstrating that these dimers are formed in vivo.  HLA-B27 has 
already been shown to have a propensity to misfold forming dimers compared with other 
alleles, whether this is also the case for dimers in exosomes remains to be determined.  
Our preliminary data from primary cells indicate that some class I alleles do have more of 
a tendency to form dimers in exosomes, and the FACs data suggests that one of those 
alleles is HLA-B27.   
 
Whether HLA-B27 has a tendency to form dimers in exosomes, and how these dimers are 
seen by the immune system requires further investigation.  Considering the 
immunomodulatory properties reported so far for exosomes it certainly seems important 
to determine the possible role of HLA-B27 positive exosomes in the disease process.  
The availability of exosomes from plasma of patients, and also the availability of the 
transgenic HLA-B27 rat model make the study of exosomes extremely feasible. 
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Chapter VI: Conclusions and Future Work 
 
The reason for the strong association of HLA-B27 with spondyloarthropathies still 
remains unresolved, despite over 3 decades of research.  Several hypothesies have been 
put forward to explain this relationship, but so far no concensus on which hypothesis is 
right has been agreed.  The work presented here investigates biochemical features of 
HLA-B27 in an attempt to provide insights into how it contributes to pathogenesis.  In the 
first chapter of results, I have investigated the role of HLA-B27 in the activation of an ER 
stress response, leading us to conclude that in vitro studies of this potential mechanism 
are complicated, prone to a number of technical issues, and may therefore not be 
appropriate for gaining information that would be of significant use when comparing to 
the real disease scenario.   
 
Secondly, I then also studied the formation of non-B27 dimers and suggest that this may 
be strongly influenced by the overexpression of class I heavy chain expression.   
 
In the final chapter I have presented data that show that novel fully folded β2m-associated 
MHC class I homodimers can be found at enhanced levels in the small 
immunomodulatory vesicles known as exosomes.  We have characterised these exosomes 
and detected the presence of CD48 and GILT, two proteins that have not previously been 
reported in exosomes.  We have also provided evidence as to how and why these dimers 
are able to form in exosomes.  Intriguingly, the formation of these dimers is not limited to 
HLA-B27, in fact many MHC class I molecules would have the potential to form such 
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dimer structures, induced by the possession of cysteine residues in the cytoplasmic tail 
domain.  
 
The work presented in this thesis provides new data that will contribute to the continued 
study of HLA-B27 and its strong association with disease. 
 
HLA-B27 and the UPR 
 
Using cell line models we investigated whether the expression of HLA-B27 could 
activate an ER stress response known as the UPR.  To study this we looked at BiP, XBP1 
and ATF6, important components in the main pathways of UPR stress activation.  The 
results presented in this chapter suggest that in vitro expression models that study the 
UPR and HLA-B27 should be interpreted with care. 
 
We have demonstrated that BiP levels are increased in cell lines that transiently or stably 
express both disease-associated, non-disease associated and folding-mutant class I 
molecules (Figures 3.2, 3.7 & 3.11).  The increase in BiP could not be correlated to HLA-
B27 expression and in both the HeLa stable and transient expression models, the levels of 
BiP were higher in the more efficient folding HLA-A2 molecule (Figures 3.2 & 3.7). 
 
Cleavage of ATF6 is stimulated in response to UPR activation.  In a previous report it 
was shown that using a transient expression model of HLA-B27 expression, ATF6 
cleavage product could be detected in those cells expressing HLA-B27 (Lemin et al., 
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2007).  However, using a stable expression model we were unable to detect ATF6 
cleavage in response to HLA-B27 expression (Figure 3.10).  On very long exposures a 
faint cleavage band was detected in the HLA-B27 sample but also in the wild-type 
sample, suggesting that the causative factor was not HLA-B27 (data not shown).  
 
We also looked at XBP1 mRNA, which is constitutively expressed (XBP1u) but, 
following activation of an UPR, is spliced to produce XBP1s.  XBP1 splicing has 
previously been studied using a transient expression model of HLA-B27 expression, 
these authors show that transient expression of HLA-B27 does activate the UPR (Lemin 
et al., 2007).  However our results suggest that transient transfection with other class I 
alleles also results in XBP1 splicing (Figures 3.4 & 3.5).  In the stable expression system 
we were able to detect an increase in XBP1 splicing in the cell line transfected with 
HLA-B27 (Figures 3.8 & 3.9), however we were unable to show a similar UPR activation 
signal using BiP expression or ATF6 cleavage (Figures 3.7 & 3.10).   
 
The work presented here indicates that in vitro expression systems may not be ideal for 
studying the effects of HLA-B27 and the UPR.  Data obtained from transgenic animal 
studies or patient samples may be of more relevance than in vitro cell-line models in this 
area of study. 
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Non-HLA-B27 Dimers 
 
HLA-B27 homodimers have been implicated in the pathogenesis of AS and other 
spondyloarthropathies.  Approximately 90-95 % of patients with AS are HLA-B27 
positive, showing that AS can occur in patients that express other class I alleles.  If 
dimers do play an important role in disease development, then studying what conditions 
influence other class I alleles to form dimers may provide important insights into disease 
development. 
 
It is, however, reasonably well reported that other MHC class I alleles can form dimers 
(Capps et al., 1993, Santos et al., 2004).  The relationship of these structures to the HLA-
B27 versions could be of significant relevance.  We have primarily studied the formation 
of HLA-B8 dimers in the .220 cell line.  This same .220 cell line has previously been 
used to study the formation of HLA-B27 homodimers (Bird et al., 2003).  HLA-B8 
dimers form in .220 cells that co-express HLA-B8 and human tapasin.  The expression of 
HLA-B8 heavy chains increased when htpn was co-expressed.  Dimers could also be 
detected at the cell surface where they would be available for immunosurveilance. 
 
We were unable to detect dimers in the .220.B8 cell line that were not transfected with 
tapasin, nor in a .220.B27 cell line expressing low levels of HLA-B27 heavy chain 
(Figure 4.2).  These data implicate the level of expression of the class I heavy chain in 
dimer formation.  In support of this hypothesis we have shown that over-expression of 
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several other non-disease associated alleles in HEK293 cells resulted in dimer formation 
(Figure 4.14). 
 
Increased expression of HLA-B27 has already been shown to be important in transgenic 
animal models, and increased HLA-B27 expression has been detected in HLA-B27+ 
patient samples compared with HLA-B27+ controls (Taurog et al., 1993, Cauli et al., 
2002).  The data presented here suggest that under some circumstances, enhanced 
expression of non-B27 alleles can lead to dimer formation.  These non-B27 dimers could 
conceivably contribute to disease pathogenesis in the same way as HLA-B27 dimers, 
through altered recognition by immune receptors at the cell surface, or by contributing to 
ER stress activation. 
 
Studies on HLA-B27 that was mutated to express a cysteine residue at position 42, an 
HLA-G specific cysteine, suggest that the dimers formed by HLA-B8 may have a more 
folded structure than previously reported HC10 reactive HLA-B27 dimers (Figure 4.10).  
We have also demonstrated that incubating .220.B8.htpn cells with diamide, which 
rapidly depletes GSH, results in an increase in dimer formation, and can induce formation 
of dimers in the .220.B8 cell line (Figure 4.8).  This result is particularly interesting 
considering the data presented in chapter V.  In this work we showed that HLA-B27 
dimers in exosomes and Jesthom cells could be influenced by the redox status of the 
cellular environment.  This leads to an interesting question as to whether the dimers 
detected in .220.B8.htpn cells represent a fully folded β2m-associated dimer structure, 
similar to exosome dimers.  For this reason it would be extremely interesting to perform 
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immunopreciptation experiments on .220.B8.htpn cell line to try to ascertain some further 
information about the structure of these dimers i.e. whether they represent folded of 
misfolded dimers. 
 
The dimers formed by HLA-B27 and other class I alleles are not necessarily 
quantitatively or qualitatively the same.  Indeed HLA-B27 expresses a cysteine residue at 
position 67 that has been implicated in HLA-B27 dimer formation and is relatively rare 
among class I molecules (Allen et al., 1999, Dangoria et al., 2002, Bird et al., 2003).  
Dimers formed between this residue may be seen differently to dimers formed through 
other cysteine residues and may be what makes HLA-B27 so strongly associated with AS 
and other spondyloarthropathies.  However, as previously mentioned, approximately 5-10 
% of AS patients do not express HLA-B27, indicating that neither HLA-B27, nor the 
cysteine residue at position 67, are absolutely required for the disease to occur.  Any 
MHC class I dimer structure present at the cell surface could potentially alter how the cell 
is seen by different immune cells, and any misfolded dimer structure could promote 
inflammation through ER stress activation.  Therefore, studying the formation of non-
B27 dimers may provide insights into the triggering processes that lead to the 
development of disease. 
 
HLA-B27, MHC class I and Exosomes 
 
In this work we have shown that exosomes, isolated from human cell lines, peripheral 
lymphocytes, monocyte-derived dendritic cells and blood plasma, show an enhanced 
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level of MHC class I homodimers compared with cell lysates.  In particular we have 
studied HLA-B27 dimers in the context of exosomes, using a cell line naturally 
expressing HLA-B27 and primary cells derived from both HLA-B27+ and HLA-B27- 
individuals. 
 
We have shown that MHC class I dimers that form in exosomes are fully folded and 
maintain their association with β2m ((Figure 5.11).  We hypothesise that these dimers are 
forming through an interaction between cysteine residues in the cytoplasmic tail.  Our 
preliminary data presented here using an HLA-A2 mutant devoid of its cytoplasmic tail 
supports this hypothesis (Figure 5.14).  Work is already underway in our lab to create 
new HLA-B27 mutants that have cysteine to alanine substitutions at either Cys308 or 
Cys325, or at both positions, in the cytoplasmic tail. 
 
The cysteine residues that are present in MHC class I molecules can be different 
depending on the allele.  For example HLA-A alleles all posses Cys339 in the cytoplasmic 
tail, whereas HLA-B alleles all contain Cys308 but are split when it comes to Cys325, with 
some alleles containing this cysteine residue and some being without.  If dimer formation 
can occur between any cysteine residues in the cytoplasmic tail then potentially all of the 
HLA-A and -B alleles could form dimers.  However, the cysteines involved may 
influence dimer formation with some residues being more likely to react than others.  
This may lead to a scenario in which an individuals HLA haplotype would influence their 
potential class I dimer formation.  Indeed the results presented here, from exosomes 
derived from primary lymphocytes and monocyte-derived dendritic cells, do suggest that 
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dimer formation can be influenced by the HLA alleles that are expressed.  We have also 
shown that, in exosomes isolated from Jesthom cell supernatants, novel mixed dimers are 
able to form between an HLA-B27 molecule and an HLA-A2 molecule.  These results 
imply that the potential for novel class I dimer structures is apparently quite large, 
essentially adding another level of polymorphism to the range of structures that might be 
recognised by immune system receptors. 
 
Although the work in primary cells that is presented here is preliminary, it does suggest 
that HLA-B27 is more prone to forming MHC class I dimer structures in exosomes 
(Figures 5.20, 5.21 & 5.22).  To further clarify this point it would be extremely 
interesting to compare exosomes derived from HLA-B27+ samples with HLA-B27- 
controls.  It would also be interesting to compare exosomes derived from HLA-B27+ 
patients compared with HLA-B27+ controls, this would allow us to determine whether 
the formation of dimers in exosomes can be influenced by disease, or if it is a potential 
biomarker for disease activity.   
 
The results presented here suggest that dimers in exosomes are able to form because of 
reduced levels of GSH.  GSH is an essential antioxidant within the cell that prevents 
aberrant disulfide bonds from forming.  We have shown that exosomes contain a lower 
concentration of GSH than whole cells (Figure 5.19) and have also demonstrated that 
increasing the extracellular GSH concentration can prevent dimers in exosomes from 
forming (Figure 5.17).  In the reverse scenario, incubating Jesthom cells with the 
oxidising agent diamide was able to induce the formation of folded dimers in a 
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concentration dependent manner (Figure 5.18).  This result indicates that folded dimer 
structures can also form in cells under certain conditions.  Interestingly, the work carried 
out on .220.B8 and B8.htpn cell lines also indicates that incubating cells with diamide 
can drive the formation of class I dimers (Figure 4.8).  Immunoprecipitations would have 
to be carried out in order to determine whether the dimers formed in these cell lines are 
also fully folded. 
 
Another important avenue of work would be to determine whether dimers on exosomes 
are peptide receptive, and if so, what type of peptides these dimers usually bind.  The 
assumption from the data presented here is that these MHC class I dimers are indeed fully 
loaded with peptides, because they are recognised by conformational-dependent 
antibodies. Purification and mass spectrometric analysis of peptides eluted from 
exosomal MHC class I molecules would be informative.  This would be particularly 
important considering the route taken for exosomes biogenesis.  Within the endosome the 
class I molecules will have been exposed to exogenous peptide antigen, possibly destined 
for MHC class II molecules, and may in some cases have been able to bind. 
 
It would also be very interesting to determine whether exosomes expressing class I 
dimers can interact with NK cells, and whether this would lead to an inhibitory or an 
activatory effect.  MHC class I interaction with NK cells is relatively peptide independent 
and usually results in an inhibitory signal, however if the class I molecule cannot interact 
with the NK receptor this would result in apoptosis.  Previously characterised HLA-B27 
homodimers have been shown to interact with different subsets of NK cells when 
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compared with the HLA-B27 monomer (Allen et al., 2001, Kollnberger et al., 2002).  The 
fully folded class I dimers that we have detected in exosomes may also be differently 
recognised by NK cell subsets.  It is interesting to note that the non-classical class I 
molecule, HLA-G, exists as a monomer or as fully folded dimers.  Of great potential 
significance, although HLA-G monomers and dimers are recognised by the same 
receptor, they have been shown to interact with different strengths, with dimers forming a 
much stronger interaction (Gonen-Gross et al., 2003, Shiroishi et al., 2006, Apps et al., 
2007).  This suggests that the formation of dimers can influence the interaction between 
MHC molecules and NK receptors. 
 
To this regard it is also interesting to note that we detected the presence of CD48 on our 
Jesthom exosome populations.  CD48 is the ligand for the 2B4 receptor that is expressed 
on NK cells and some T cell subsets (Brown et al., 1998b, Latchman et al., 1998, 
Valiante and Trinchieri, 1993, Garni-Wagner et al., 1993).  The interaction between 
CD48 and 2B4 promotes IL-2 expression, which is important in the expansion and 
activation of NK cells (Lee et al., 2006).  Jesthom cells are an EBV transformed human B 
cell line and the expression of CD48 in these exosomes may be associated with this fact.  
However, if class I dimers are not seen in the same way as monomers their expression in 
exosomes at times of infection may promote and enhance NK cell activity. 
 
To enable further studies to distinguish if a particular detected response was due to class I 
dimers or class I monomers it would be important to be able to control the formation of 
dimers in exosomes, resulting in the formation of exosomes containing only dimers or 
 257 
only monomers.  In an attempt to manipulate the formation of dimers in exosomes we 
incubated cells and exosomes with MBC, a cholesterol-depleting agent that has been 
shown to cause clustering of class I molecules at the cell surface (Fooksman et al., 2006), 
however incubation of exosomes, or cells and exosomes, with MBC did not affect dimer 
formation (Figures 5.15 & 5.16).  As we have now demonstrated that the redox 
environment is important in dimer formation, manipulating these conditions may allow us 
to produce exosomes that express either only dimers or only monomers.  However 
changing the redox environment is likely to cause global problems within the cell and it 
would therefore be important to determine that any exosomes produced under these 
conditions are as we have previously characterised.   
 
Exosomes have been implicated in many aspects of immunomodulation and can have 
activatory or inhibitory effects.  How this occurs has not been fully elucidated.  It is 
proposed that exosomes can have direct effects on other cells of the immune system or 
that exosomes may bind to, or fuse with, professional antigen presenting cells, having an 
indirect effect (Admyre et al., 2006, Hwang et al., 2003, Thery et al., 2002a, Denzer et 
al., 2000).  We have been able to demonstrate the transfer of HLA-B27 dimers from 
exosomes onto KG1 dendritic cell-like cells, and flow cytometry data indicates that 
exosomes have transferred HLA molecules to the surface of KG1 cells (Figures 5.2 & 
5.24).  These data suggest that if exosomes do interact with the other cells of the immune 
system indirectly, dimers can be transferred from exosomes to other cells, making them 
available for immunosurveillance.  
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Molecular modelling would allow us to predict a possible structure of the dimers present 
in exosomes.  Results from IP experiments allow us to make some statements about the 
structure of dimers on exosomes.  W6/32 reactivity implies that the α2 domain remains 
fully folded and ME1 reactivity suggests that the α1 domain also remains intact.  
However, bonding in the cytoplasmic tail may alter the extracellular domains in some 
ways.  For example, cytoplasmic tail interactions may effect the orientation of the class I 
molecules at the cell surface.  It has previously been demonstrated that class I molecules 
in the cell membrane adopt a supine orientation (Mitra et al., 2004).  Bringing class I 
molecules together through interactions in the cytoplasmic tail may affect this property, 
changing how the molecules are recognised by other immune receptors. 
 
A commercial ‘class I dimer’ reagent is available from BD bioscience, known as 
DimerX.  This structure consists of the extracellular domains of class I molecules fused 
to the N terminal VH domain of mouse IgG, an immunoglobulin light chain disulphide 
bonded to the heavy chain, and a non-covalently associated human β2m molecule. 
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Figure 6.1: Schematic diagram of BD bioscience DimerX molecule.  The DimerX 
molecule is a three-chain complex molecule consisting of a recombinant heavy chain of 
MHC-Ig fusion chain (blue and purple), an immunoglobulin light chain (yellow) 
disulphide bonded to the heavy chain, and a non-covalently associated human β2m 
molecule (red). 
 
Although in the schematic diagram the class I molecules appear quite far apart this may 
not represent the physiological structure of this recombinant protein.  Indeed the hinge 
region of the antibody is likely to allow movement of the class I molecules closer 
together.  The use of this reagent may allow us to investigate the function of fully folded 
dimers.  Adaptation of this structure may be possible, perhaps with a further disulfide 
bridge in the VH chain of the mouse IgG, ensuring the class I molecules are brought 
closer together.  The generation of these reagents results in the fomation of soluble class I 
dimers that can then be used in numerous experiments.  An important caveat of using 
these molecules is that they lack the cytoplasmic tail, and this may be important for 
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downstream signalling and should be taken into account if these synthetic class I dimers 
are used to investigate the function of fully folded class I dimers.   
 
The work presented here on HLA-B27 in exosomes presents a potentially new avenue of 
research for AS and other spondyloarthropathies.  The formation of dimers in exosomes 
does not necessarily form the basis of a new theory for disease pathogenesis but could in 
fact support some of the previously proposed theories for disease.  For example, if dimers 
on exosomes are shown to retain the same structure and peptide binding ability as 
monomeric class I molecules, they could potentially be involved in the arthritogenic 
peptide hypothesis.  To this regard, previous studies have already demonstrated the effect 
dimeric class I molecules can have on T cell stimulation, and in some cases dimers can 
elicit a T cell response where a monomeric class I allele cannot (Abastado et al., 1995, 
O'Herrin et al., 2001, Fried et al., 2005).  Alternatively, if these dimer structures are 
recognised differently to monomeric class I molecules, perhaps by receptors of the NK 
family lineage, then they may promote disease in the same way as is proposed for 
misfolded HLA-B27 dimers at the cell surface.  Whether HLA-B27 dimers and exosomes 
are related to disease pathogenesis remains to be determined, but continued study into 
this area in the future is likely to yield important information about both AS and the 
potential immunoregulatory role of exosomes. 
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